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Abstract 
Tertiary alcohols are a common functional group in many natural products, 
pharmaceuticals and agrochemicals. The ability to produce highly enantiomerically 
pure tertiary alcohols is therefore an important goal in synthetic chemistry. 
The synthesis of chiral tertiary alcohol precursors has been achieved via enzymatic 
desymmetrisation with the lipase Amano L, AK to generate (S)-(2-
(hydroxymethyl)oxiran-2-yl)methyl acetate 50 in 42% isolated yield and 97% 
enantiomeric excess. The reaction was also attempted with an immobilised lipase 
from R. miehei yielding the product in 82-90% yield and up to 89% ee, Figure 1.  
The enantioselective ring-opening of the epoxide using different amines has been 
developed in high yields generating enantiomerically pure β-amino tertiary alcohol 
products. However, an undesired intramolecular migration of the acetyl group was 
observed during the epoxide opening with aliphatic primary amines resulting in 
prochiral triol products. To avoid such an intramolecular migration a TBS-protected 
derivative 99 has been used to prepare the tertiary alcohol products with primary 
amines in good yields (43%-83%), without any loss of enantiomeric excess of the 
formed ‘pseudo’-enantiomer 100a-c. 
(S)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 has the potential to generate a 
large diversity of compounds; this reagent was also used as the starting material to 
generate azetidines 114a-j in high yields. 
 
Figure 1: Overview. 
best result with 
4-fluoroaniline: 97% ee 
best result with 
benzylamine: 97% ee 
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NATURAL PRODUCTS AND THEIR CHIRALITY 
During the past 25 years the search for biologically active natural products has been 
critical for the pharmaceutical and agrochemical industries. Huge efforts have been 
made to develop synthetic routes to these pharmacologically important compounds.1  
Many pharmaceutical compounds and medicines are isolated and purified from 
natural sources due to the complexity of their syntheses on an industrial scale.2 
Todays efforts tend to focus on developing new synthetic or semi-synthetic routes to 
drugs as well as utilising biosynthetic intermediates to generate natural products.3 
Therefore, it is important to develop new synthetic methods to generate these 
compounds using chemical or biochemical tools and thus improve the diversity of 
resources.  
 
 
Scheme 1: Examples of pharmaceutical compounds isolated from nature. 
 
Scheme 1 shows two examples of pharmacologically active compounds isolated 
from natural sources. Taxol 1 is present in the plant kingdom, isolated from the yew 
tree and possesses anticancer activity,4 another example is the aminoglycosides such 
as streptomycin 2, present in the microbial world;5 this compound is active against 
bacteria and itself is isolated from the bacteria, Legionella pneumophila.6  
Pharmacognosy is the science of extracting medicinal compounds from natural 
sources. This science has the tools to identify, treat and isolate a target compound 
from a natural resource for pharmacological use, although this process is very slow, 
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expensive and inefficient, and the active ingredient is present in low concentrations.7 
However, there is still a need to investigate and develop new efficient synthetic 
routes to generate not only natural products, but also their analogues and other 
nature-inspired compounds for potential use as medicines.  
 
1. CHIRAL TERTIARY ALCOHOLS AND THEIR DERIVATIVES IN 
NATURAL PRODUCTS AND PHARMACOLOGICALLY ACTIVE 
COMPOUNDS 
One of the common functional groups present in the natural products shown in 
Scheme 1 is a chiral tertiary alcohol; a moiety present in many natural products and 
pharmacologically active compounds.8-15 
Scheme 2 shows seven more examples of natural products or pharmaceutical 
compounds containing a chiral tertiary alcohol or derivative which have been 
isolated either from nature or synthesised in the laboratory for industrial applications.  
In numerous cases, drugs and other targets containing a chiral tertiary alcohol or 
derivative display activity whereby one enantiomer is more active than the other or 
that only one shows activity altogether; this is the case with citalopram 4.16 Most of 
the bioactivity of this drug resides in the (S)-(+)-enantiomer. (S)-(+)-citalopram is a 
selective inhibitor of serotonin re-uptake and has proven to be an efficient 
antidepressant.17 This pharmaceutical compound is produced synthetically and in one 
particular route, the stereogenic centre on the tertiary alcohol 3 is generated via 
enzymatic methods. Similar key enzymatic steps are used for the syntheses of 
voriconazole 5,18 an antifungal agent, frontalin 7,19 an insect pheromone derived 
from a chiral tertiary alcohol, and the essential oil linalool 9.20 Enzymatic syntheses 
of citalopram and frontalin will be discussed in detail in Section 3.2.  
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 Scheme 2: Natural products and pharmaceutical drugs containing a chiral tertiary 
alcohol or functionality which is prepared from a chiral tertiary alcohol. 
 
Pumiliotoxin 251D 8 is one of the toxins present in poison arrow frogs, used for 
chemical self-defence against predators.21,22 This natural product has been 
chemically synthesised using a chiral pool approach,23 from L-proline.  
(S)-Oxybutynin 10 is an anticholinergic used to treat urinary and bladder-control 
problems.24 The (S)-enantiomer possesses anticholinergic activity and several 
approaches have been developed to generate the hydroxy-bearing quaternary 
stereocentre. Grignard addition into α-ketoesters derived from chiral cis-
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aminoindanols,25 aldol reactions of dioxolones derived from chiral mandelic acid,26 
Sharpless asymmetric dihydroxylation of α-cyclohexylstirene,27 using gadolinium 
complexes catalytic enantioselective cyanosilylation of cycloalkyl phenyl ketones28 
or kinetic resolution of tertiary α-hydroxynitriles with Pseudomonas cepacia (PSL-
C)29 have all been reported to synthesise the key α-hydroxy acid  precursor to (S)-
oxybutynin. 
Camptothecin 11 was isolated from Camptotheca acuminata decene, a tree native in 
China, in 1966 by M. E. Wall and M. C. Wani.30 This compound showed excellent 
anticancer activity.31 The (R)-isomer is inactive and several chemical and enzymatic 
routes have been published in the past four decades describing methods to generate 
the (S)-enantiomer and its derivatives.32  
Some of these pharmacologically active compounds possessing a chiral tertiary 
alcohol require the tertiary alcohol for biological activity, or the activity increases in 
the presence of this functional group. For example, Chaetomugilin A 12 is an 
antitumour compound isolated from the marine fish Mugil cephalus (Figure 2), and it 
has been demonstrated that the analogue containing a chiral tertiary alcohol exhibits 
a higher cytotoxic activity than the methoxy analogue 13 (Chaetomugilin B). 33,34 
 
 
Figure 2: Chaetomugilins A 12 and B 13, two antitumor agents. 
 
Linezolid 14 is an important antibacterial agent and the first member of the 
oxazolidinone family known to possess such activity.35 Whereas linezolid is usually 
a well tolerated drug, long treatments with this compound are sometimes 
complicated due to a reversible myelosuppression concluding with the suspension of 
this treatment. However, the tertiary alcohol-containing analogue 15 presents similar 
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antibacterial activity and could be better tolerated for prolonged treatments (Figure 
3). 
 
 
Figure 3: Linezolid 14 and a 4-hydroxy-piperidine analogue, 15. 
 
Quinic acid 16 is isolated from the woody plant Uncaria and possesses anti-
inflammatory activity (Figure 4), and it is another example of a compound with 
higher biological activity due to the presence of chiral secondary and tertiary 
alcohols. Acetylation of the hydroxyl groups giving derivative 17 reduces the anti-
inflammatory activity.36 
 
Figure 4: Quinic acid 16 and its tetra-acetylated derivative 17. 
 
Due to the importance of generating compounds in a single enantiomeric form, the 
next section will introduce general methods used to accomplish this. 
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2. METHODS TO GENERATE ENANTIOPURE PRODUCTS 
Many classic reactions in organic chemistry do not have the ability to produce 
selectively one enantiomeric form of a compound. However the need to produce 
pharmaceutical products as single enantiomers led to the development of many 
different synthetic methods and resolution techniques to achieve this (Scheme 3).37,38 
 
Chiral pool                                  total synthesis 
                                                                                    enzymatic 
                                                   kinetic/dynamic 
                                                                                    chemical 
Racemate         resolution          crystallisation                                                               lly  
                                                                                                                         
                                                   chiral chromatography  
Prochiral substrate               enantioselective         chiral reagents 
                                              transformation            or catalysts 
 
Scheme 3: Current methods to generate enantiopure products. 
 
There are three general ways to generate chiral products, the first one is using the 
chiral pool approach, the second is resolution of a racemic mixture and the third is to 
use prochiral substrates. These three routes are described in more detail in the next 
sections. 
 
2.1 Chiral pool 
The chiral pool is a limited number of commercially available enantiopure reagents, 
such as carbohydrates, amino acids, terpenes and steroids, which are isolated from 
natural sources. These reagents are used as precursors or intermediates in a synthetic 
route to allow the introduction of the desired stereogenic centre in the final 
compound. The chiral pool approach is an efficient method to produce chiral 
compounds at low cost and 100% enantiomeric excess, so long as the synthetic route 
avoids racemisation of the products. However, there are a limited number of 
Enantiomerically 
pure compound 
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commercially available chiral compounds, therefore, it may be difficult to find a 
suitable reagent with the necessary structure and stereochemistry for a synthesis.  
Lactose is a disaccharide which is isolated from the sweet or sour whey of milk.39 
This natural product is used as a chiral pool precursor for the synthesis of the 
anthracycline antibiotics, daunorubicin 20 and doxorubicin 21 (Scheme 4).39,40 These 
compounds are useful drugs for the treatment of a range of human cancers and can be 
synthesised from the readily available precursor α-D-isosaccharino-1,4-lactone 19, 
obtained on large scale from lactose 18.41,42 
 
O
O
O
OHOHHO
OH
OH
OH
HO
OH
O
O
HO
OHHO H3CO
O
O
OH
OH O
R
OH
O
NH2OH
daunorubicin 20; R=COCH3
doxorubicin 21; R=COCH2OH
18 19
Scheme 4: Synthesis of daunorubicin 20 and doxorubicin 21 from lactose 18. 
 
2.2 Kinetic resolution 
The development of single enantiomers can also be achieved by the kinetic 
resolution of a racemic mixture. Kinetic resolution is a process in which both 
enantiomers of a racemic mixture are transformed into two products at different rates 
(Scheme 5).43-45 When the kinetic resolution is efficient, only one enantiomer of the 
racemic mixture is transformed into the desired product. This process displays the 
limitation of this method, in that a maximum yield of only 50 % is achievable, i.e. 
the undesired enantiomer is also isolated in 50% yield, which requires time-
consuming and costly removal. Kinetic resolution resolves the racemic mixture 
because one enantiomer reacts faster than the other.46 
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                                                  P 
   SR+SS 
                                                  Q 
Scheme 5: Kinetic resolution of a racemate. SR and SS are racemic substrates; P and 
Q are the enantiomeric products.  If k1>>k2, product P will dominate with a high ee. 
 
Scheme 5 represents the kinetic resolution of a racemate (SR+SS) to produce two 
enantiomeric products (P and Q) at different reaction rates. The apparent first-order 
rate constants (k1 and k2) determine the reaction rate, in the case where k1>>k2, 
product P will dominate with high ee. The selectivity of the reaction (α) is only a 
function of the apparent first-order rate constants, determined by the ratio k1/k2. This 
parameter is not dependent on the conversion of the reaction and therefore will be 
constant over the process. Consequently, the enantiomeric excess of the product (ee) 
depends only on the selectivity of the reaction. When the enzyme is selective for a 
substrate, one rate constant will be higher than the other and thus the optical purity 
will be higher. 
A quantitative analysis of the enantioselectivity of a kinetic resolution is the 
enantiomeric ratio (E). The equation is a relationship between the enantiomeric 
excess of the product (eep) and the degree of conversion (c).47  
E = ln[(1-c)(1-eeP)] / ln[(1+c)(1-eeP)] 
This parameter is independent of the time of reaction and substrate concentrations. 
When the enzyme is totally selective, 50% of enantiopure product will be obtained 
but when the enzyme is less selective, the biotransformation gives lower 
enantioselectivity, however higher enantiomeric purity can be achieved with a higher 
degree of conversion.47 Therefore, the relationship between enantiomeric excess and 
conversion is important for making useful predictions and this information is 
generated with the enantiomeric ratio.  
k1 
k2 
 =
 − 1
 + 1
=
 − 
 + 
 
α = k1 / k2 
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T. Loh and co-workers have reported a kinetic resolution of different bis-homoallylic 
alcohols with high enantioselectivity (Scheme 6).48 An oxonium-ene cyclisation 
catalysed by In(OTf)3 resulted in remarkable 1,4-stereocomunication. Only the (S)-
isomer reacts with the catalyst and the (R)-isomer is recovered with high 
enantiomeric purity. Finally, they applied this method to the resolution of the natural 
product (R)-sulcatol 27 with >98% ee; this compound is biologically active as an 
insect pest control agent. 
Scheme 6: Kinetic resolution of bishomoallylic alcohols. 
 
2.2.1 Dynamic kinetic resolution 
Dynamic kinetic resolution (DKR) combines the classic procedure of kinetic 
resolution (Section 2.2) with an additional feature; an in situ racemisation step of the 
unreacted substrate (Scheme 7).43 The resolution is performed using conditions under 
which both enantiomers of the substrate are in a fast equilibrium or racemising, 
therefore, all the substrate is reacted leading to an efficient use of all starting 
material. Depending on the substrate stability and the rate of the equilibrium, 
racemisation may occur spontaneously or with the help of a catalyst. This catalyst 
can be either chemical or enzymatic. In dynamic kinetic resolution all the substrate 
can, under optimal conditions, be converted to a single enantiomer in 100% yield and 
enantiomeric excess.49-51 
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Chemoenzymatic DKR is a very attractive process which combines traditional 
chemical synthesis with high regio- and enantioselectivity with the use of enzymatic 
catalysis.49,51,52 Unfortunately, in the majority of cases, racemisation and resolution 
of a racemic compound require different reaction conditions; consequently, the 
reaction conditions of each process can be incompatible. Finding the fine balance 
between both processes can give rise to a dynamic kinetic resolution.53 
 
 
 
 
 
 
Scheme 7: Kinetic dynamic resolution showing production of the (R)-product in 
excellent yield and ee. 
 
J. Bäckvall and co-workers studied a chemoenzymatic DKR of secondary alcohols 
30 via racemisation with a Ru-catalyst combined with lipase B from Candida 
antarctica, which resulted in a dynamic kinetic resolution to generate chiral 
secondary alcohols in high yields and >99% ee (Scheme 8).49,50 This DKR is 
performed via hydrogen transfer catalysed by the Ru-complex and the acetylation of 
the secondary alcohol is catalysed by lipase B from Candida antarctica with p-
chlorophenyl acetate.  
(R)- substrate                                      (R)- product 
                 racemisation 
(S)- substrate                                      (S)- product 
fast 
slow 
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Scheme 8: Chemoenzymatic dynamic kinetic resolution of 1-phenylethanol 30. 
 
2.3 Asymmetric catalysis 
Another technique for the development of enantiomerically enriched compounds is 
asymmetric catalysis. In this case, the chirality is present in the catalyst used in the 
reaction. Only one chiral molecule is needed to introduce chirality in a million 
molecules of the reaction product. The catalyst could be an enzyme,54-56 or a metal-
based catalyst.57,58 This process can be very efficient, both on an industrial scale and 
synthetically in the laboratory. 
The asymmetric catalysis of meso or prochiral compounds by enzymes is a powerful 
strategy in organic synthesis due to the ability to reveal and/or generate multiple 
stereogenic centers in one step.54,59 The prochiral substrate needs to be recognised by 
the enzyme in order to catalyse the desymmetrisation. The desymmetrisation of meso 
and prochiral compounds has been investigated with different functional groups such 
as epoxides,60,61 anhydrides,62 diols,63,64 dienes65 and ketones66 and applied to the 
synthesis of many natural products.67-69 
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Scheme 9: General enzymatic asymmetric catalysis of diols. 
 
Scheme 9 shows a general example of enzymatic asymmetric catalysis with a lipase 
to transform a prochiral diol to a chiral product by selectively modify one primary 
alcohol function to an acetate. 
As discussed, there are three general methods to produce chiral compounds, chiral 
pool, kinetic resolution or asymmetric catalysis, and these can be performed 
chemically or enzymatically. The next sections will introduce the applicability of 
these methods to generate enantiomerically pure chiral tertiary alcohols using 
enzyme catalysis.  
 
3 ENZYMATIC CATALYSIS LEADING TO ENANTIOMERICALLY 
PURE TERTIARY ALCOHOLS. 
Enantiomerically pure chiral tertiary alcohols are not easy to synthesise both 
chemically and enzymatically due to their bulkiness and as a consequence, difficult 
accessibility. Due to the importance of this moiety in nature, the next sections will 
endeavor to explain some common methods for making tertiary alcohols, using 
enzymatic kinetic resolution or enzymatic desymmetrisation. 
Enzymes are the catalysts of biological systems, accelerating the rate of reaction by 
factors of a million or more compared to the corresponding non-catalysed reaction.43 
Enzymatic catalysis has a number of advantages over non-enzymatic catalysis, such 
as the chemo-, regio-, stereo-, and enantioselectivity under mild conditions.44 
Enzymes can typically catalyse a broad range of reactions, including ester hydrolysis 
and formation, oxidation and reduction, addition and elimination, halogenation and 
dehalogenation. The enzymes which catalyse the chemical reactions are formed from 
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chiral components ie. amino acids.43 These enzymes are able to differentiate both 
enantiomeric forms of their substrate, and therefore give the product as a single 
enantiomer.46 
Figure 5 shows the energy differences between a catalysed (∆G#ES) and uncatalyzed 
reaction (∆G#). The enzyme accelerates the reaction rate by decreasing the free 
energy (∆G#) of the transition state. The enzyme stabilises the transition state of the 
reaction but is not capable of modifying the equilibrium of the process. The 
activation energy required to perform the catalysed reaction with an enzyme (∆G#ES-
∆GS) is much smaller than the same reaction without catalyst (∆G#-∆GS).43 
 
 
 
 
 
 
 
 
Figure 5: Free energy profile for an uncatalysed reaction (      ) and enzyme catalysed 
reaction (       ).43 
 
For instance, the catalysed reaction is faster than the uncatalysed one due to the 
energy reduction of the enzyme-substrate transition state. While Figure 5 compares 
catalysed and uncatalysed reactions, Figure 6 compares the energy difference 
between two enantiomers and therefore the reason why one enantiomer reacts faster 
than the other in a catalytic reaction. 
In an enzymatic reaction, both enantiomeric substrates, A and B, are competing for 
access to the active site of the enzyme. A selective enzyme with a specific substrate 
∆G≠ 
∆G≠ES 
∆GS 
Enzyme + product 
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Enzyme with 
bound substrate 
Enzyme + 
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can distinguish between both enantiomers due to the chiral environment of the active 
site. The catalytically active functional groups of the enzyme act as a nucleophile or 
electrophile with the groups of the substrate differentiating A and B; therefore, 
generating different free energies (∆G) of the transition states complexes, [EA]≠ and 
[EB]≠. The result is a difference in the activation energy (∆∆G≠) meaning that one 
enantiomer, B, reacts faster than the other, A.44 
 
 
 
 
 
 
Figure 6: Free energy diagram for an enzyme catalysed enantioselective reaction. E = 
enzyme, A and B = enantiomeric substrates, P and Q = enantiomeric products, [EA]≠ 
and [EB]≠ = transition states of diastereomeric enzyme substrate complexes, ∆∆G≠ = 
differences between free energies of the transition states of [EA] and [EB].44 
 
3.1 Hydrolases and their catalytic activity 
Hydrolases catalyse hydrolysis, esterification or transesterification reactions.43 
Scheme 10 shows a general example of a transesterification process where the 
enzyme reacts with the ester (acyl donor) to give an enzyme-substrate intermediate. 
The process is followed by a nuclephilic attack by an alcohol to produce a new ester. 
If the enzyme is selective only one enantiomeric form of the product will be 
generated.46 
Their natural function is to hydrolyse triglycerides into fatty acids and glycerol. 
Lipases are the most frequently used class of hydrolases in organic synthesis, playing 
an important role in industrial manufacture.44 
[EA]≠ 
[EB] ≠ 
E+(A or B) 
E+P E+Q 
 
                [EA]            E+P 
E 
                [EB]            E+Q 
+A 
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Scheme 10: An example of lipase catalysed transesterification. 
 
The mechanism for the hydrolysis reaction follows four general steps (Scheme 11), 
and is catalysed by a group of three amino acids: histidine (His), serine (Ser) and 
aspartic acid (Asp).  
1) There is a reorganisation of the hydrogen atoms allowing the substrate to 
react with the active site serine residue, generating a tetrahedral 
intermediate which is stabilised by the histidine and aspartic acid. 
2) The alcohol is eliminated and there is a covalent bond between the acyl 
group and the serine residue. 
3) Nucleophilic attack takes place on the acyl-serine intermediate by a 
molecule of water (in the case of hydrolysis) or an alcohol (in the case of 
the transesterification), generating a tetrahedral complex stabilised by the 
other two amino acids. 
4) Finally, elimination of the acid (or ester) regenerates the enzyme to 
catalyse another cycle. 
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Scheme 11: Mechanism of a lipase-catalysed transesterification.43 
 
Lipase-catalysed reactions can be used to generate enantiopure products or 
intermediates leading to chiral tertiary alcohols. A racemic tertiary alcohol can react 
selectively with the enzyme to transform one of the enantiomers into its 
corresponding acetate leaving the other enantiomer optically pure (see examples in 
section 3.2).  
 
3.2 Enzymatic kinetic resolution leading to enantiomerically pure chiral 
tertiary alcohols 
Only a small number of lipases are able to accept tertiary alcohols into their active 
site due to their bulky and spherical shape, however when they do, the enzymes 
cannot distinguish easily between the enantiomers.29,70-78 The kinetic resolution of 
tertiary alcohols directly is difficult, only a few hydrolyses show activity, which 
typically give low to modest ee’s, and are limited to small substituents.  
One example is the hydrolytic resolution of tertiary acetate esters with a lipase from 
Candida cylindracea (Scheme 12).79 Four different tertiary acetates were tested (35-
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38) and the most successful result was the hydrolysis of 1,1,1-trifluoro-2-phenylbut-
3-yn-2-yl acetate 38, when the reaction was taken to 40% conversion, resulting in 
87% and 75% enantiomeric excess of the chiral alcohol and acetate respectively. 
 
 
Scheme 12: Kinetic resolution of tertiary acetate esters with a lipase from Candida 
cylindracea. 
 
Further work showed that a double mutant of Bacillus subtilis esterase displayed 
activity against the same tertiary trifluoromethyl acetate 38 with completely opposite 
selectivity, 93% enantiomeric excess after 42% conversion.80 This particular esterase 
was identified as GGG(A)X-hydrolase (A = alanine, G = glycine and X = any amino 
acid), an amino acid sequence shown to be involved in the stabilisation of the 
oxyanion hole present in the active site which is able to accommodate more sterically 
demanding tertiary alcohols due to a larger, more open active site.81 
An enantioselective esterification process of tertiary alcohol 40 was also attempted, 
and achieved with lipase A from Candida anatarctica and vinyl acetate in 97% 
enantiomeric excess albeit in low conversion (Scheme 13). Initially, eight different 
lipases and esterases were investigated for the kinetic resolution of 2-phenylbut-3-
yn-2-ol 40 with vinyl acetate in hexane. Four of these enzymes, those containing the 
GGGX-motif at the active site, showed activity and selectivity in the enzymatic 
esterification.77 
Therefore, the amino acid motif GGGX located in the oxyanion binding pocket of 
esterases and lipases tend to show activity in the kinetic resolution of bulky tertiary 
acetate esters and alcohols.78 
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Scheme 13: Enantioselective esterification of 2-phenylbut-3-yn-2-ol, 40. 
 
Another enzymatic route to generate chiral tertiary alcohols is an indirect lipase-
catalysed kinetic resolution. Lipase catalysis is performed on a primary or secondary 
alcohol near the stereogenic centre resulting in a resolution of the racemic mixture. 
The indirect resolution of tertiary alcohols via the hydrolysis or esterification of a 
proximal primary or secondary alcohol is a useful tool in enzymatic kinetic 
resolution.16  
 
Scheme 14: Kinetic resolution of 4-[(4-dimethylamino)-1-(4’-fluorophenyl)-1-
hydroxy-1-butyl]-3-(hydroxymethyl)-benzonitrile 3. 
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One example of such an approach is the enzymatic kinetic resolution of 4-[(4-
dimethylamino)-1-(4’-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymethyl)-
benzonitrile 3, a useful intermediate in the synthesis of citalopram 4 (Scheme 14). 
Good yields and high enantioselectivities can be achieved by an appropriate selection 
of the reaction parameters.16 Gotor et al. reported the kinetic resolution of 
benzonitrile 3 with lipase B from Candida antarctica and vinyl acetate in acetonitrile 
to generate the desired configuration for the synthesis of (S)-(+)-citalopram 5.16 A 
reaction performed due to the enzyme-catalysed acetylation of the distal primary 
alchohol. 
Due to the simplicity and facile scale-up of lipase catalysed reactions, this method 
could be applied to the industrial preparation of the antidepressant (S)-(+)-citalopram 
4.  
As shown, this method can be used to achieve the enzyme catalysed resolution of a 
quaternary stereogenic centre by performing a transesterification or hydrolysis 
reaction in organic solvent.16 It is remarkable, that the enantioselective recognition 
can be achieved by the enzyme at a primary hydroxyl group four bonds removed 
from the stereogenic centre!16 
The kinetic resolution utilised a primary alcohol handle to resolve the (S)-(-)-
citalopram intermediate 3, however, this method is not necessary suitable for all 
tertiary alcohols as the compounds must possess suitably positioned primary or 
secondary alcohol functionality near to the stereogenic centre for enzyme 
recognition. As such, there is an unmet need to develop a single, general and flexible 
route to access chiral tertiary alcohols. 
One particular method for the synthesis of chiral tertiary alcohols can be achieved via 
the kinetic resolution of chiral epoxides followed by ring-opening, whereby the 
enzyme is able to resolve the epoxide by modification of a pendant primary alcohol, 
as seen with (±)-2,3-epoxy-2-(4-pentenyl)-propanol 41 (Scheme 15). Santaniello and 
coworkers have reported such an enantioselective esterification reaction with a lipase 
from Pseudomonas fluorescens and vinyl acetate in organic solvents to resolve the 
racemic epoxyalcohol 41 in 98% enantiomeric excess and 38% isolated yield; a 
chiral intermediate for the synthesis of both enantiomers of frontalin 7.82 
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Scheme 15: Kinetic resolution of (±)-2,3-epoxy-2-(4-pentenyl)-propanol 41. 
 
Another example of a kinetic resolution of an epoxide to generate a chiral tertiary 
alcohol was also reported by Santaniello the following year.83 In this example, 
itaconic acid 44 was used as the starting material for the synthesis of useful building 
blocks. It was shown that a methyl substituted chiral tertiary alcohol 45 could be 
formed by using a lipase catalysed resolution of racemic epoxide 42 to generate the 
desired enantiopure epoxide in 90% ee and 30% yield. Exhaustive reduction with 
LiAlH4 finally achieved the desired product 45 (Scheme 16). 
 
 
Scheme 16: Synthesis of a chiral tertiary alcohol 45 via the kinetic resolution of ethyl 
2,2-(hydroxymethyl)oxiran-2-yl acetate 42. 
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Three different kinetic resolution methods to generate chiral tertiary alcohols with 
high enantiomeric excesses have been discussed. The principal inconvenience of 
using a kinetic resolution method is that only 50% yield of the desired enantiomer 
can be achieved with optimum conditions. 
 
3.2.1 Enantioselective transformation of prochiral substrates to   
produce chiral tertiary alcohols in high yields 
Recently, numerous isolated enzymes have been shown to catalyse asymmetric 
reactions with perfect stereoselectivity. Due to the availability of numerous enzymes 
such as esterases, lipases and amylases, etc., biocatalysts can play an important role 
in asymmetric synthesis.43,46  The principle limitation of this method is the high 
specificity of enzymes, leading to long process times to discover and develop an 
efficient biocatalyst for a wide range of substrates.44 The use of lipases to carry out 
ester hydrolyses and transesterification reactions have been used successfully for the 
desymmetrisation of different meso and prochiral alcohols. This enzymatic process 
could potentially generate single enantiomers in up to 100% enantiomeric excesses 
and yields.37,54,84 
For example, Sugai and co-workers reported a lipase catalysed desymmetrisation of 
(±)-2-hydroxy-2-(prop-2-ynyl)cyclohexane-1,3-diyl diacetate 46, an intermediate for 
the synthesis of aquayamycin, 48 (Scheme 17).85 The diacetate 46 was successfully 
hydrolysed in high yields and enantioselectivities with a lipase from Candida 
antarctica to give the desired (R)-enantiomer, 47. The biotransformation on a 10 g 
scale employed 1.8 g of enzyme to generate diol (+)-47 in 94% yield and >99% ee, 
Scheme 17. 
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Scheme 17: Enzymatic desymmetrisation of (±)-2-hydroxy-2-(prop-2-
ynyl)cyclohexane-1,3-diyl diacetate 46, an intermediate for the synthesis of 
aquayamycin 48. 
 
As discussed in section 3.2, the kinetic resolution of an epoxide followed by an 
epoxide ring-opening is an attractive approach to generate chiral tertiary alcohols. A 
similar process can also be applied to the enzymatic desymmetrisation of a prochiral 
epoxide, where in this case, a single enantiomer, in up to 100% yield and ee, can be 
accessed. 
Both approaches have been used for the synthesis of frontalin 7. The first, described 
in Section 3.2, used a kinetic resolution of racemic epoxyalcohol 41 which gave rise 
to enantiomerically pure (S)-41 (Scheme 15). Similarly, a desymmetrisation of 
prochiral epoxide 49 has also been reported (Scheme 18). 
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Scheme 18: Enzymatic desymmetrisation of oxirane-2,2-diylbis(methylene) diacetate 
49 towards the synthesis of (1S,2R)-frontalin 7. 
 
The optically active epoxide 50 is a versatile building block for the synthesis of 
tertiary alcohols. Initially, Seu and Kho reported a simple preparation of the chiral 
methyl substituted tertiary carbinol 51 via the asymmetric hydrolysis of oxirane-2,2-
diylbis(methylene) diacetate 49 with porcine pancreas lipase (PPL) in 92% ee and 
77% yield (Scheme 18) to obtain (R)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 
50.86 The results were further optimised with a lipase from Pseudomonas sp. to 
achieve the same isomer in 98.7% ee and 95% yield.87 
The ring-opening reaction of enantiopure epoxides is an attractive and powerful tool 
in asymmetric synthesis, and a high number of products can be synthesised by 
employing nucleophiles such as thiols, Grignard reagents, reducing agents, amines 
and alcohols, amongst others. 
Another example of a chiral epoxide as a useful building block is the synthesis of 
glycidyl sulfide 58 as an intermediate for the synthesis of chiral tertiary alcohols, 
reported by T. Itoh.88,89 They studied three pathways to prepare (R)-2-
(phenylthiomethyl)pent-4-ene-1,2-diol 57 (Scheme 19). Path A is a kinetic resolution 
of tertiary alcohol 52, whereas paths B and C employed enzymatic desymmetrisation. 
Unfortunately there was no enzyme capable of hydrolysing the acetate of compound 
52 and path B needs a tertiary hydroxyl protection with the expensive 2-(tri-
methylsilyl)ethoxymethyl (SEM). The best route to generate the chiral tertiary 
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alcohol 57 was following the asymmetric catalysis of the epoxide 55 with porcine 
pancreas lipase to generate the epoxy monoacetate 56 with 96% ee and 89% yield, 
path C. 
 
 
Scheme 19: Three pathways for the synthesis of 2-allyl-2-(phenylthiomethyl)oxirane 
58. 
 
A few routes to generate enantiopure tertiary alcohols have been introduced, paying 
particular attention to the enzymatic desymmetrisation of prochiral epoxides 
followed by nucleophilic ring-opening. This synthetic route is of interest due to its 
flexibility of generating chiral tertiary alcohols with various functionalities. The 
enzymatic ester hydrolysis or transesterification of a prochiral epoxide with 
hydrolases have been investigated to generate enantiopure products.  This process is 
followed by the ring-opening to achieve the final chiral tertiary alcohols. There are 
numerous synthetic methods to generate tertiary alcohols by epoxide ring-opening 
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with various functionalities. The following sections will introduce the synthesis of 
chiral β-amino tertiary alcohols in particular due to the importance of these 
compounds in medicinal chemistry and natural products.88-98 
 
4 SYNTHESIS OF CHIRAL β-AMINO TERTIARY ALCOHOLS 
Chiral β-amino tertiary alcohols are useful building blocks for the synthesis of 
biologically active compounds, and outlined in Scheme 20 are a number of 
interesting structures containing such a motif. β-Amino tertiary alcohols have been 
investigated for use as intermediates in the management of cardiovascular 
disorders,90 including hypertension91,92 and other conditions related to the 
sympathetic nervous system.93-97 This moiety is present in natural products and 
pharmacologically active compounds such as (+)-setoclavine 59 which has 
immunomodulatory activity.98 Hydroxy-azetidines 60 are another example of such 
compounds, and Renslo and co-workers demonstrated these linezolid analogues 
exhibited antibacterial activity.99 Paraherquamide A 61, which was first isolated from 
cultures of Penicillium paraherquei by Yamazaki and co-workers in 1981, displays 
potent anthelmintic activity and antinematodal properties.100,101 Similarly, the poison 
arrow frog toxin pumiliotoxin A 62 was isolated from the skin of the frog from the 
dendrobates species, and the anticancer compound vincristine 63, isolated from 
Catharanthus roseus, is a mitotic inhibitor used in cancer chemotherapy also possess 
a β-amino tertiary alcohol.102,103 Bacilosarcin A 64 was isolated from the marine 
bacterium Bacillus subtilis and exhibits antibacterial, cytotoxic and antiulcer 
activities.104-106 Finally, Sadeé and co-workers investigated the naloxone analogue 65 
as a possible treatment for opioid overdose.107-109 
The nucleophilic ring-opening of epoxides by amines is one of the most common 
reactions in synthetic organic chemistry. The results of such a reaction are a variety 
of β-amino alcohols, which represent a large number of intermediates present in 
biologically active natural products and synthetic chemistry building blocks. 
The classical approach for the synthesis of β-amino alcohols involves the treatment 
of epoxides with amines under thermal conditions, usually this procedure requires an 
excess of the amine and elevated temperatures.110 However, when poorly 
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nucleophilic and sterically hindered amines are used, yields of the corresponding β-
amino alcohols are usually poor and often necessitate the use of catalysts or 
promoters.111-121 The next sections describe some examples of generating β-amino 
tertiary alcohols using ring-opening reactions of epoxides. 
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Scheme 20: Structures of biologically active compounds or natural products 
containing a β-amino tertiary alcohols. 
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4.1 Epoxide ring-opening with amine nucleophiles using catalyst/promoters 
Various protocols have been developed to activate epoxides and make them more 
susceptible to nucleophilic ring-opening reactions.111-121 One such protocol utilises 
the surface of solids, like alumina or silica gel, to promote the reaction. An example 
was reported by Chakraborti and co-workers; they studied the ring-opening of the 
symmetrical epoxide cyclohexene oxide with different amines using 
chromatographic silica gel to promote the process (Scheme 21).122 The reaction was 
complete in 3 hours at room temperature, in the absence of solvent, using aromatic 
amines with different electronic properties such as aniline (90% yield), 4-
methylaniline (87% yield) and 4-chloroaniline (92% yield) to give the trans-2-
arylaminocyclohexanol products. The reaction also worked well with aliphatic 
amines such as pyrrolidine to give the trans-2-alkylaminocyclohexanol in 90% 
yield.122 
 
 
Scheme 21: Reaction of cyclohexene oxide with different amines in the presence of 
silica gel.122 
 
Shivani and co-workers reported on such protocols for the synthesis of this moiety 
using metal perchlorates, such as the commercially available zinc(II) perchlorate 
hexahydrate [Zn(ClO4)2·6H2O], to promote an epoxide ring-opening using various 
amines (Scheme 22).123 This new and highly active catalyst was found to catalyses 
epoxide ring-opening with a number of aromatic and aliphatic amines, obtaining β-
amino alcohols in high yields, under solvent-free conditions, at room temperature 
with high regioselectivities.123 
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Scheme 22: Epoxide ring-opening with amines in the presence of metal 
perchlorates.123 
 
To prevent the limitations of the classical procedure, such as elevated temperatures, 
long reaction times and low yields with poorly nucleophilic or sterically bulky 
amines, several activators/promoters, such as Lewis acids and lithium salts, have 
been investigated.124,125 Lithium perchlorate in Et2O (LPDE) catalyses the ring 
opening of epoxides using amines.126 Heydari and co-workers investigated the use of 
this catalyst to open different epoxides with various aromatic and aliphatic amines in 
high yields.127 One example is the epoxide ring-opening of 2,2-dimethyloxirane 72 
with aniline 67a to generate the symmetrical alcohol 73 in 98% yield (Scheme 23).127 
The reaction was highly regioselective, in all cases only one product was detected. 
However, the use of perchlorates is dangerous and the work-up with Lewis acids is 
often complicated by the emulsions formed and this procedure is normally unsuitable 
to perform on a large scale.112 
 
 
Scheme 23: Epoxide ring-opening with amines catalysed by LPDE. 
 
Epoxide ring-opening can also be catalysed by metal catalysts such (S)-(-)-BINOL-
Ti complexes.128-130 One example of this process was reported by Kureshy and co-
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workers in the asymmetric epoxide ring-opening of meso-stilbene oxide with aniline 
at room temperature (Scheme 24).131 The reaction was catalysed by (S)-(-)-BINOL-
Ti(OiPr)4 76 to give β-amino alcohol 75 in high yield (90%) and enantiomeric excess 
(78% ee) when triphenylphosphine was used as an additive. The enantioselectivity of 
the product was improved to 98% after a single recrystallisation step. The catalyst 
can be recovered after the use and recycled four times with retention of activity, 
making the process favourable for an industrial use. 
 
 
Scheme 24: Asymmetric catalytic ring-opening of meso-stilbene oxide with (S)-(-)-
BINOL-Ti complex 76.131 
 
Fagnou and co-workers investigated a possible catalyst for epoxide ring-opening 
with aromatic amines, [Rh(CO)2Cl]2.132 High yields, diastereo- and regioselectivities 
are obtained during the ring-opening of vinyl epoxides with aromatic amines in the 
presence of this catalyst to give trans-1,2-amino alcohols at room temperature under 
neutral conditions with selectivities exceeding 20:1. One example is the epoxide 
ring-opening of 7-oxabicyclo[4.1.0]hept-2-ene 77 with N-methylaniline in 91% yield 
(Scheme 25). Aliphatic amines failed to react under these conditions since the amine 
strongly binds to the rhodium metal destroying the catalyst. Aromatic amines are less 
basic than aliphatic amines, and consequently the bonding would be reduced. 
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Scheme 25: Rhodium-catalysed aminolysis of vinyl epoxides. 
 
4.2 Epoxide ring-opening with amine nucleophiles in water 
The preparation of β-amino alcohols in water is desirable, since water reduces the 
environmental impact of the reaction compared to conventional organic solvents.133 
However, purification of the reaction products on a large scale is sometimes difficult 
and certainly not always applicable on an industrial scale. Ring-opening of epoxides 
with a variety of amines, in water at room temperature have however been 
investigated.134-139 Two examples will be described involving such a process. The 
first example, a regioselective addition of amines in water, was reported by Azizi and 
co-workers.135 The reaction was performed by adding 1.2 equivalents of amine 80 to 
an epoxide 79, in water at room temperature, to give the β-amino alcohol product 81 
in 97% yields.135 In some cases, the β-amino alcohols precipitate from solution and 
are easily separated by filtration, but usually, extraction with organic solvent is 
required. The reaction rate of aminolysis in water depends on the structure of the 
epoxide and the nucleophilicity or bulky nature of the amine (Scheme 26).135 
 
 
Scheme 26: Aminolysis of 2-(phenoxymethyl)oxirane 79 with morpholine 80 in 
water.135 
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The second example is the catalytic asymmetric ring-opening of epoxide 76 with 
aromatic amines in water, reported by Azoulay and co-workers.136 The reactions 
were performed in the presence of 1 mol% of Sc(OSO3C12H25)3 and 1.2 mol% of a 
chiral bipyridyl ligand to produce the β-amino alcohols in high yields and 
enantioselectivities.136 The best result was obtained when the reaction was performed 
with N-methylaniline 67g in the presence of the catalyst (Scheme 27). 
 
 
Scheme 27: Catalytic asymmetric ring-opening of (2R,3S)-2,3-diphenyloxirane 76 
with N-methylaniline 67g. 
 
4.3 Epoxide ring-opening with amine nucleophiles using microwave 
irradiation 
Another technique that could be applied to asymmetric epoxide ring-opening is 
microwave irradiation.128,140-144 Microwave irradiation has revolutionised organic 
synthesis; a large number of compounds can now be constructed in a much reduced 
reaction time compared to that required by classical thermal conditions. This 
technique has been accepted rapidly as an important tool for the discovery of new 
drugs and the development of chemical processes.145 
Epoxide ring-opening by amines can also be conducted under microwave irradiation 
without the need of catalysts and under mild conditions.140 One example of this 
reaction was reported by Robin and co-workers.146 The microwave-assisted reaction 
can be performed cleanly with 1.5 equivalents of amine in ethanol in only 4 minutes 
at 140 ºC (80 W). They investigated the synthesis of a large number of β-amino 
Chapter 1: INTRODUCTION 
 
46 
 
alcohols using a variety of primary and secondary amines under short reaction times 
and in high yields.146 When the epoxide ring-opening of 2-(benzyloxymethyl)oxirane 
83 was performed with diethylamine 84 under microwave irradiation the 
corresponding β-amino alcohol 85 was obtained in 96% yield (Scheme 28). 
 
 
Scheme 28: Epoxide ring-opening of 2-(benzyloxymethyl)oxirane 83 with 
diethylamine 84 under microwave irradiation.146 
 
Different routes have been introduced for epoxide ring-opening with amines in high 
yields. In general, the use of catalysts increase the activity and selectivity of the 
reaction, microwave irradiation accelerates the reaction generating products in only a 
few minutes and the reaction can also be performed in water for a more 
environmentally friendly approach.  
 
5 AIMS 
Tertiary alcohols are a common functional group in many natural products, 
pharmaceuticals and agrochemicals (Figure 7). The ability to produce high 
enantiomerically pure tertiary alcohols is therefore an important goal in synthetic 
chemistry; especially important is the need to develop a general and flexible route to 
generate these compounds. 
 
                                                                    
Figure 7: A chiral tertiary alcohol. 
R1≠R2≠R3≠H 
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Only a few examples for generating enantiopure tertiary alcohols have been 
reported16,70,77-81,83 due to the unfavorable steric interactions resulting from the bulky 
substituents on the stereogenic centre, making them more difficult to access for 
biotransformations and chemical modifications; only a few hydrolases show activity 
towards tertiary alcohols.77,78,80,81 Moreover, a general and flexible route to generate 
chiral tertiary alcohols is not currently known. 
Our flexible synthetic route to generate chiral tertiary alcohols is via the enzymatic 
desymmetrisation of symmetrical epoxide 87 and it is outlined in scheme 29. The 
process starts with the epoxidation of commercially available 2-methylenepropane-
1,3-diol 86 to generate the prochiral epoxy diol 87. A subsequent biotransformation 
is performed to obtain the chiral epoxy monoacetate 50, following which, the 
epoxide may be opened with different nucleophiles (C, N, O, S, etc.) to generate 
chiral tertiary alcohols with different functionalities 92-97 (Scheme 32) from a 
common intermediate (Scheme 29). 
 
 
Scheme 29: Proposed general synthetic route to generate chiral tertiary alcohols via 
enzymatic desymmetrisation of an epoxide. 
 
The enzymatic desymmetrisation of prochiral compounds potentially can generate a 
single enantiomer in up to 100 % enantiomeric excess and yield.43,54,64,147 The 
biotransformation of prochiral diol 87 with the appropriate lipase, acyl donor and 
organic solvent would therefore achieve this goal (Scheme 29).148 Our aim is to 
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discover the optimum conditions to perform this biotransfomation and thus maximise 
the yield and enantiomeric excess of the products (Scheme 30), before opening the 
epoxide with various nucleophiles to generate enantiomerically pure tertiary 
alcohols. 
 
 
Scheme 30: Enzymatic desymmetrisation of prochiral epoxy diol 87. 
 
The enzymatic hydrolysis of oxirane-2,2-diylbis(methylene) diacetate 49 is known 
(Scheme 31).86 In 1992, Seu and Kho reported the hydrolysis of the epoxy diacetate 
49 with porcine pancreatic lipase (PPL) in acetone and phosphate buffer (pH 6.5) at 0 
°C for 7 hours to obtain the epoxy monoacetate (R)-50 in 77% yield and 92% ee. The 
enantiomerically pure epoxy monoacetate (R)-50, has been shown to be a useful 
building block for the synthesis of natural products, such frontalin 7,149 
bicyclomycin150 and α-tocopherol.151 
 
 
Scheme 31: Enzymatic hydrolysis of oxirane-2,2-diylbis(methylene) diacetate 49.86 
 
We aimed to develop an enzymatic route to generate enantiopure (2-
(hydroxymethyl)oxiran-2-yl)methyl acetate 50 in organic solvents thus enabling 
subsequent reactions to be performed in “one pot” avoiding further purifications 
thereby minimising waste and reducing costs. 37,54,147,152,153 Numerous organic 
products are not stable in aqueous solution and water is a poor solvent for industrial 
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chemistry.147 Thus, the possibility of performing the biotransformation in organic 
solvents would ease both product recovery and minimise side reactions. 
There are a number of nucleophiles that generate different chiral tertiary alcohols via 
opening enantiopure epoxides (Scheme 32). 125,127,135,154-157 It is anticipated that the 
nucleophilic epoxide ring-opening process will maintain enantiomeric purity and not 
give rise to racemic tertiary alcohols through racemisation processes (such as acyl 
transfer). 
Scheme 32 shows some examples of epoxide ring-opening with different 
nucleophiles138 such as sulfides,158,159 amines,160,161 allyl indium species, nitriles,162 
alcohols163 and Grignard reagents.164,165 
Amine nucleophiles were chosen to screen the epoxide ring-opening process to 
generate chiral β-amino tertiary alcohols.123,136,160,161,166-171 These products constitute 
an important class of well-known organic compounds that are important in natural 
and non-natural products.35,98,101,103,172-174 The epoxide ring-opening of (±)-(2-
(hydroxymethyl)oxiran-2-yl)methyl acetate 50 with different amines was 
investigated initially to generate β-amino tertiary alcohols via this process.  
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Scheme 32: Epoxide ring-opening with different nucleophiles. 
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The ability to produce high enantiomerically pure compounds is critical to the 
pharmaceutical industry, since the resolution of racemic products is difficult and 
expensive. For this reason, it is important to synthesise enantiomerically pure 
intermediates. 
It is important to use these compounds as intermediates for the synthesis of natural 
products and pharmaceutical compounds on an industrial scale since production of 
the unwanted enantiomer is kept to a minimum. If the yield and enantioselectivity is 
high, the reactions (desymmetrisation and epoxide ring-opening) could be carried out 
in “one pot” precluding the need for purification at the intermediates stages. This is 
an important consideration in industry where purification is expensive. 
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6 SYNTHESIS OF TARGETS 
6.1 Synthesis of oxirane-2,2-diyldimethanol 87 
The epoxidation of 2-methylenepropane-1,3-diol 86 with 1.1 equivalents of m-
chloroperoxybenzoic acid (m-CPBA) was achieved in 98% yield (Scheme 33). The 
product was purified using column chromatography, however traces of m-CPBA or 
m-CBA were detected using 1H-NMR when the reaction was performed on a larger 
scale. After further experimentation it was observed that the traces of m-CPBA/m-
CBA could promote the decomposition of epoxy diol 87 upon storage. With this in 
mind the reaction was performed always on small scale and repeated more often to 
obtain fresh and pure material for use in the biotransformation process. Epoxy diol 
87 was used in the enzymatic transesterification in organic solvents. 
 
 
Scheme 33: Synthesis of epoxy diol 87. 
 
6.2 Synthesis of oxirane-2,2-diylbis(methylene) diacetate 49 
The synthesis of oxirane-2,2-diylbis(methylene) diacetate 49 was achieved via three 
different routes, each generating the product in moderate yield but with good purity 
(Scheme 34). The synthesis of diacetate 49 was developed to perform the hydrolysis 
and obtain a sample of enantiopure epoxy monoacetate (R)-50 in order to optimise 
the GC conditions required to assign the (R)-isomer, reported in the literature.86 
The first synthetic route to epoxy diacetate 49 was the double acetylation of 3-
chloro-2-(chloromethyl)prop-1-ene 95 with sodium acetate in DMF followed by the 
epoxidation of the product with m-CPBA (Scheme 34, reaction A). 3-Chloro-2-
(chloromethyl)prop-1-ene 95 was studied due its low cost however only a 42% yield 
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The second and prefered route developed, started with the epoxidation of 2-
methylenepropane-1,3-diol 86 with m-CPBA followed by double acetylation with 2 
equivalents of acetyl chloride, triethylamine (TEA) and 4-dimethylaminopyridine 
(DMAP) to obtain the epoxy diacetate 49 in an overall yield of 73% (Scheme 34, 
reaction B).  
Scheme 34: Three methods for the synthesis of epoxy diacetate 49. 
 
In an attempt to improve the yield further the last method attempted for the synthesis 
of epoxy diacetate 49 proceeded via a diacetylation of 2-methylenepropane-1,3-diol 
86 with acetyl chloride, triethylamine and 4-dimethylaminopyridine in 100% yield, 
followed by epoxidation of the product with m-CPBA in only 55% yield (Scheme 19, 
reaction C). In this case the diacetylation is performed in quantitative yield but the 
epoxidation step proved more difficult, presumably due to the bulky acetates 
lowering accessibility and deactivating the double bond.  
We decided to use route B to generate the epoxy diacetate 49, due to the higher yield 
of the overall process, for all subsequent reactions.  
 
HO OH
Cl Cl
2. CH3COCl, TEA, DMAP, RT
1. CH3COONa, DMF, RT
2. m-CPBA, DCM, RT
42 % yield (2 steps)
1. CH3COCl, TEA, DMAP, RT
2. m-CPBA, DCM, RT
55% yield (2 steps)
1. m-CPBA, DCM, RT
HO OH
AcO OAc
O
73 % yield (2 steps)
A
B
C
86
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6.3 Synthesis of (±)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 
The synthesis of (±)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate (±)-50 was 
performed after monoacetylation of 2-methylenepropane-1,3-diol 86 using acetyl 
chloride, triethylamine and 4-dimethylaminopyridine, followed by epoxidation of the 
product with m-CPBA in 70% yield overall. The crude epoxidated product was 
difficult to purify by column chromatography since the epoxy monoacetate (±)-50 
appeared to be unstable under acidic media. The best method found to purify the 
epoxy monoacetate (±)-50 from m-CPBA and its by-product was by treating the 
reaction with K2CO3 (Scheme 35). 
Two equivalents of 2-methylenepropane-1,3-diol 86 were used to perform the 
monoacetylation and an increased yield from 68% (1 equivalent of 86) to 77% (2 
equivalent 86) was seen. The excess 2-methylenepropane-1,3-diol 86 was isolated 
and recycled.  
Racemic monoacetate (±)-50 was used to optimise the GC analysis conditions and 
generate racemic standards. 
 
HO OH
1. CH3COCl, TEA, DMAP, RT
2. m-CPBA, DCM/ RT
HO OAc
O
70 % yield (2 steps)86 (±)-50
 
Scheme 35: Synthesis of epoxy monoacetate (±)-50. 
 
7 ENZYME CATALYSIS TO GENERATE CHIRAL EPOXIDES 
7.1 Enzymatic desymmetrisation in buffer 
The biotranformation of oxirane-2,2-diylbis(methylene) diacetate 49 under buffered 
conditions to give (R)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate (R)-50 is 
known (Scheme 36).86,87 Reported by Seu and co-workers, the hydrolysis of diacetate 
49 in buffer solution with porcine pancreas lipase type II (PPL) generated acetate 
(R)-50 in 92% ee and 77% yield.86 
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Scheme 36: Hydrolysis of oxirane-2,2-diylbis(methylene) diacetate 49. 
 
There are examples in the literature reporting that lipases can catalyse the reaction in 
both directions, ie. perform ester hydrolysis and the transesterification process.64 
Initially, we wanted to develop the process in both directions, perform the reaction in 
water and organic solvents and therefore increase the flexibility for further chemical 
modifications. Most of the reactions for further modifications are suitable in organic 
solvents. When biotransformations are performed in water provides the advantage of 
minimising solvent waste and environmental impact during the reaction but, in this 
case the purification process is more difficult.The product needs to be extracted and 
purify for the next step making the process more unlikely for industrial scale. When 
the process is performed in organic solvents the purification is easier and the process 
can be performed in “one pot” making the process more likely to develop on 
industrial scale, minimising solvent waste and time. 
The synthesis of chiral tertiary alcohols was attempted initially by following the 
literature procedure. The hydrolysis of epoxide 49 using porcine pancreas lipase type 
II (PPL) in pH 6.5 buffer giving epoxy monoacetae (R)-50 in 80% yield and 76% 
enantiomeric excess. However this result could not be repeated reliably and thus we 
decided focus on the use of organic solvents.  
 
7.2 Enzymatic desymmetrisation in organic solvents 
The next sections detail a screening programme for the enzymatic desymmetrisation 
of oxirane-2,2-diyldimethanol 87 with a range of hydrolases and acyl donors in 
different organic solvents to give enantiopure (S)-(2-(hydroxymethyl)oxiran-2-
yl)methyl acetate 50 (Scheme 37). Then, a few immobilised enzymes were tested to 
improve further the scope of the reaction.  
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Scheme 37: Enzymatic desymmetrisation of oxirane-2,2-diyldimethanol, 87 in 
organic solvents. 
 
7.2.1 Screening conditions 
To our knowledge, the enzymatic desymmetrisation of epoxy diol 87 in organic 
solvents was unknown. Therefore, it was necessary to screen the reaction with 
different enzymes, acyl donors and organic solvents at various temperatures in an 
attempt to obtain high enantiomeric excess and yield.  
Due to the large number of possibilities, initially, we attempted the reaction on a 
small scale and estimated the conversion by TLC to establish enzymes activity. The 
best results, with respect to conversion, were repeated on a larger scale, purified and 
the enantiomeric excess was determinated by GC of isolated material (Table 1). 
The enzymatic desymmetrisation of epoxy diol 87 in organic solvents produced the 
(S)-isomer as expected due to the symmetry between the hydrolysis and 
transesterification reactions. The epoxy monoacetate 50 generated during the 
enzymatic desymmetrisation in organic solvents was analysed by GC and the results 
compared with those obtained from the hydrolysis of diacetate 49.  
 
 
Scheme 38: Enzymatic desymmetrisation of 87 in organic solvents. 
 
The enzymatic desymmetrisation of 87 with lipase B from Candida antarctica 
(CAL-B) gave low conversions and selectivities (Table 1, entries 1-6). The best 
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result of 20% ee in 12% yield was obtained when the reaction was performed with 
acetic anhydride in DCM at room temperature (Table 1, entry 5).  
Porcine pancreas lipase type II (PPL type II) was also examined in organic solvents 
and enantiomeric excesses were very low under all conditions (Table 1, entry 7-9). It 
appears, this enzyme is efficient for performing the hydrolytic process, (77% yield 
and 92% ee) (Scheme 31),86 but when performed in organic solvents, gave epoxy 
monoacetate 50 in only 21% yield and 19% ee (Table 1, entry 8). There are several 
documented cases, where enzyme selectivity (enantio-, regio- and chemoselectivity) 
changes with the solvent used.153 The enantioselectivity of an enzyme with the same 
substrate can be modified or even inverted going from water to organic solvents.175 
The role of water in an enzymatic reaction is to generate a specific activity, 
specificity and flexibility. The aqueous media generates specific interactions with the 
substrate and these are modified in the absence of water.176 
Further attempts to improve the reaction yields and ee’s resulted in the reaction being 
carried out with the enzyme Amano L, PS from Burkholderia cepacia (Pseudomonas 
cepacia) and enantiomeric excesses were significantly higher, but still too low to be 
synthetically useful (Table 1, entries 12-19). The best result was 66% ee when 
monoacetate (S)-50 was isolated in 62% yield. The reaction with this enzyme also 
gave the diacetylated product, oxirane-2,2-diylbis(methylene) diacetate, 49 in 40% 
yield (Table 1, entry 16).  
The final enzyme screened was Amano L, AK from Pseudomonas fluorescens (Table 
1, entries 20-30). This enzyme gave the best results with respect to enantiomeric 
excess; a 95% ee was obtained when the reaction was carried out with one equivalent 
of acetic anhydride, two weight equivalents of enzyme and DCM at 37 ºC for 0.5 
hour (Table 1, entry 30). Although, the reaction with Amano L, AK gave good 
enantiomeric excesses, the yield of monoacetylated product was very low (11%). 
After further experimentation it was discovered that the starting material had 
decomposed upon storage, which affected the process and therefore isolated yields. 
Thus, the reaction was optimised with pure starting material. 
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Table 1: Results of the enzymatic desymmetrisation of 87 in organic solvents.a 
Entry Enzyme 
Time 
(h) 
Temp. 
(ºC) 
Acyl 
donorb 
Solvent 
% 
50c 
% 
eed 
% 
49c 
1  1 25 VA CHCl3 30 6 14 
2  1 25 VA MTBE 38 4 21 
3 CAL-B 68 4 VA CHCl3 36 10 36 
4 Candida 68 4 VA MTBE 42 2 12 
5e antarctica 1 25 Ac2O DCM 12 20 56 
6e  1 25 iPrOAc DCM 48 12 10 
Entry Enzyme 
Time 
(h) 
Temp. 
(ºC) 
Acyl 
donorb 
Solvent 
% 
50c 
% 
eed 
% 
49c 
7 PPL 168 30 VA CHCl3 18 0 3 
8 Porcine pancreas 48 25 Ac2O DCM 21 19 5 
9e Type II 143 25 iPrOAc DCM 25 2 0 
10 CRL 192 30 VA CHCl3 10 0 0 
11e Candida rugosa 143 25 Ac2O DCM 6 0 0 
12  47 25 VA CHCl3 43 16 18 
13  62 25 VA EtOAc 32 23 62 
14  144 25 EtOAc EtOAc 38 38 18 
15 Amano L, PS 168 25 EtOAc CHCl3 - - - 
16 Pseudomonas 24 25 Ac2O DCM 62 66 40 
17 cepacia 24 25 iPrOAc DCM 2 20 0 
18e  22 25 Ac2O DCM 39 49 7 
19e  48 25 VA DCM 27 47 1 
20  18 25 VA CHCl3 22 1 12 
21  48 25 iPrOAc CHCl3 - - - 
22e  0.5 30 Ac2O CHCl3 3 82 2 
23e  4 25 Ac2O DCM 31 71 9 
24e Amano L, AK 3 0 Ac2O DCM 12 67 8 
25e Pseudomonas 2 30 Ac2O DCM 6 92 13 
26e fluorescens 0.5 30 Ac2O DCM 22 82 9 
27e  2 30 Ac2O DCM 9 68 10 
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28e Amano L, AK 0,5 37ºC Ac2O DCM 6 88 9 
29e Pseudomonas 1 30ºC Ac2O DCM 12 91 11 
30e fluorescens 0.5 37ºC Ac2O DCM 11 95 11 
a
 Biotransformations were carried out in organic solvent (0.1 M) using prochiral diol 
87 (100 mg), acyl donor (1 molar equivalent) and enzyme (1 weight equivalent). b 
Abbreviations: acetic anhydride (Ac2O), vinyl acetate (VA), iso-propylacetate 
(iPrOAc), ethyl acetate (EtOAc). c Isolated yield. d Results from GC of the crude 
reaction mixture. e Reactions performed with impure epoxy diol. 
 
7.2.2 Enzymatic desymmetrisation of 90 with Amano L, AK 
The biotransformation process with Amano L, AK was repeated with fresh and pure 
diol 87, at different temperatures and weight equivalents of enzyme in DCM (Table 
2). Using pure starting material led to an increase in the yield but unfortunately this 
was accompanied by a decrease in the enantiomeric excess.  
 
Table 2: Enzymatic biotransformation of 87 with Amano L, AK in DCM.a 
Entry 
Temperature 
(ºC) 
Time 
(h) 
Equivalent 
enzyme 
% 50b % eec % 49b 
1 0 22 2 51 62 5 
2 37 0.5 5 56 66 16 
3 37 4.5 0.5 49 73 7 
4 37 1.5 2 62 74 8 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride (1 molar equivalent) and Amano L, AK (2 weight equivalent). 
b
 Isolated yields. c Results from GC of the crude reaction.  
 
Comparing the best results of pure and impure material, the biotransformation 
process employing 2 weight equivalents of Amano L, AK at 37 ºC, the yield 
increased from 11% to 62% whilst the enantiomeric excess decreased from 95% to 
74% (Table 1, entry 11 and Table 2, entry 4). 
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Initially, it was believed that these differences could be due to impurities present in 
the starting material. When the reaction was carried out with impure material the 
proposed polymer impurity could potentially stabilise the enzyme, and thus we 
postulated that the use of additives would increase the enantiomeric excess whilst 
maintaining high yields and the results of these studies are displayed in the next 
section.  
 
7.2.3 Use of additives 
Certain additives are able to increase the performance of enzymatic hydrolysis in 
organic solvents.43,177-181 As such, a range of additives, for example: sodium chloride 
(NaCl), triethylamine (TEA), polyethyleneglycol (PEG) (Table 3) were screened in 
attempts to improve the selectivity of the enzyme.  
 
Table 3: Enzymatic biotransformation of 87 with Amano L, AK in DCM using 
various additives.a 
Entry Time (h) Additive 
Equivalent 
additive 
% 50b % eec % 49b 
1 1.5 NaCl 0.5 51 78 17 
2 1 TEA 0.5 45 81 17 
3 1.5 PEG 0.5 51 67 7 
4 1.5 NaCl 2 63 65 6 
5 1.5 TEA 2 50 62 7 
6 1.5 PEG 2 47 67 15 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride (1 molar equivalent), Amano L, AK (2 weight equivalent) and 
the additive. b Isolated yields. c Results from GC of the crude reaction mixture. 
 
Table 3 shows that the yields of epoxy monoacetate 50 are similar to the results with 
pure epoxy diol 87 in the absence of additives (Table 2). However, an 81% ee and 
45% yield was obtained when the reaction was carried out with 0.5 equivalents of 
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triethylamine (Table 3, entry 2). The ee values decreased when 2 equivalents of 
triethylamine were used (Table 3, entry 5).  
Based on these results, we believe that these differences were not due to the proposed 
polymer impurities present in the starting material but due to the biotransformation 
following a two-step process, Section 7.2.4. 
 
7.2.4 Two-step process 
Another potential reason for obtaining lower enantiomeric excesses (ee’s) with pure 
material could be that using the impure epoxy diol 87 leaves an excess of acyl donor. 
Failing to repeat the high enantiomeric excesses when performing the 
biotransformation with impure starting material (Table 1) we focussed our attention 
to varying the amount of acyl donor added to the reaction. When the reaction was 
carried out with impure starting material the acetic anhydride (acyl donor) was, 
unknown at the time, in excess, and therefore not completely consumed in the 
reaction.  
The enzymatic desymmetrisation of 87 using Amano L, AK gives the epoxy 
monoacetate 50 and epoxy diacetate 49 as a consequence of a two-step process. The 
first step is an enantioselective biotransformation followed by a second step, a kinetic 
resolution of the newly formed chiral material (Scheme 39). 
The enzymatic biotransformation of epoxy diol 87 gives both enantiomers of the 
desymmetrised material. The (S)-isomer is formed faster than the (R)-isomer. At the 
same time, a kinetic resolution of these enantiomers is performed by the enzyme, 
reacting faster with the (R)-isomer (Scheme 39). This two-step process increases the 
enantiomeric excess of the (S)-enantiomer considerably by removing the undesired 
(R)-enantiomer as a function of time, but with an associated decrease in the yield. It 
was therefore necessary to find a balance between high ee together with a 
synthetically useful yield. By varying the molar equivalents of acyl donor and the 
reaction time it is possible to increase each parameter independently, but 
unfortunately, when one increases the other decreases.55 
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Scheme 39: Enzymatic desymmetrisation of epoxy diol 87 with Amano L, AK and 
an excess of acyl donor. 
 
7.2.5 Kinetic resolution 
To confirm the selectivity of the second step of the two-step process and to better 
understand the biotransformation, a kinetic resolution of (±)-50 was performed 
(Scheme 40).  
 
Scheme 40: Kinetic resolution of (±)-50 with 2 weight equivalents of Amano L, AK 
and Ac2O in DCM at 37 ºC. 
 
To compare this result with the enzymatic desymmetrisation of 87, the kinetic 
resolution of (±)-50 was performed under the same conditions (see section 7.2.6), 
two weight equivalents of Amano L, AK and 1.8 molar equivalents of acetic 
anhydride in DCM at 37 ºC. The reaction was very fast, in only 30 minutes the 
process was complete giving (S)-50 in 99% ee and 20% yield, as well as epoxy 
diacetate 49 in 32% yield which will decrease in the amount of (S)-50 obtained in the 
process. Amano L, AK gaves good selectivity for the kinetic resolution of (±)-50, the 
 63 
 
second part of the two-step process; by removing the (R)-isomer it is possible to 
generate the (S)-enantiomer in very high ee.  
 
7.2.6 Equivalents of the acyl donor 
To optimise the two-step process, the enzymatic desymmetrisation with Amano L, 
AK was performed varying the equivalents of acetic anhydride (Figure 8). Increasing 
the amount of acetic anhydride in the biotransformation will provide enough acyl 
donor to remove the undesired (R)-isomer during the kinetic resolution of (±)-50. 
The biotranformation process using 1.8 equivalents of acetic anhydride gave 44% 
yield of (S)-50 in 96% enantiomeric excess (Apendix, Table 1). 
The enzymatic biotransformation with Amano L, AK gave a high enantiomeric 
excess with a moderate reaction rate. Biotransformations were carried out in DCM 
(0.1 M) using prochiral diol 87 (100 mg), different equivalents of acetic anhydride 
and 2 weight equivalents of Amano L, AK. Yields of (S)-50 were isolated and the 
ee’s were determined by GC (Appendix, Table 1 and 2).  
 
 
Figure 8: Graphical representation of the enzymatic desymmetrisation with different 
equivalents of acyl donor. Reactions were performed in DCM and Ac2O at 37 ºC for 
one hour. See Appendix, Table 1 and 2 for raw data. 
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As can be seen in Figure 8, the enantiomeric excess increases markedly when the 
amount of acetic anhydride increases from 1.2 to 1.5 equivalents (Figure 8, red line). 
As expected, the opposite trend is obtained with the yield of monoacetate (S)-50 
(Figure 8, blue line) along with an increase in the yield of epoxy diacetate 49 as 
enantiomer (R)-50 is consumed. The enzymatic biotransformation of epoxide 87 can 
proceed with a high enantiomeric excess, but with a decreasing yield of epoxy 
monoacetate (S)-50.55 
In summary, the kinetic resolution of (±)-50 generates the desired epoxide (S)-50 in 
99% ee and 20% yield whilst the enzymatic desymmetrisation generates the same 
enantiomer in 44% yield and 96% ee using, in both cases, 1.8 equivalents of Ac2O. 
The process was performed with the same commercially available starting material 
diol 86. Monoacetate (±)-50 was synthesised in two steps in 70% yield and one step 
for prochiral diol 87 in 98% yield (Scheme 41). It is concluded that the enzymatic 
desymmetrisation of prochiral diol 87 to generate (S)-50 is the most efficient route 
from diol 86. 
 
Scheme 41: Kinetic resolution vs enzymetic desymmetrisation. 
 
7.2.7 Enzymatic desymmetrisation as a function of time 
For a better understanding of the enzymatic process, the reaction was studied over 
different reaction times using 1.5 and 1.8 equivalents of the acyl donor. The results 
of the GC analysis of the crude reaction mixture are described below. 
 65 
 
The enzymatic desymmetrisation of epoxy diol 87 with 1.5 equivalents of acetic 
anhydride was very fast. In 40 minutes the enantiomeric excess was 99% and the 
monoacetate (S)-50 was isolated in 42% (Appendix, Table 3). 
To ascertain if we could maximise the yield under these conditions, we studied the 
reaction over the course of 1 hour. 
 
 
Figure 9: Graphical representation of the enzymatic desymmetrisation of prochiral 
diol 87 (10 mg) with 1.5 equivalents of Ac2O over 1 hour. Reactions were performed 
in DCM (0.1 M) at 37 ºC. Raw data in Appendix, Table 3. 
 
The enzymatic desymmetrisation with Amano L, AK with 1.5 equivalents of acetic 
anhydride, over 1 hour, shows an increasing enantiomeric excess of (S)-50 until it 
reaches a maximum after about 40 minutes (Figure 9, red line). The conversion of 
epoxy monoacetate (S)-50 increases very fast during the first 10 minutes to 55%. 
However, the conversion of epoxy monoacetate (S)-50 starts to decrease as the 
kinetic resolution of the enantiomers begins to occur (Figure 9, blue line). For the 
same reason, after the first 10 minutes of the reaction, the conversion of epoxy 
diacetate 49 increases very fast as a consequence of the kinetic resolution of (R)-50 
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(Figure 9, green line). The epoxy diol 87 is consumed within 30 minutes (Figure 9, 
violet line).  
The enzymatic desymmetrisation was also studied with 1.8 equivalents of acetic 
anhydride and as expected, it was observed to be faster than the biotransformation 
with 1.5 equivalents. Unfortunately, the yields of (S)-50 were lower along with 
concomitant higher enantiomeric excesses (compare Figures 9 and 10). 
Figure 10 depicts the same trends as Figure 9, but using 1.8 molar equivalents of 
acetic anhydride the enantiomeric excess increases faster than with 1.5 molar 
equivalents, as would be expected. The consumption of epoxy diol 87 using 1.8 
equivalents of acetic anhydride takes only 30 minutes, whereby the epoxy 
monoacetate 50 is achieved in 40% yield and 98% ee. 
 
 
Figure 10: Graphical representation of the enzymatic desymmetrisation of prochiral 
diol 87 (10 mg) with 1.8 equivalents of Ac2O over 1 hour. Reactions were performed 
in DCM (0.1 M) at 37 ºC. Raw data in Appendix, Table 4. 
 
In conclusion, the enzymatic desymmetrisation of 87 has been achieved with Amano 
L, AK, acetic anhydride in DCM at 37 ºC. The biotransformation occurs via a two 
step process whereby the enzymatic desymmetrisation of the epoxy diol 87 is 
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followed by a kinetic resolution of epoxy monoacetate 50. After optimisation of the 
reaction over an average of four repeat reactions, a 46% isolated yield and 97% 
enantiomeric excess was obtained when using 2 equivalents of acetic anhydride in 
DCM at 37 ºC in one hour.  
 
7.3 Enzymatic desymmetrisation with immobilised enzymes 
The enzymatic desymmetrisation of prochiral epoxy diol 87 could potentially 
generate a single enantiomer in 100 % enantiomeric excess and yield.182 If such a 
result could be achieved, it would minimise waste and post-reaction processing, 
therefore creating a process more appropriate for industry for the synthesis of 
enantiopure tertiary alcohols. In order to develop an enzymatic method to achieve 
this we focussed our attention on immobilised enzymes, where the enzyme is 
attached to a solid support in the hope of improving the desymmetrisation process. 
The immobilisation of enzymes is known to improve purification and recycling, 
since many enzymes are soluble in many solvents. The use of enzyme 
immobilisation makes separation from the reaction mixture very simple leading to 
the ability to scale-up the biotransformation making it applicable on an industrial 
scale. The selectivity and stability of enzymes may also be improved upon 
immobilisation. Many enzymes are not stable under operational conditions in a 
biotransformation process and can quickly lose their catalytic activity during the 
reaction.  Usually, enzymes suffer from denaturation by organic solvents, however, 
the increase in stability due to immobilisation can overcome this.43,183-189 
Attempts to improve our results of the enzymatic desymmetrisation of epoxy diol 87, 
led us to employ a kit of immobilised enzymes which were screened using different 
acyl donors (Scheme 42). The biotransformation was attempted with 9 lipases and 6 
proteases using 10 different acyl donors. The first screening was performed at 37 ºC 
in dichloromethane and the reactions were left until no further changes were 
observed by TLC. The conditions selected were consistent with the 
biotransformation with non-immobilised Amano L, AK (Section 7.2). 
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Scheme 42: Enzymatic desymmetrisation of oxirane-2,2-diyldimethanol 87 with 
immobilised enzymes. 
The kit of enzymes used was provided by Codexis and the acyl donors used were: 
acetic anhydride, vinyl acetate, iso-propylacetate, allyl acetate, pentyl acetate, ethyl 
acetate, 2-ethoxyethyl acetate, lauryl acetate, 2-methoxyphenyl acetate, and 2-
methoxyethyl acetate. The biotransformations were carried out on 10 mg of oxirane-
2,2-diyldimethanol 87 and the crude reaction mixture was injected directly into the 
GC to determine the enantiomeric excess and conversion of the product. The results 
of the enzymatic desymmetrisation of epoxy diol 87 with immobilised enzymes are 
shown in Table 4. 
Lipase A from Candida antarctica (NZL-101) presents low activity with the 
substrate (Table 4, entries 1-10). The enzyme is active with Ac2O generating acetate 
(S)-50 in 74% yield but low enantioselectivity, only 7% ee was obtained (Table 4, 
entry 1). Similar results were obtained with lipase B from Candida antarctica (NZL-
102), presenting moderate activity and low selectivity (Table 4, entries 11-20). 
Rhizomucor miehei (NZL-103) displayed higher activity and enantioselectivity with 
epoxy diol 87 (Table 4, entries 21-30). The reaction temperature, weight equivalents 
of enzyme, molar equivalents of acyl donor and the use of additives were all 
screened to optimise the biotransformation process with this enzyme vide infra. The 
enzyme displayed the highest activity and selectivity with acetic anhydride and vinyl 
acetate. A high enantiomeric excess (94%) was obtained using acetic anhydride with 
69% conversion to the desired product (S)-50 (Table 4, entry 21). In this case, 31% 
epoxy diacetate 49 was obtained due to the kinetic resolution described in Scheme 
39.  Optimisation and scaling-up of the process using acetic anhydride would be 
more difficult due to the need to remove the undesired diacetate by-product. In 
contrast, only 3% conversion to the epoxy diacetate 49 was observed when using 
vinyl acetate with this enzyme, the desired product obtained in 79% enantiomeric 
excess and 79% conversion (Table 4, entry 22). R. miehei appeared to be more 
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selective in the first step of the biotransformation using vinyl acetate due to the 
observed higher conversion and high enantiomeric excess (the kinetic resolution of 
the undesired enantiomer is kept to a minimum) than the process performed with 
Amano L, AK and Ac2O (the kinetic resolution remove the undesired enantiomer 
increasing the enantiomeric excess and decreasing the conversion of product). 
Therefore, the use of vinyl acetate would appear to be more suited for further study 
for this system.  
 
Table 4: Results of the enzymatic desymmetrisation of epoxy diol 87 with 
immobilised enzymes.a 
 
 
Entry Enzymeb Acyl donorc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
1  Ac2O 1 74 7 17 9 
2  VA 4 14 7 8 78 
3  iPrOAc 24 5 0 0 95 
4 NZL-101 AllylOAc 24 0 _ 0 100 
5 Lipase A from PentylOAc 93 0 _ 0 100 
6 Candida antarctica EtOAc 24 0 _ 0 100 
7  EthoxyethylOAc 48 0 _ 0 100 
8  LaurylOAc 24 0 _ 0 100 
9  MethoxyPhOAc 24 0 _ 0 100 
10  MethoxyethylOAc 24 0 _ 0 100       
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Entry Enzymeb Acyl donorc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
11  Ac2O 1 29 48 70 1 
12  VA 1 9 71 90 0 
13  iPrOAc 1 31 39 67 2 
14 NZL-102 AllylOAc 24 53 1 24 23 
15 Lipase B from PentylOAc 21 53 0 10 47 
16 Candida antarctica EtOAc 24 50 1 29 21 
17  EthoxyethylOAc 48 0 _ 0 100 
18  LaurylAc 24 49 1 11 40 
19 NZL-102 MethoxyPhAc 24 29 2 71 0 
20  MethoxyethylAc 24 52 0 30 17 
21  Ac2O 1 69 94 31 0 
22  VA 1 79 79 3 18 
23  iPrOAc 24 11 60 0 89 
24 NZL-103 AllylOAc 24 5 20 0 95 
25 Lipase from PentylOAc 93 0 _ 0 100 
26 Rhizomucor miehei EtOAc 24 0 _ 0 100 
27  EthoxyethylOAc 48 0 _ 0 100 
28  LaurylOAc 24 0 _ 0 100 
29  MethoxyPhOAc 24 0 _ 0 100 
30  MethoxyethylOAc 24 0 _ 0 100 
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Entry Enzymeb Acyl donorc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
31  Ac2O 1 56 9 7 37 
32  VA 4 61 14 32 6 
33 NZL-104 iPrOAc 24 9 11 0 91 
34 Lipase from AllylOAc 24 8 11 0 92 
35 Thermomyces PentylOAc 93 0 _ 0 100 
36 lanuginosus EtOAc 24 0 _ 0 100 
37  EthoxyethylOAc 48 0 _ 0 100 
38  LaurylOAc 24 0 _ 0 100 
39 NZL-104 MethoxyPhOAc 24 4 15 0 96 
40  MethoxyethylOAc 24 0 _ 0 100 
41  Ac2O 1 20 79 80 0 
42  VA 1 40 55 58 1 
43 NZL-105 iPrOAc 24 13 10 0 87 
44 Lipase from AllylOAc 24 4 26 0 96 
45 Thermomyces PentylOAc 93 0 _ 0 100 
46 lanuginosus, EtOAc 24 0 _ 0 100 
47 Mutant 1 EthoxyethylOAc 48 0 _ 0 100 
48  LaurylOAc 24 0 _ 0 100 
49  MethoxyPhOAc 24 32 4 0 68 
50  MethoxyethylOAc 24 3 25 0 97 
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Entry Enzymeb Acyl donorc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
51  Ac2O 1 29 46 69 2 
52  VA 1 10 40 90 0 
53 NZL-106 iPrOAc 24 53 5 13 34 
54 Lipase from AllylOAc 24 41 5 4 55 
55 Thermomyces PentylOAc 93 0 _ 0 100 
56 lanuginosus, EtOAc 24 12 5 0 88 
57 Mutant 2 EthoxyethylOAc 48 0 _ 0 100 
58  LaurylOAc 24 0 _ 0 100 
59  MethoxyPhOAc 24 37 5 2 61 
60 NZL-106 MethoxyethylOAc 24 9 16 0 91 
61  Ac2O 1 26 3 72 1 
62  VA 1 22 1 76 1 
63 NZL-107 iPrOAc 1 14 2 86 0 
64 Lipase accepting bulky AllylOAc 24 53 1 27 20 
65 substrates PentylOAc 21 45 0 12 43 
66 Fungal mutant EtOAc 24 51 1 38 11 
67  EthoxyethylOAc 48 0 _ 0 100 
68  LaurylOAc 24 50 1 38 12 
69  MethoxyPhOAc 24 0 _ 0 100 
70  MethoxyethylOAc 24 55 1 15 30 
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Entry Enzymeb Acyl donorc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
71  Ac2O 1 75 18 16 8 
72  VA 4 53 27 3 44 
73  iPrOAc 24 21 11 0 79 
74 NZL-108 AllylOAc 24 3 15 0 97 
75 Lipase broad range PentylOAc 93 0 _ 0 100 
76 Fungal EtOAc 24 0 _ 0 100 
77  EthoxyethylOAc 48 0 _ 0 100 
78  LaurylOAc 24 0 _ 0 100 
79  MethoxyPhOAc 24 4 14 0 96 
80  MethoxyethylOAc 24 0 _ 0 100 
81  Ac2O 1 34 9 66 0 
82  VA 4 73 24 22 5 
83  iPrOAc 24 35 18 1 64 
84 NZL-109 AllylOAc 24 17 12 0 83 
85 Lipase broad range PentylOAc 93 0 _ 0 100 
86 Fungal mutant EtOAc 24 0 _ 0 100 
87  EthoxyethylOAc 48 0 _ 0 100 
88  LaurylOAc 24 0 _ 0 100 
89  MethoxyPhOAc 24 8 12 0 92 
90  MethoxyethylOAc 24 0 _ 0 100 
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a
 Biotransformations were carried out in dichloromethane (0.1 M) at 37 ºC using 
prochiral diol 87 (10 mg), acyl donor (1 equivalent) and immobilised enzyme (1 
weight equivalent) (biotransformations were followed by TLC until no further 
changes were seen). b Enzyme provided by Codexis. cAbbreviations: acetic 
anhydride (Ac2O), vinyl acetate (VA), iso-propyl acetate (iPrOAc), allyl acetate 
(AllylOAc), pentyl acetate (PentylOAc), ethyl acetate (EtOAc), 2-ethoxyethyl 
acetate (EthoxyethylOAc), laury acetate (LaurylOAc), 2-methoxyphenyl acetate 
(MethoxyPhOAc), 2-methoxyethyl acetate (MethoxyethylOAc). d Results from GC 
of the crude reaction mixture. 
 
Another enzyme tested was a lipase from Thermomyces lanuginosus (NZL-104) 
which resulted in poor activity and selectivity with the substrate (Table 4, entries 31-
40). Codexis provided two mutants of this enzyme (Table 4, entries 41-60), the first 
(NZL-105) gave the product with high ee, 79% when Ac2O was used but in 20% 
yield (Table 4, entry 41). The second mutant (NZL-106) generated the product in 
46% ee and 29% yield (Table 4, entry 51).  
Finally three more lipases from a fungus were tested (NZL-107, NZL-108 and NZL-
109) with little success (Table 4, entries 61-90). In all cases the enzyme generated 
the product in low yields and poor enantiopurities. 
Five immobilised proteases were also screened using the same acyl donor unders the 
same reaction conditions however, none of them gave successful results (see data in 
Appendix, Table 5). 
 
7.3.1 Equivalents of R. miehei used 
Attempts to improve the yield and enantiomeric excess of the desymmetrised product 
(S)-50 using the lipase from R. miehei with vinyl acetate were undertaken with 
varying molar equivalents of the enzyme.  
Reducing the amount of enzyme only served to slow down the process and did not 
improve either the enantiomeric excess or yield (Table 5). Interestingly, increasing 
the equivalents of enzyme in the reaction gave higher enantiomeric excesses, such 
that using 2 weight equivalents of enzyme resulted in 99% ee but with only 24% 
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conversion obtained (Table 5, entry 4). Whilst using 1 weight equivalent of enzyme a 
81% ee was achieved but accompanied by a substantial increase in product 
conversion (90%) in 8 hours (Table 5, entry 3). Gratifyingly, the conversion of epoxy 
diacetate 49 in the process with 1 weight equivalent of enzyme was very low (Table 
5, entry 3). These results are consistent with a second kinetic resolution of 
desymmetrised product (see scheme 39) and a simultaneous increase in the amount 
of the epoxy diacetate 49 to 76% when using 2 weight equivalents of the enzyme 
(Table 5, entry 4).  
 
Table 5: Enzymatic biotransformation of 87 using different equivalents of R. miehei.a 
Entry 
Weight 
equivalent 
enzyme 
Time (h) % 50b % eeb % 49b % 87b 
1 0.2 24 22 41 0 78 
2 0.5 24 36 64 0 36 
3 1 8 90 81 4 6 
4 2 8 24 99 76 0 
a
 Biotransformations were carried out in dichloromethane (0.1 M) using prochiral 
diol 87 (10 mg), vinyl acetate (1 equivalent) and the correspondent weight equivalent 
of the immobilised R. miehei at 37 ºC. b Results from GC of the crude reaction 
mixture. 
 
The enzymatic desymmetrisation of epoxy diol 87 was further optimised with 1 
weight equivalent of enzyme (see below). 
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7.3.2 Temperature of the reaction 
Table 6: Enzymatic biotransformation of compound 87 using different reaction 
temperatures.a 
Entry Temperature (ºC) % 50b % eeb % 49b % 87b 
1 0 88 85 11 1 
2 25 82 89 18 0 
3 37 90 81 4 6 
a Biotransformations were carried out in dichloromethane (0.1 M) using prochiral-
diol 87 (10 mg), vinyl acetate (1 equivalent) and immobilised R. miehei (1 weight 
equivalent) for 8 hours. b Results from GC of the crude reaction mixture. 
It was found that the temperature of the reaction plays a small role in the process. At 
25 ºC the enzyme displayed optimum selectivity, but, due to the two-step 
biotransformation process (Scheme 39), when the enantiomeric excess increases the 
conversion of the epoxy monoacetate 50 decreases (Table 6). 
 
7.3.3 Equivalents of acyl donor 
The process was also studied by varying the amount of acyl donor (1.1 to 1.5 molar 
equivalents) at different temperatures (Table 7).  
A big difference was observed with respect to enantiomeric excess and yields upon 
increasing the amount of vinyl acetate over all temperatures. The enantiomeric 
excess increases rapidly with a concominant decrease in the conversion of the epoxy 
monoacetate (S)-50 at all temperatures. Simultaneously, a higher proportion of epoxy 
diacetate 49 was obtained as expected, concluding that 1 equivalent of vinyl acetate 
is optimal for future optimisation. 
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Table 7: Enzymatic biotransformation of diol 87 using different equivalents of vinyl 
acetate at different reaction temperatures.a 
Entry Temperature (ºC) Equivalents acyl donor % 50b % eeb % 49b 
1 37 1.1 12 99 88 
2 37 1.3 9 99 91 
3 37 1.5 8 99 92 
4 25 1.1 36 98 64 
5 25 1.3 22 99 78 
6 25 1.5 21 99 79 
7 4 1.1 21 99 79 
8 4 1.3 25 99 75 
9 4 1.5 20 99 80 
a Biotransformations were carried out in dichloromethane (0.1 M) using prochiral 
diol 87 (10 mg), vinyl acetate (see table) and immobilised R. miehei (1 weight 
equivalent) for 8 hours at different reaction temperatures. b Results from GC of the 
crude reaction mixture. 
 
 
7.3.4 Enzymatic desymmetrisation over time 
The enzymatic desymmetrisation of diol 87 over time was studied using 1 equivalent 
of vinyl acetate in dichloromethane at 37 ºC. The results were comparable with 
Amano L, AK (compare Figure 11 with Figures 9 and 10), but over a longer reaction 
period.  
The enzymatic desymmetrisation of 87 with R. miehei underwent the same two-step 
process as when the biotransformations were performed with Amano L, AK (Scheme 
39). However, in this case, the enzyme is more selective in the first step due to the 
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higher conversion to (S)-50, and consequently a smaller amount of the (R)-50 for 
removal in the kinetic resolution step.  
 
 
Figure 11: Graphical representation of the enzymatic desymmetrisation of diol 87 
with R. miehei and vinyl acetate at 37 ºC in dichloromethane over 8 hours. Raw data 
in Appendix, Table 6. 
 
7.3.5 Use of additives 
Immobilised enzymes are more stable in organic solvents and all reactions described 
herein were run with molecular sieves (4Å) to minimise water in the reaction. 
However, the use of water as an additive can stabilise the enzyme and increase 
selectivity.43  
In order to test this hypothesis the biotransformation was performed with 0.1 to 0.5 
molar equivalents of water. The results show that the ee decreased significantly from 
94% to 58% on addition of 0.1 equivalents of water (Table 8, entries 1 and 2). The 
decrease in enantiomeric excess when the reaction was performed in the presence of 
water is presumably due to the non-selective hydrolysis of epoxy diacetate 49 
produced during the reaction which lowers the overall ee. 
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Table 8: Results of the enzymatic biotransformation of 87 and the corresponding 
additive.a 
Entry Additive 
Equivalents 
additive 
% 50b % eeb % 49b % 87b 
1 _ _ 34 94 66 0 
2 H2O 0.1 47 58 49 4 
3 H2O 0.3 53 48 39 8 
4 H2O 0.5 59 57 35 6 
5 TEA 0.1 86 82 13 0 
6 TEA 0.3 82 7 10 8 
a Biotransformations were carried out in dichloromethane (0.1 M) using prochiral 
diol 87 (10 mg), vinyl acetate (1.1 equivalents), immobilised R. miehei (1 weight 
equivalent) and the corresponding additive (see table) for 5 hours at 37 ºC. b Results 
from GC of the crude reaction mixture. 
 
 
Triethylamine is a common additive in biotranformations and an increase in 
selectivity was obtained when Amano L, AK was used with Ac2O (Section 7.2.3, 
Table 3, entry 2).43,190 Unfortunately, when R. miehei was used with 0.1 mol% of 
triethylamine, the ee decreased from 94% to 82% but surprisingly, the product yield 
increased from 34% to 86% when the biotransformation was incubated for 5 hours 
(Table 8, entries 1 and 5). However, 90% epoxy monoacetate (S)-50 with 81% ee 
was produced during the biotransformation without additives over 8 hours (Table 6, 
entry 3). 
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7.3.6 Organic solvents. 
Enzymatic regio- and enantioselectivity is remarkably dependent on the nature of the 
organic solvent.153 As such, in our studies, the lipase-catalysed transesterification of 
epoxy diol 87 was investigated employing immobilised R. miehei and vinyl acetate in 
different organic solvents (Table 9).  
The biotransformation worked best in dichloromethane with respect to the 
conversion of product and enantiomeric excess (Table 9, entry 1). Chloroform and 
dioxane improved the selectivity of the enzyme slightly but in both cases the 
conversion of product decreased drastically (Table 9, entries 3 and 9).   
 
Table 9: Results of the enzymatic biotransformation of 87 with immobilised R. 
miehei in different organic solvents.a 
Entry Time (h) Solvent % 50b % eeb % 49b % 87b 
1 5 DCM 90 81 4 6 
2 48 1-Hexene 0 _ 100 0 
3 48 CHCl3 12 87 88 0 
4 48 Toluene 4 0 96 0 
5 48 THF 40 91 58 2 
6 48 Acetone 65 69 14 21 
7 24 DMSO 0 _ 0 100 
8 24 DMF 0 _ 0 100 
9 24 Dioxane 24 89 76 0 
10 24 Pyridine 0 _ 0 100 
11 24 Et2O 0 _ 0 100 
12 24 Pentane 15 4 85 0 
 81 
 
13 24 Cyclohexane 4 18 96 0 
14 24 Dodecane 0 _ 0 100 
a Biotransformations were carried out in the corresponding organic solvent (0.1 M) 
using prochiral diol 87 (10 mg), vinyl acetate (1 equivalent), immobilised R. miehei 
(1 weight equivalent) at 37 ºC (biotransformations were monitored by TLC until no 
further changes were detected). b Results from GC of the crude reaction mixture. 
 
 
7.3.7 Rhizomucor miehei immobilised as a CLEA 
Due to the improved results obtained using immobilised enzymes, an alternative 
enzyme immobilisation technique was examined. In this case, R. miehei was used as 
a cross-linked enzyme aggregate (CLEA). CLEA methodology involves the 
precipitation of the enzyme and the additional chemical cross-linking of the protein 
aggregate.191-195 
The enzymatic desymmetrisation of diol 87 was performed with 1 weight equivalent 
of R. miehei CLEA in DCM, using vinyl acetate at 37 ºC. The biotransformation was 
incubated for 5 hours and the crude reaction mixture was analysed by GC. The 
reaction gave the desired product with 13% conversion and 90% ee. Unfortunately, 
CLEA immobilisation did not improve the results as desired although the use of 
different immobilisation methods can potentially modify the enantio- and 
regioselectivity of enzymes in a biotransformation.44 
 
7.3.8 Non-immobilised enzyme 
So far, a different enzyme had been used for the enzyme immobilisation work 
compared to previous work without immobilisation (Amano L, AK from P. 
fluorescens), therefore we deemed it necessary to compare the results more directly 
by using non-immobilised R. miehei.  
The reaction was carried out with a non-immobilised lipase from R. miehei in 
dichloromethane (0.1 M), using vinyl acetate (1 equivalent) at 37 ºC. The 
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biotransformation was incubated for 8 hours and the crude reaction mixture was 
analysed by GC which gave the same product, (S)-(+)-50, in 75% conversion (81% 
ee), demonstrating the success of immobilisation on this enzymatic desymmetrisation 
(90% conversion and 82% ee). The enzymatic desymmetrisation of diol 87 has been 
optimised from non-immobilised Pseudomonas fluorescens (46% yield of (S)-50 
(97% ee)) to immobilised Rhizomucor miehei (90% conversion of (S)-50 (81% ee)).  
 
7.4 Silica encapsulation of Amano L, AK. 
Due to the improved yield observed using immobilised Rhizomucor miehei on a solid 
support from Codexis, and comparing this result with the same reaction performed 
with free enzyme under the same conditions, we wanted to apply the reaction to 
immobilised Amano L, AK.  
We tried initially a commercially available immobilised enzyme. Lipase immobilised 
on Sol-Gel-AK from Pseudomonas fluorescens was tested using 1 equivalent of 
Ac2O in dichloromethane and the biotransformation was incubated at 37 ºC for 3 
hours to generate (S)-50 in 50% yield and 74% ee. Sol-Gel is a chemical synthesis to 
produce gels, glasses, and ceramic powders. The Sol-Gel process generally involves 
the use of metal alkoxides, which undergo via hydrolysis and condensation to give 
polymerization reactions and synthetise gels. 
The biotransformation was performed with Ac2O to be consistent with the acyl donor 
used with non-immobilised Amano L, AK. Comparing this result with the non-
immobilised Amano L, AK under the same conditions, the selectivity maintains 
roughly constant but the conversion to products decreases when immobilised 
Pseudomonas fluorescens was used. The contact of an enzyme with a support may 
modify its activity due to the interactions between enzyme and carrier.43 With this in 
mind, it was considered that not all the solid supports would increase the activity of 
the enzyme for our biotransformation. However, no information available from 
Codexis was on the support used to immobilise their enzyme. For this reason, the 
immobilisation of Amano L, AK encapsulated on silica was employed; this work was 
performed in collaboration with the University of Strathclyde (Scheme 43). 
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Scheme 43: Enzymatic desymmetrisation of 87 with silica-immobilised Amano L, 
AK. 
  
The immobilisation technique used to encapsulate the enzyme was via an entrapment 
into inorganic matrix such as silica gel.196 This entrapment is a mild immobilisation 
method where the biocatalyst is physically encaged in a macroscopic matrix. This 
immobilisation constitutes an inorganic matrix with a highly stable porous matrix 
that grows around the enzyme in a three-dimensional space. Sol-gel aggregates 
exhibit higher stability towards changes in temperature, pH and mechanical stability 
than other biological matrices such agar gels or alginate gels.43,184 
Many studies have been reported with lipase immobilisation in silica using different 
techniques such as cross-linking,185,186 covalent coupling183 and entrapment,188 
increasing the activity, stability, selectivity and recycling of the enzyme. 
Amano L, AK was immobilised in silica with sodium metasilicate (Si-Na), 
pentaethylenehexamine (PEHA), a catalyst for silica formation, distilled/deionised 
water (ddH2O) and the enzyme required for the entrapment.  
The biotransformation with immobilised Amano L, AK on silica was performed on a 
10 mg scale and the crude reaction mixture was injected into the GC to determine the 
yield and optical purity of 50. The immobilisation of the enzyme on silica provided 
us with four different samples and their supernatants, two blanks at different pHs 
(sample 1 at pH 3 and sample 2 at pH 6.5) and their corresponding supernatants (sup. 
1 and sup. 2 respectively), two samples with immobilised of Amano L, AK at 
different pHs (sample 3 at pH 8 and sample 4 at pH 7) and their corresponding 
supernatants (sup. 3 and sup. 4 respectively). Initially, the biotransformations were 
performed with 2 weight equivalents of immobilised Amano L, AK on silica and 1.5 
molar equivalents of Ac2O in DCM and the samples were incubated at 37 ºC. Ac2O 
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was used as acyl donor due to the higher enzyme selectivity exhibited in previous 
work with non-immobilised Amano L, AK (Section 7.2).  
The reaction with blanks and their corresponding supernatants were performed under 
the described conditions and the reaction yielding up to 4% product (S)-50 (Table 10, 
entries 1 and 2; table 11, entries 1 and 2; table 12, entry1).  
The biotransformation was performed with the encapsulated enzyme and surprisingly 
the activity increased whilst maintining its high selectivity. Amano L, AK 
immobilised on silica at pH 8 carried out the biotransformation generating (S)-50 in 
76% yield and 95% ee (Table 10, entry 3). The biotransformation with non-
immobilised Amano L, AK, performed under the same conditions, gave (S)-50 42% 
yield and 97% ee (Appendix, Table 1) concluding that the enzyme has a better 
activity when immobilised on silica.  
The activity of this immobilised enzyme increases but the supernatants of the 
corresponding samples also exhibit activity and selectivity for the substrate 90. The 
supernatant of sample 4 catalysed the biotransformation achieving the desired 
enantiomer in 74% yield and 93% ee (Table 10, entry 9)! Supernatants contains 
enzyme that was not immobilised. When the encapsulation is efficient, the 
concentration of enzyme in the supernatants should be zero and therefore inactive 
with the substrate. Since it is difficult to estimate the amount of enzyme encapsulated 
on silica we used the following assay: the supernatants were collected and the mass 
of enzyme present in the supernatants was determined (a mg) by a standard enzyme 
assay or a protein assay (e.g. Bradford).197 From this estimation and with the mass of 
enzyme present initially (45 mg in 30 mL batch), the difference (b = 45- a) will be 
the mass of enzyme present on silica. 
Enzyme encapsulation efficiency (%) = b*100/45. 
In this case, we obtained 64.9 mg for sup.3 and 69.5 mg for sup.4 giving negative 
enzyme encapsulation efficiency. The weight of supernatant after freeze-drying was 
higher than initially used for the encapsulation. The immobilisation method should 
be repeated due to the unusual results obtained. 
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Table 10: Results of enzymatic desymmetrisation of epoxy diol 87 with 2 weight 
equivalents of immobilised Amano L, AK on silica.a 
Entry Name Description Time (h) % 50b % eeb % 49b 
1 1  ‘blank’ (pH 3) 1 4 50 0 
2 2  ‘blank’ (pH 6.5) 1 1 50 0 
3 3  Silica-enzyme (pH 8) 1 76 95 21 
4 4  Silica-enzyme (pH 7) 1 67 89 9 
5 Sup. 1 Supernatant sample 1 1 3 50 0 
6 Sup. 2 Supernatant sample 2 1 4 50 0 
7 Sup. 3 Supernatant sample 3 1 33 78 2 
9 Sup. 4 Supernatant sample 4 1 74 93 23 
a
 Biotransformations were carried out in dichloromethane (0.1 M) at 37 ºC using 
prochiral diol 87 (10 mg), Ac2O (1.5 molar equivalent) and immobilised Amano L, 
AK (2 weight equivalent) for 1 hour. bResults from GC of the crude reaction mixture. 
 
As the enzyme encapsulation on silica was performed on a small scale the 
biotransformations were performed under the same conditions but using only 1 
weight equivalent of enzyme to investigate if an excess of catalyst was required. The 
same biotransformations were performed without drastic modification; in this case 
the reactions with the blank only gave 1% yield of product due to the reduction of 
silica in the reaction mixture (Table 11, entry 1 and 2). 
As commented before, again there is active enzyme in the supernatant solution; in 
this case the solid dried from sup. 3 gave (S)-50 in 70% yield and 98% ee (Table 11, 
entry 10). More studies of the immobilisation and biotransformations are required to 
understand these unusual results.  
With these interesting results it was decided to scale-up the immobilisation of 
Amano L, AK and screen more reaction conditions. 
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Table 11: Results of enzymatic desymmetrisation of epoxy diol 87 with 1 weight 
equivalent of immobilised Amano L, AK on silica.a 
Entry Name Description Time (h) % 50b % eeb % 49b 
1 1 ‘blank’ (pH 3) 1 1 50 0 
2 2 ‘blank’ (pH 6.5) 1 1 50 0 
3 3 Silica-enzyme (pH 8) 1 75 95 22 
4 4 Silica-enzyme (pH 7) 1 73 91 20 
5 Sup. 1 Supernatant sample 1 1 1 50 0 
6 Sup. 1 Supernatant sample 1 5 1 50 0 
7 Sup. 2 Supernatant sample 2 1 2 50 0 
8 Sup. 2 Supernatant sample 2 5 1 50 0 
9 Sup. 3 Supernatant sample 3 1 29 78 1 
10 Sup. 3 Supernatant sample 3 5 70 98 30 
11 Sup. 4 Supernatant sample 4 1 19 76 1 
12 Sup. 4 Supernatant sample 4 5 54 66 4 
a
 Biotransformations were carried out in dichloromethane (0.1 M) at 37 ºC using 
prochiral diol 87 (10 mg), Ac2O (1.5 molar equivalent) and immobilised Amano L, 
AK (1 weight equivalent) for 1 hour. bResults from GC of the crude reaction mixture. 
 
The encapsulation of Amano L, AK on a larger scale, 180 mg of free enzyme, 
produced 212.3 mg of enzyme encapsulated onsilica and 88 mg of freeze-dried 
supernatant with an encapsulation efficiency of 51%. In this case, the immobilisation 
was only performed at pH 7 generating two samples (sample 1: blank; sample 2: 
Amano L, AK on silica; sup. 2: supernatants of sample 2).  
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Table 12: Results of enzymatic desymmetrisation of epoxy diol 87 with 1 weight 
equivalent of immobilised Amano L, AK on silica.a 
Entry Name Description Time (h) % 50b % eeb % 49b 
1 1 ‘blank’ (pH 6.5) 1 1 50 0 
2 2 Silica-enzyme (pH 7) 1 66 84 7 
3 2 Silica-enzyme (pH 7) 5 59 >99 41 
4 Sup. 2 Supernatant sample 3 1 7 63 0 
5 Sup. 2 Supernatant sample 3 5 26 60 1 
a
 Biotransformations were carried out in dichloromethane (0.1 M) at 37 ºC using 
prochiral diol 87 (10 mg), Ac2O (1.8 molar equivalent) and immobilised Amano L, 
AK (1 weight equivalent) for 1 hour. bResults from GC of the crude reaction mixture. 
 
As we wanted to screen more reaction conditions with the immobilised enzyme, the 
biotransformations were performed using 1.8 molar equivalents of Ac2O. Following 
the two step process, the expected results were an increase in the optical purity with a 
concominant decrease in the yield. Surprisingly, optical purity and yield decreased 
when the biotransformations were performed with 1.8 equivalents of Ac2O (compare 
results from tables 11 and 12). The biotransformation performed with sample 2 
generated (S)-50 with 66% yield and 84% ee in 1 hour (Table 12, entry 2) but when 
the reaction was incubated longer, (S)-50 was obtained in 59% yield and >99% ee 
(Table 12, entry 3). In this case, the optical purity of (S)-50 was excellent but the 
yield of reaction decreased as expected. The enzyme isolated from the supernatant 
(sup. 2) performed the reaction in very low yield presumably due to an encapsulation 
efficiency of 50%.  
To determine if the immobilisation of the enzyme on a larger scale provides the same 
activity and selectivity as on small scale, the enzymatic desymmetrisation of diol 87 
was performed using 1 weight equivalent of immobilised Amano L, AK, 1.5 molar 
equivalents of Ac2O in DCM and the reaction was incubated for 1 hour. The results 
gave (S)-50 in 71% yield and 84% ee, with a decreasing on yield from 73% to 71% 
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and the enantiomeric excess from 91% to 84%. The encapsulation efficiency and the 
biotransformation results changed when the process was scaled-up due to unknown 
factors. Unfortunately, there was no more time to continue developing the 
immobilisation process, however the initial results of the biotransformation shows 
that the immobilised of Amano L, AK on silica improved the activity of the enzyme. 
 
8 EPOXIDE OPENING TO GENERATE CHIRAL TERTIARY 
ALCOHOLS 
8.1 Epoxide ring-opening of epoxy monoacetate 50 with nitrogen 
nucleophiles 
Chiral β-amino tertiary alcohols are present in natural products and pharmaceuticals 
including pumiliotoxin A 62198 and alkaloids from the poison dart frogs of the 
dendrobates genus, setoclavine 59,98 paraherquamide A 61,101 as well as the 
anticancer compound vincristine 63 (Scheme 20).103 Likewise, numerous 
biologically active non-natural compounds possess this moiety.35,172-174 With our 
asymmetric synthesis of (S)-50, we chose several amine nucleophiles to open the 
epoxide thus generating enantiomerically pure β-amino tertiary alcohols (Scheme 
44). 
 
 
 
Scheme 44: Our synthesis of enantiopure β-amino tertiary alcohols. 
 
Numerous protocols have been developed for activating epoxides towards 
nucleophilic ring-opening by amines.123,135,136,160,161,166-171 Some of these methods 
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were investigated and are discussed in detail below (Scheme 45). The reactions were 
performed initially with (±)-50 to save costly material. 
 
 
Scheme 45: Proposed scheme for the epoxide ring-opening of (±)-50 using amines. 
 
Since the enzymatic desymmetrisation was carried out in dichloromethane, it allows 
the possibility of performing the epoxide ring-opening reaction in “one pot”. 
Performing the reaction in “one pot” would be advantageous due to a reduction in 
synthetic steps and lengthy purification process, therefore saving time and resources. 
Initial approaches to develop the reaction utilised 100 mg of (±)-50 with 1.1 
equivalents of the amine in DCM. Benzylamine and allylamine were tested and the 
reactions were left for three days at room temperature. Unfortunately, no product was 
detected in either reaction. 
 
8.1.1 Microwave irradiation 
The ring-opening of epoxides by amines promoted by microwave irradiation is 
known.161 Normally, the reactions are faster than the corresponding thermally 
controlled reaction and thus it is not necessary to use a catalyst or promoter. 
Reactions were carried out on a 50 mg scale of (±)-50, using 1.1 equivalents of 
amine in dichloromethane. The reactions were left from between 5 to 30 minutes at 
100 ºC to 140 ºC (200W). The amines screened were benzylamine, allylamine, 
morpholine and piperidine. 
Unfortunately, it was not possible to isolate the desired ring-opened product. The 
reactions were not clean and gave a complex mixture of products which prevented 
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purification of any desired product. As such, it was necessary to find another 
protocol to prepare the β-amino tertiary alcohols from (±)-50. 
 
8.1.2 Use of promoters/activators. 
 
 
Scheme 46: General scheme for the ring-opening of (±)-50 with amines, promoted by 
Ti(OiPr)4, in DCM at room temperature. 
 
There are many catalytic promoters to activate the ring-opening of epoxides using 
amines,160,169 as such, the ring-opening of (±)-50 was studied using the Lewis acid 
Ti(OiPr)4 as a catalyst. The reactions were performed on a 100 mg scale, using 0.1 
equivalent of Ti(OiPr)4, 1.1 equivalents of the amine in dichloromethane at room 
temperature (Scheme 46). When the reaction was carried out with piperidine, the 
tertiary alcohol 99b was obtained, but in a disappointing 25% yield after purification. 
Benzylamine was also used but, in this case, no product was obtained, and only 
starting material was recovered. The ring-opening reaction was also attempted with 
2-(piperidin-4-yl)ethanol, but this too was unsuccessful. After these disappointing 
results, other methods were examined to open the epoxide. 
 
8.1.3 Classical conditions. 
Epoxide ring-opening was attempted in dichloromethane using classical conditions, 
an excess of amine (benzylamine, allylamine and piperidine) and heating to reflux. 
However, under such conditions, there was no product formed, even after 48 hours 
heating the reaction to reflux.  
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Better results were obtained when the reaction was performed with an excess of 
amine refluxing in EtOH.170,171 In this case, the epoxide ring-opening was carried out 
on a 200 mg scale of (±)-50, three equivalents of the amine at 78 ºC over 1 to 4 hours 
in EtOH (Scheme 47). After this time the products were purified and characterised as 
β-amino tertiary alcohols (Table 13). 
 
 
Scheme 47: General reaction for the ring-opening of (±)-50 with an excess of amine 
refluxing in EtOH. 
 
When aliphatic secondary amines were used, the reaction produced the desired β-
amino tertiary alcohols (Table 13, entries 1 to 5, 10, 12 and 14). Using piperidine as 
a nucleophile gave a modest yield (55%) of 96b (Table 13, entry 2). However, the 
other secondary amines morpholine, 2,6-dimethylmorpholine and 2-(piperidin-4-
yl)ethanol gave yields of 76, 84 and 77% respectively (Table 13, entries 3-5). 
Interestingly, the tertiary alcohol was not obtained with pyrrolidine (Table 13, entry 
1); the un-repeatable reaction product obtained was tentatively assigned as N-acetyl 
pyrrolidine, presumably formed via an acyl exchange reaction with the acetate 
starting material (±)-50. 
 
Table 13: Results of the ring-opening of (±)-50 with three equivalents of amine 
refluxing in EtOH.a 
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Entry Nucleophile Product type Yieldb (%) Yieldd (%) 
   1 Hour 4 Hours 
1c 
 
96a - - 
2 
 
96b 55 - 
3 
 
96c 76 81 
4 
 
96d 84 79 
5 
 
96e 77 - 
6 
 
97a 89 89 
7 
 
97b 21  18 
8 
 
97c 31 - 
9 
 
97d 93 - 
 93 
 
10e 
 
96f - 80 
11 
 
97e 96 - 
12 
 
96g - 55 
13 
 
97f 74 - 
14 
 
96h 63 - 
15 
 
97g 54 - 
16 
 
96i 96 94 
17 
 
96j 93 96 
a Reagents and conditions: Epoxide (±)-50 in ethanol (0.1 M), amine (3 equivalents) 
and reflux for 1 or 4 hours. b Isolated yields. c Trace product was observed after 1 h 
at reflux. d The reaction was repeated and left at reflux for 4 hours. e The reaction 
was purified by the removal of excess amine under high vacuum.  
 
Aliphatic primary amines were also screened in the reaction and interestingly 
different results were obtained than using secondary aliphatic amines under the same 
conditions (See Scheme 47 and Table 13, entries 6 to 9, 11, 13 and 15). NMR 
analysis of products together with X-ray crystallography of the crystalline products 
derived from propargylamine and allylamine (Figures 12 and 13 respectively) 
revealed an intramolecular migration of the acetyl group had occurred during the 
reaction onto the newly, mldk formed secondary amine to give acetamides 97d and 
97e.  
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Figure 12: X-ray structure of prochiral triol 97d; obtained when propargylamine was 
reacted with epoxide (±)-50.  
 
 
Figure 13: X-ray structure of prochiral triol 97e, obtained when allylamine was 
reacted with epoxide (±)-50.  
 
The chiral centre in products 97a-g is lost due to the intramolecular O to N-migration 
of the acetyl group, resulting in a prochiral triol, when primary amines 4-(2-
aminoethyl)morpholine, iso-propylamine, cyclopentylamine, propargylamine, 
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allylamine, benzylamine and phenylethylamine were used (Table 13, entries 6-9, 11, 
13 and 15).  
To confirm that migration of the acetyl group takes place when using primary 
amines, analogous secondary amines were used. It was thought that a lack of a 
replaceable hydrogen atom in the products would prevent acyl migration. Three 
secondary N-methylated amines were reacted alongside their analogous primary 
amines, N-methylprop-2-yn-1-amine, N-methylprop-2-en-1-amine and N-methyl-1-
phenylmethanamine (Table 13, entries 9 and 10; 11 and 12; 13 and 14). Indeed it was 
found that the reactions of the N-methylated compounds (Table 13, entries 10, 12 and 
14) gave the desired products 96f, 96g and 96h exclusively in good yields without 
the concomitant acyl migration seen in the cases of the primary amines (Table 13, 
entries 9, 11 and 13).  
The N-methylated amines produce the desired compounds albeit in lower yields than 
the corresponding primary amines (Table 13, entries 10, 12 and 14), presumably due 
to the increased steric hindrance in these cases.  
In conclusion, it appears as though using primary aliphatic amines in the reaction 
gives an intramolecular O to N-migration of the acetyl group onto the newly formed 
secondary amine resulting in a prochiral triol, whilst secondary aliphatic amines give 
the desired products exclusively. 
Primary aromatic amines, such as 4-fluoroaniline and o-anisidine were used in the 
reaction with epoxide (±)-50, and interestingly, tertiary alcohols 96i and 96j were 
obtained in both cases, with no migration of the acetyl group, in high yields (Table 
13, entries 16 and 17 respectively). It would appear as though primary aromatic 
amines are not nucleophilic enough to attack the acetyl group and initiate 
intramolecular O to N-migration.135,136,154,160 Confirmation of the structure of 96i was 
proved by X-ray crystallography (Figure 14). 
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Figure 14: X-ray structure of tertiary alcohol 96i; obtained when 4-fluoroaniline was 
reacted with epoxide (±)-50. 
 
A number of differences between diol 96 and triol 97 could be seen by 1H and 13C 
NMR. For example, with 96g and 97e, 1H NMR of the pure products from the 
reaction of (±)-50 with allylamine and N-methylprop-2-en-1-amine respectively 
show a difference in the signal splitting patterns. Allylamine derived product 97e is 
achivable as a result of acyl migration, thus there is only one signal integrating to 
four protons for the two equivalent -CH2OH groups (Figures 16 and 17). However, 
N-methylprop-2-en-1-amine derived product 96g is chiral, and thus the two 
methylene protons appear as diastereotopic AB systems (Figures 15 and 19).  
 
 
  
Figure 15: Diastereotopic protons are seen 
by 1H-NMR in the asymmetric tertiary 96. 
Figure 16: Symmetrical protons are seen by 
1H-NMR with the prochiral triol product 97.  
Alocohol. 
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The difference in structure in all examples, is also evident from 13C NMR, since the 
ester carbonyl of the tertiary alcohols appears at 171 ppm and the amide carbonyl of 
the prochiral triol appears at 174 ppm. 
 
Figure 17: 1H NMR of allylamine derived product 97e in CDCl3. 
 
 
Figure 19: 1H NMR of N-methylprop-2-en-1-amine derived product 96g in CDCl3. 
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8.1.4 Epoxide ring-opening of enantiopure epoxide (S)-50 with o-anisidine 
and 4-fluoroaniline. 
The reaction was attemped with enantiomerically pure epoxide (S)-50 to determine if 
these conditions can allow us to develop an asymmetric synthesis of enantiomerically 
pure β-amino tertiary alcohols. The enantiomers of racemic 96i and 96j were 
separated by chiral HPLC, thus o-anisidine and 4-fluoroaniline were selected to open 
the epoxide of enantiomerically pure material. To avoid purification of intermediates, 
the reaction was performed in “one pot” (Scheme 48).  
 
 
Scheme 48: Enzymatic desymmetrisation and epoxide ring-opening in “one pot”. 
 
The reaction was carried out on a 100 mg of prochiral diol 87, 1.8 equivalents of 
Ac2O and 2 weight equivalents of Amano L, AK in DCM at 37 ºC for 1 hour (97% 
ee). After this time, the enzyme was filtered and the solvent evaporated in vacuo. 
Ethanol was added to the reaction mixture along with 3 equivalents of the amine, and 
the reaction was heated at reflux for 4 hours. After this time the solvent was removed 
and the mixture purified by column chromatography.  
Using this “one pot” procedure, the chiral tertiary alcohols were prepared with no 
loss of enantiomeric excess; in both cases the enantiomeric excess was 97% (Table 
15). 
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Table 15: Results obtained in the enzymatic desymmetrisation and epoxide ring-
opening in “one pot”.a 
Entry Nucleophile Product type ee (%) 
1 
 
96i 97 
2 
 
96j 97 
a
 These reactions were performed in “one-pot” as follows: To a solution of 87 (100 
mg, 0.96 mmol), Amano L, AK (200 mg, 2 weight equivalents) and molecular sieves 
(4 Å) in dichloromethane (10 ml, 0.1 M) was added acetic anhydride (1.8 
equivalents) and the reaction left for 1 hour at 37 ºC. The mixture was filtered 
through Celite ® and the filtrate was reduced in vacuo. Ethanol (10 ml, 0.1M) and 
the corresponding amine (see Table 15) was added and the mixture was heated at 
reflux for 4 hours. The mixture was reduced in vacuo and purified by column 
chromatography (SiO2; 20% EtOH in EtOAc). The enantiomeric purity was 
determined by HPLC; Agilent 1100 Series. Chiralpack AD, 1 ml/min, 80/20 iso-
hexene in EtOH at 25 ºC.  
 
 
8.2 Preventing the O to N-migration of the acetyl group. 
To avoid the intramolecular migration of the acetyl group when using primary 
aliphatic amines and thus avoid the conversion of chiral products 96 into prochiral 
triols 100, an alternative synthetic route was developed introducing a more stable 
protecting group (Scheme 49). It was found that, as expected, a silyl protecting group 
does not migrate during the epoxide opening reaction therefore allowing the use of 
aliphatic primary amines to make chiral β-amino tertiary alcohols, however, the 
opposite enantiomer of the β-amino tertiary alcohols was generated. 
 
 100 
 
 
Scheme 49: Synthetic route to avoid the intramolecular migration of the acetate 
group using primary aliphatic amines. 
 
 The new synthetic route began with the protection of racemic (2-
(hydroxymethyl)oxiran-2-yl)methyl acetate (±)-50 using tert-butyldimethylsilyl 
chloride, triethylamine and 4-dimethylaminopyridine in dichloromethane. The 
product was purified by column chromatography and the resulting yield was 82%. 
The process was followed by the removal of the acetyl group with potassium 
carbonate in methanol, giving a 91% yield after aqueous work-up. The protected 
epoxide, (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methanol (±)-99 was 
reacted with three primary amines, propargylamine, allylamine and benzylamine 
respectively. No migration of the tert-butyldimethylsilyl protecting group was 
detected, yields are summarised in Table 16. The epoxide was reacted with three 
equivalents of the amine in ethanol and the mixture was refluxed for 1 hour to obtain 
the racemic β-amino tertiary alcohols, 100a-c.  
This route was also performed with enantiopure epoxide (S)-50 to determinate if 
these conditions enable us to develop an asymmetric synthesis of β-amino tertiary 
alcohols using aliphatic primary amines. When the enantiomerically enriched 
epoxide (R)-99 (97% ee) was reacted with benzylamine, no loss of enantiomeric 
excess was observed, confirming that the method is suitable for the synthesis of 
chiral β-amino tertiary alcohols with aliphatic primary amines which were previously 
unobtainable due to acyl migration. The “pseudo”-enantiomer was obtained when the 
chiral tertiary alcohols were synthesised with this alternative route. However, simple 
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protecting group manipulations could allow them to be converted to the other (R)-
enantiomer (Scheme 50).199,200 
 
Table 16: Reaction of (±)-99 with primary amines.a 
a Reagents and conditions: Epoxide (±)-99 was dissolved in ethanol (0.1 M), the 
amine added (3 equivalents) and the reaction heated to reflux for 4 hours. b Isolated 
yields. 
 
HO OAc
OH
NR1R2
(R)
TBSO OH
OH
NHR
(S)
 
Scheme 50: Absolute configuration of the chiral tertiary alcohols. 
 
 
8.3 Synthesis of β-amino methyl alcohols, 101.  
β-Amino methyl alcohols are a common functional group in many natural products 
and non-natural products.106,201,202 Some examples are: pumilitoxin A, B and 251D203 
initially isolated from dendrobatid frogs; setoclavine98 which has immunomodulatory 
activity, paraherquamide A100,101 displays potent anthelmintic activity and 
antinematodal properties, bacilosarcin A105,106 exhibits antibacterial, cytotoxicity and 
antiulcer activities (see structures in Schemes 2 and 20). 
Entry Amine Product type Yield (%)b 
1 
 
100a 43 
2 
 
100b 70 
3 
 
100c 
83 
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With such a plethora of tertiary alcohols we focused our efforts on developing a new 
building block which would lead to chiral β-amino methyl alcohols (Figure 21).  In 
the next sections we try to find a synthetic route to achieve this potentially useful 
building block.  
 
Figure 21: β-amino tertiary methyl alcohols 101. 
 
8.3.1 Synthesis of β-amino methyl alcohols 101 via oxidation followed by 
reductive amination. 
The first route proposed to generate enantiomerically enriched alcohols of type 101 
(R1=OH) was to oxidise the primary alcohol of (±)-50 followed by a reductive 
amination (Scheme 51). The oxidation of the primary alcohol was performed using 
different reagents (Table 17).204-211 The oxidation reaction was optimised to obtain 
aldehyde 102 in 33% - 66% yields using tetra-propylammonium perruthenate 
(TPAP) and N-methylmorpholine-N-oxide (NMO) in dichloromethane at room 
temperature. Other oxidants were unsuccessful. Experimentally, the starting material 
was disappearing but no product was observed (TLC) during the reaction probably 
due to the decomposition of the aldehyde product 102. 
 
 
Scheme 51: Proposed synthetic route for the synthesis of chiral β-amino methyl 
alcohols. 
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Table 17: Reagents used to perform the oxidation of (±)-50. 
Entry Oxidising reagents Yield (%) 
1212 NMO/TPAP in anhydrous DCM at RT 33-66 
2205 KMnO4 / MnO2 in DCM at RT - 
3209 CrO3 / H5IO6 in MeCN at 0ºC - 
4206 PCC / H5IO6 in MeCN at 0ºC - 
5 PCC in DMF - 
6 PCC in DCM - 
7 PCC in DCM with CeliteTM - 
8213,214 Swern oxidation - 
9215 Parikh-Doering oxidation - 
10210 IBX (o-iodoxibenzoic acid) and β-cyclodextrin - 
11211 NaOCl2 / TEMPO - 
 
 
The reductive amination of 102 was performed using piperidine in anhydrous 
dichloromethane, but a mixture of products was obtained without the isolation of the 
desired tertiary alcohol. Initially, the process was performed in two steps; starting 
with the amination of the aldehyde with piperidine in the presence of 4Å molecular 
sieves or magnesium sulphate. This was followed by an exhaustive reduction with 
lithium aluminium hydride. The conversion of the reaction by TLC was poor and as 
such, the process was repeated in one step to prevent problems associated with the 
instability of imine 103.216,217 Using this approach, the amine and reducing agent 
were added at the same time; theoretically the reduction step would force the 
equilibrium over to the side of the products and it would not be necessary to use a 
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drying reagent to remove the water. When the process was performed a mixture of 
products were obtained, none of which was the desired tertiary alcohol.  
The low yield of the oxidation reaction and the poor results of reductive amination 
did not prove to be synthetically useful. Thus, we decided to develop an alternative 
route to make the chiral β-amino tertiary methyl alcohols. 
 
8.3.2 Synthesis of β-amino methyl alcohol 101 via the tosylation of primary 
alcohol 96i followed by an exhaustive reduction 
Another route to make the desired compound is shown in Scheme 52 and consists of 
the tosylation of the previously synthesise alcohol 96i to give 104a, followed by 
exhaustive reduction with lithium aluminium hydride to give the desired tertiary 
alcohol 105a (Scheme 52). 
 
Scheme 52: Possible synthetic route to make the β-amino methyl alcohols. 
 
The tosylation reaction was performed with an excess of 4-toluenesulfonyl chloride 
(1.5 equivalents) in pyridine at room temperature. After purification and 
characterisation of the final product (after reduction) it was observed that the 
secondary amine was tosylated, making a very stable bond which is very difficult to 
cleave, as well as the desired tosylation of the less hindered primary alcohol and its 
subsequent reduction with lithium aluminium hydride (Figure 22). β-Amino methyl 
alcohols were made using this synthetic route but the tosylated amine is too stable 
and difficult to deprotect, as such, the final product is not useful for further 
modifications leading to pharmaceuticals or natural products; the nitrogen-sulphur 
 105 
 
bond is too stable and the reactivity is too low for additional alterations. Therefore, 
this route, with primary amines, was not repeated further. 
 
 
Figure 22: Undesired product obtained by performing the tosylation of 96i with an 
excess of 4-toluenesulfonyl chloride and subsequent reduction. 
 
A similar synthetic route was attempted with secondary amines to avoid this 
undesired N-tosylation, as outlined in scheme 53. The tosylation of the primary 
alcohol was performed following the same procedure above, but surprisingly, no 
reaction ocurred. After 24 hours at room temperature only starting material was 
recovered, and the crude NMR showed decomposition of compound 96h. 
 
Scheme 53: Proposed synthetic route to make the β-amino methyl alcohols. 
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8.3.3 Synthesis of β-amino methyl alcohol 101 via tert-butyldimethylsilyl 
chloride protection. 
One explanation for the decomposition of the starting material observed in the above 
reaction could be the sensitivity of the acetate group. Thus a modification of the 
protecting group strategy was introduced, a more robust tert-butyldimethylsilyl 
maybe beneficial. (Scheme 54).  
 
 
Scheme 54: Possible synthetic route to make the β-amino tertiary methyl alcohols. 
 
The alternative route follows the selective protection of the primary alcohol of 2,3-
dihydroxy-2-(morpholinomethyl)propyl acetate 96c with tert-butyldimethylsilyl 
chloride, triethylamine and 4-dimethylaminopyridine in dichloromethane. Protection 
of this primary alcohol, before the hydrolysis of the acetate group, is essential to 
maintain the stereogenic centre of the tertiary alcohol when the process performed 
with enantiopure material (the diol would be prochiral). After the hydrolysis of the 
acetate group with potassium carbonate in MeOH, the newly formed primary alcohol 
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can be tosylated followed by a subsequent reduction with lithium aluminium hydride 
to reveal the desired compound 109 (Scheme 54). 
To attempt the new synthetic route, primary alcohol 96c was used due its stability as 
demonstrated in previous work (Section 8.1.3). Unfortunately, protection of primary 
alcohol 96c with tert-butyldimethylsilyl chloride was met with no success. The 
reaction was left at reflux for 8 hours and no product was seen by TLC. 
 
8.3.4 Synthesis of β-amino methyl alcohol 101 via tert-butyldimethylsilyl 
chloride protection of epoxide (±)-50. 
Due to the adjacent quaternary centre in 96c, the accessibility to the primary alcohol 
is difficult due to the sterically encumbering functional groups attached to the 
stereogenic centre. Therefore, we decided to protect epoxy monoacetate and open the 
epoxide after the protection of the primary alcohol (Scheme 55). The protection was 
performed with tert-butyldimethylsilyl chloride, triethylamine and 4-
dimethylaminopyridine in dichloromethane in 82% yield. The epoxide was 
subsequently reacted with morpholine to arriving at the chiral tertiary alcohol 107 in 
a gratifying 95% yield (Scheme 55). Hydrolysis of the acetate group was performed 
with potassium carbonate in methanol in 98% yield generating diol 100d. However, 
tosylation of primary alcohol 100d using 4-toluenesulfonyl chloride in pyridine met 
with no success.  
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Scheme 55: Proposed synthetic route to make the β-amino methyl alcohols from (±)-
50. 
 
8.3.5 Synthesis of β-amino methyl alcohol 101 using (±)-50. 
Since modification of the tertiary alcohols was problematic presumably due to the 
increased steric bulk, the reaction of tosyl epoxide 110 towards amines was 
investigated. This would give the desired alcohols 108 with the required tosylate 
functionality (Scheme 56). Derivatisation of the primary alcohol (±)-99 with 4-
toluenesulfonyl chloride, triethylamine and 4-dimethylaminopyridine in 
dichloromethane was achieved in 90% yield to obtain the desired epoxide (2-((tert-
butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 4-methylbenzenesulfonate 110 
(Scheme 56). 
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Scheme 56: Proposed synthetic route to make β-amino tertiary methyl alcohols. 
 
The ring-opening of epoxide 110 was performed using four different amines, 4-
fluoroaniline, allylamine, propargylamine and benzylamine. The reaction with 4-
fluoroaniline gave very low conversion by TLC after 48 hours at reflux, presumably 
due to the low nucleophility of the aromatic amine (especially being electron 
deficient) and the product was not isolated. When the epoxide ring-opening was 
performed with propargylamine and benzylamine the tosyl group was lost during the 
process. However, when allylamine was used the desired compound 108 was 
obtained. Reduction of alcohol 108 with lithium aluminium hydride gave a product 
without the expected methyl group! 
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Scheme 57: Proposed products for the epoxide ring-opening with aliphatic primary 
amines. 
 
Scheme 57 shows the tentatively assigned products for the epoxide ring-opening with 
aliphatic primary amines. Product 108 was obtained when the reaction was 
performed with allylamine in EtOH at reflux for 1 hour. In this case, the signals from 
the tosyl group were observed by 1H-NMR of the purified material. The mass 
spectrum in conjunction with 1H-NMR data of the products obtained when 
propargylamine and benzylamine were used as a nucleophiles discount products 108, 
112 and 113. Finally, azetidines can be differentiated from structure 111 by 13C-
NMR due to the symmetry of azetidines 114. After analysing all possibilities we 
concluded that the products made from the epoxide ring-opening using 
propargylamine and benzylamine in EtOH at reflux for 1 hour were azetidines 114. 
Confirmation of the azetidine structures for products as 114a and 114b (R = allyl and 
propargyl respectively) generated by the epoxide ring-opening of 110, was obtained 
using X-ray crystallography (Figure 23 and 24). 
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Figure 23: X-ray structure of azetidine 114a; obtained when allylamine was used to 
open epoxide 110.  
 
 
Figure 24: X-ray structure of azetidine 114b; obtained when propargylamine was 
used to open epoxide 110.  
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In an effort to generate β-amino methyl alcohols 101 and avoid azetidine formation 
the reactions were repeated at room temperature. Allylamine, N-methylallylamine 
and benzylamine were used as nucleophiles for the epoxide ring-opening of tosylate 
epoxide 110; the reactions were performed in ethanol at room temperature for 24 
hours. In the cases of allylamine and benzylamine, azetidines 114a and 114c were 
obtained in 31% and 51% yields respectively. Interestingly, the reaction with 
allylamine gave azetidine 114a at room temperature in 24 hours, but tertiary alcohol 
108b when left at reflux for 1 hour. In both cases the yields were low. Unfortunately, 
it was not possible to isolate again 108b and the compound was only characterised 
by 1H-NMR. However, 1H-NMR data of the product obtained after reduction of 
tertiary alcohol 108b with lithium aluminium hydride was the same azetidine 114a as 
the one produced via epoxide ring-opening with allylamine at room temperature 
(Scheme 58). In the first reaction, lithium aluminium hydride acts as a base to 
deprotonate the NH proton of amine 108b and the resulting anion perform a 4-exo-tet 
cyclisation to displace the tosylate. Possible mechanisms of these reactions will be 
discussed in detail in the next section. 
 
Scheme 58: Epoxide ring-opening with primary and secondary aliphatic amines. 
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The epoxide ring-opening of tosylate epoxide 110, when performed with N-
methylallylamine generated a symmetrical tertiary alcohol 115a. The reaction was 
performed with an excess of the amine and a second equivalent should attack a 
presumed second epoxide intermediate generating the symmetric tertiary alcohol (see 
later section).  
We wanted to study the possibility that compound 108b is an intermediate towards 
azetidine 114a and if the reaction is refluxed longer the yield of the azetidine may 
increase. Therefore, the reaction was performed with an excess of different amines 
under identical conditions, refluxing for 8 hours in EtOH in the hope that all 
intermediates and reaction pathways would be forced through to the azetidine 
products. 
In both cases, when using either primary or secondary amines, symmetrical 
compounds are produced and the chiral centre is lost during the reaction. Even 
though the final product loses its chirality, the biotransformation with R. miehei (see 
section 7.3) generates the epoxy monoacetate in higher yield than the reaction 
performed chemically with acetyl chloride and thus could still be a viable synthetic 
protocol.  However, it is pleasing to discover a new route to azetidines in the process 
which we decided to pursue as outlined in the section below. 
 
8.4 Proposed mechanism for the epoxide ring-opening of 110. 
As shown in section 8.3.5, we developed a synthetic route to produce azetidines via 
ring-opening of epoxide 110 using different amines. We propose two possible 
mechanisms for the formation of the azetidines from (2-((tert-
butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 4-methylbenzenesulfonate 110 and 
an excess of primary amine in EtOH (Schemes 59 and 60). 
The first mechanism begins with an amine induced epoxide ring-opening (Scheme 
59); the amine attacks the epoxide generating alkoxide intermediate 116. An 
intramolecular ring-closure follows causing the displacement of the tosylate leaving 
group producing a new epoxide 111.154,218,219 The secondary amine generated in this 
process, attacks the newly formed epoxide, opening the ring, in a 4-endo-tet 
cyclisation forming the four membered nitrogen heterocycle 114. In this case, it is 
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assumed that the alkoxide attacks faster than a proton transfer in intermediate 116 
(see the alternative mechanism (Scheme 60)). 
Scheme 59: Proposed mechanism for the synthesis of azetidines. 
 
During this process, the chiral centre is lost by the formation of the azetidine. 
Following Baldwin’s rules of epoxide ring-opening, the second intramolecular 
reaction is a 4-endo-tet cyclisation and therefore a disfavoured heterocyclic 
formation (Figure 24).220 Baldwin suggests that this type of three-membered ring 
generally prefers exo-modes, thus following his rules, the proposed mechanism is not 
favoured for the synthesis of azetidines using epoxide 110.220  
 
Y X
endo
exo
 
Figure 24: Baldwin’s rules for opening three-membered rings to form cyclic 
structures.220 
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The second mechanism proceeds via the tertiary alcohol (Scheme 60). The reaction 
begins with the same epoxide ring-opening as before with the amine attacking the 
epoxide generating a quaternary ammonium ion and an alkoxide intermediate 116, 
however, immediately it undergoes a proton transfer generating the tertiary alcohol 
108. Finally, the formation of the azetidine is via an intramolecular attack of the 
amine via an SN2 reaction onto the neopentyl carbon with the better leaving group, 
and a consequent elimination of the tosylate. Normally, direct SN2 to a neopentyl 
centre are very rare, the neopentyl centre is too hindered to react via SN2, although 
when the reaction is intramolecular SN2 substitutions can proceed.221  
 
 
Scheme 60: Alternative proposed mechanism for the synthesis of azetidines using 
primary amines. 
 
Similarly, following Baldwin’s rules, the intramolecular cyclisation in this case is 4-
exo-tet and therefore a favoured reaction, making this mechanism more likely.220 
The reaction with secondary amines produced a symmetrical tertiary alcohol. The 
first mechanism proposed agrees with the product produced via double epoxide ring-
opening. The reactions were performed with an excess of the amine and there was 
enough to open the second epoxide to generate the tertiary alcohol (Scheme 61).  
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Scheme 61: Proposed mechanism for the synthesis of tertiary alcohol 115 using a 
secondary amine. 
 
Considering the second mechanism proposed, when reactions were performed with 
secondary amines, the second equivalent of the amine attacks intermolecularly to a 
neopentyl centre and this reaction is very slow and normally unfavoured (Scheme 62, 
mechanism via 1). Having in mind that intramolecular SN2 reactions at neopentyl 
centres can proceed via rearrangement of the atoms, it is more likely that the reaction 
progresses through an azetidinium ion 117,221,222 rather than direct attack at the 
neopentyl centre (Scheme 62, mechanism via 2) followed by the azetidinium ion 
ring-opening to produce the final product 115. Azetidinium ions are stable enough to 
be isolated and store for months without significant decomposition and the 
heterocycle can be easily opened due to the strong activation of the amonium 
group.223 There are some examples of azetidine formation from epoxides via 
azetidinium ions making this mechanism more suitable for the synthesis of tertiary 
alcohol 115.224-227 
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Scheme 62: Alternative proposed mechanism for the synthesis of tertiary alcohol 115 
using secondary amines. 
 
Considering only the epoxide ring-opening of 110 with primary amines to generate 
azetidine 114, the second mechanism proposed would be the more likely following 
Baldwin’s rules. The reaction was attempted with one equivalent of allylamine (see 
section 8.4.5) without isolation of the expected β-amino epoxide 101, and when the 
reaction was attempted for the first time with an excess of allylamine refluxing for 1 
hour, the chiral tertiary alcohol 108 was isolated. Unfortunately, it was not possible 
to isolate this intermediate again.  
On the other hand, reactions with secondary amines rarely go via SN2 substitution at 
neopentyl centres and it is more likely that these go via azetidinium ion formation.  
Even though the second mechanism is more likely to generate both products, more 
experiments needs to be performed.  
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8.4.1 Synthesis of azetidines with primary amines. 
Recently, it has been demonstrated that azetidines find wide application as an 
important functional group in many pharmacologically active compounds making 
them an interesting synthetic topic. However, there is a remarkable lack of general 
methods for the synthesis of azetidines.222,223,228-233  
 
 
Scheme 63: Epoxide ring-opening with primary aliphatic and primary aromatic 
amines to produce azetidines. 
 
The epoxide ring-opening of (2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-
yl)methyl 4-methylbenzenesulfonate 110 was performed with different primary 
aliphatic and primary aromatic amines to generate a range of azetidines (Table 18). 
The reactions were performed in ethanol, with an excess of the amines (3 
equivalents) and refluxed for 8 hours to produce different amino substituted 
azetidines in high yields (43% - 92%). 
When the reaction was performed with 4-fluoroaniline the yield of azetidine 114d 
was low, presumably due to the lower nucleophility of the electron-deficient 
aromatic amine. The only product isolated from the reaction was the azetidine; even 
with the low nuclophility of the aromatic amines, none of the proposed intermediates 
from Schemes 59 and 60 could be isolated to provide evidence as to which reaction 
mechanism was taking place.  
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Table 18: Results of the ring-opening of epoxide 110 with 3 equivalents of primary 
amines in EtOH at 78 ºC.a  
Entry Amine Product type Yield (%)b 
1 
 
114a 50 
2 
 
114b 88 
3 
 
114c 84 
4 
 
114d 43 
5 
 
114e - 
6 
 
114f 80 
7 
 
114g 92 
a Reagents and conditions: Epoxide 110 was dissolved in ethanol (0.1 M), the amine 
added (3 equivalents) and the reaction heated at reflux for 8 hours. b Isolated yields.  
 
 
8.4.2 Synthesis of azetidines with chiral aliphatic primary amines. 
The ring-opening of epoxide 110 was performed with a small number of chiral 
amines in high yields (Scheme 64). Though the stereogenic centre in the epoxide 110 
is lost during the azetidine formation, the final azetidine is chiral due to the chirality 
of the amine. 
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Scheme 64: Epoxide ring-opening with chiral amines to produce chiral azetidines. 
 
Table 19: Results of the ring-opening of 110 with 3 equivalents of chiral amine in 
EtOH at 78 ºC to produce chiral azetidines.a  
Entry Amine Product type Yield (%)b 
1 
 
114h 88 
2 
 
114i 78 
3 
 
114j 97 
a Reagents and conditions: Epoxide 110 was dissolved in ethanol (0.1 M), the amine 
added (3 equivalents) and the reaction heated at reflux for 8 hours. b Isolated yields.  
 
Table 19 summarises the results obtained in these reactions. Chiral amines, such as: 
(R)-(+)-α-methylbenzylamine (entry 1), (R)-(+)-α-ethylbenzylamine (entry 2) and 
(R)-(+)-1-(2-naphthyl)ethylamine (entry 3) were reacted with epoxide 110 and the 
corresponding chiral azetidine was produced in high yield in each case. 
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8.4.3 Epoxide ring-opening with secondary amines. 
The experiment was performed with secondary amines to gain a better understanding 
of the process. Three secondary amines, N-benzylmethylamine, N-
methylprogargylamine and N-allylmethylamine, were reacted with epoxide 11 
(Scheme 65). As previously observed, the reaction with secondary amines gave 
prochiral product 115.  
 
 Scheme 65: Epoxide ring-opening with secondary amines. 
 
The epoxide ring-opening of (2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-
yl)methyl-4-methylbenzenesulfonate 110 with an excess of secondary amines agrees 
with both mechanisms proposed in Schemes 61 an 62. The products were obtained in 
high yields and are summarised in Table 20. 
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Table 20: Results of the ring-opening of epoxide 110 with 3 equivalents of secondary 
amines in EtOH at 78 ºC.a  
Entry Amine Product type Yield (%)b 
1 
 
115a 81 
2 
 
115b 78 
3 
 
115c 83 
a Reagents and conditions: Epoxide 110 was dissolved in ethanol (0.1 M), the amine 
added (3 equivalents) and the reaction heated to reflux for 8 hours. b Isolated yields.  
 
 
8.4.4 Epoxide ring-opening with two different amines. 
Our interest in developing a synthetic route to chiral tertiary alcohols using this 
process focused our attention on ascertaining the outcome of the reaction depicted in 
Scheme 65. Could chiral, non-symmetrical products be made by a judicious choice 
of two amines? To avoid the intramolecular cyclisation and therefore the generation 
of azetidines, two secondary amines with different reactivities were used in the 
reaction. Performing the reaction with a mixture of two amines with different 
chemical properties in the hope that the reaction may be more selective for the less 
bulky amine to attack the epoxide, leaving the more bulky amine for the second 
(epoxide or azetidinium ion) ring-opening step to generate a product without loss of 
the stereogenic centre. A mixture of N-methylpropargylamine and N-
benzylmethylamine were tested to attempt such a formation of a chiral tertiary 
alcohol (Scheme 66). One equivalent of each amine was refluxed for 8 hours in 
ethanol. Unfortunately, after this time, a mixture of products was observed by TLC 
and the crude reaction mixture was not able to be purified. 
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 Scheme 66: Failed attempt at epoxide ring-opening with two different secondary 
amines to produce asymmetric tertiary alcohols. 
 
8.4.5 Epoxide ring-opening with 1 equivalent of amine. 
In order to prove that the synthesis of azetidines follow the first mechanism proposed 
(Scheme 67), via epoxide formation, we believe that it would be useful to attempt to 
isolate the proposed epoxide intermediate 111 (R=Me and Bn). This epoxide, if 
isolable, could also be a building block to generate chiral tertiary alcohols. The 
reaction was performed using only one equivalent of a secondary amine to avoid the 
second step of the process. A secondary amine, N-benzylmethylamine, was used to 
avoid the proposed intramolecular cyclisation which would give the undesired 
azetidine. Unfortunately, the starting material did not react with only one equivalent 
of the amine and no product was seen by TLC. 
 
 
Scheme 67: Attempted epoxide ring-opening with one equivalent of N-
methylbenzylamine. 
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9 CONCLUSION. 
 
The synthesis of enantiomerically pure (S)-2-acetoxymethylglycidol 50 has been 
achieved via enzymatic desymmetrisation of epoxy diol 87 with lipase Amano L, AK 
in 42% isolated yield and 97% enantiomeric excess. An improved on yield was 
observed when the enzyme was immobilised on silica (70% yield and 98% ee). 
Commercially immobilised lipase from R. miehei was also used to achieve the same 
isomer in 82-90% yield and up to 89% ee.  
The ring-opening of the biotransformed epoxide using different amines has been 
developed in high yields generating some enantiomerically pure β-amino tertiary 
alcohol products. The intramolecular migration, when primary amines were used to 
open the epoxide, was avoided using a TBS-protected compound 99 with good yields 
(43%-83%), without any loss of enantiomeric excess of the formed ‘pseudo’-
enantiomer. 
(S)-2-acetoxymethylglycidol 50 was also used as a starting material to generate 
azetidines in high yields. Tertiary alcohol-azetidines can be generated via enzymatic 
desymmetrisation with R. miehei to generate the overall process in higher yield. 
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10 FUTURE WORK 
The immobilisation of Amano L, AK on silica was promising and there is a need to 
spend more time in the future developing this encapsulation method. 
Another way to increase activity and selectivity of the enzyme could be by directed 
mutagenesis. Modifying the appropriate amino acids in the active site, the 
interactions between solvent-enzyme-acyl donor-substrate can be affected thus 
influencing the activity and specificity of the enzyme.  
(S)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 is a useful building block to 
generate chiral tertiary alcohols, we focussed our attention towards synthesising β-
amino tertiary alcohols, however there are a large number of nucleophiles that could 
open the epoxide and produce chiral tertiary alcohols (Scheme 32). We could extend 
the diversity of nucleophiles to react with the epoxide 50 and produce a large number 
of functionalised tertiary alcohols. This could expand the synthesis and applicability 
of this compound leading to pharmaceutical and agrochemical products. 
We were trying to develop a synthetic route to generate β-amino methyl alcohols 
without success. In Scheme 68 and 69 there are two new routes for the synthesis of 
this target. The first one starts with β-amino tertiary alcohol 96 and a protection of 
the diol, followed by the hydrolysis of the acetate group and tosylation of the newly 
generated primary alcohol. Finally, an exhaustive reduction with lithium aluminium 
hydride should produce β-amino methyl alcohol.  
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Scheme 68: Proposed synthetic route to generate β-amino methyl alcohols. 
 
The second possible route to generate β-amino tertiary methyl alcohols is via an 
exhaustive reduction of epoxide 98 with lithium aluminium hydride to produce a 
tertiary methyl alcohol intermediate followed by the tosylation of the primary 
alcohol. Treating compound 123 with a base to generate the tertiary alkoxide and 
posterior intramolecular SN2 attacks displacing the tosylate would generate a new 
epoxide 124. This epoxide would be a new building block that could be reacted with 
different nucleophiles to achieve a diversity of β-substituted tertiary methyl alcohols.  
 
 
Scheme 69: Proposed synthetic route to generate β-amino tertiary methyl alcohols. 
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An unexpected and interesting synthesis of tertiary hydroxyl-azetidines has been 
achieved using (S)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 in high yields. 
However, more experiments are required to determine the mechanism of this 
reaction. If the reaction proceeds via an azetidinium ion and, if stable, the isolation of 
it would be of great interest. This azetidinium species could be reacted with different 
reagents such as heteronucleophiles,234 hydrides235 and carbon nucleophiles,236 and 
therefore the synthesis of chiral tertiary alcohols (Scheme 70).  
 
 
Scheme 70: Ring-opening of azetidinium ions. 
 
Throughout this thesis we have related the importance of chiral tertiary alcohols and 
chiral β-amino tertiary alcohols in natural and non-natural products. We hope that 
these intermediates will find wide applicability in pharmaceutical and agrochemical 
industries. 
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Chapter 3: 
EXPERIMENTAL SECTION 
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11 GENERAL 
Commercially available reagents were used as received without purification. 
Analytical thin layer chromatography was performed with Keiselgel 60 F254, in a 
variety of solvents on aluminium-backed plates. The plates were visualised by UV 
light (254 nm), p-anisaldehyde and KMnO4. Flash column chromatography was 
conducted with Merck silica gel 60H (40-60 µm, 230-400 mesh) under bellows 
pressure. Nominal mass spectra were recorded on a Waters LCT mass spectrometer 
connected to a Waters Alliance 1100 LC autosampler and controlled by Waters 
Masslynx 4.1 and OpenAccess software using electrospray (ES) ionisation. 1H and 
13C NMR spectra were recorded on a Bruker Avance 300 (300 MHz) or a Bruker 
DPX 400 (400 MHz) spectrometer. All chemical shifts (δ) are quoted in parts per 
million (ppm) relative to a calibration reference of the residual protic solvent; 
CD3OD (δH 5.84, s) was used as the internal standard in 1H NMR spectra, and 13C 
NMR shifts were referenced using CD3OD (δC 49.05, hept) with broad band 
decoupling and CDCl3 (δH 7.26, s) was used as the internal standard in 1H NMR 
spectra, and 13C NMR shifts were referenced using CDCl3 (δC 77.0, t) with broad 
band decoupling. The following abbreviations were used to define the multiplicities: 
s, singlet; d, doublet; t, triplet; q, quadruplet; hept, heptet; m, multiplet. Petroleum 
ether refers to the fraction that boils between 40-60 ºC. 
 
11.1 Synthesis of (2-hydroxymethyl-oxiranyl)-methanol, 87. 
 
To a solution of 2-methylene-1,3-propanediol 86 (2.47 g, 28.0 mmol) in 
dichloromethane (280 ml, 0.1 M) was added m-CPBA (7.6 g, 30.8 mmol). The 
solution was stirred at room temperature for 4 hours. The mixture was reduced in 
vacuo and the crude material was purified by column chromatography (SiO2; 100% 
EtOAc) to yield the title compound 87 as a colourless oil (2.8 g, 96 %). 1H NMR 
(300 MHz, CDCl3) δH 2.12 (2H, dd, J = 5.4, 7.4, CCH2O), 2.88 (2H, s, OH), 3.72 
(2H, dd, J = 7.4, 12.4, CH2OH), 3.89 (2H, dd, J = 5.4, 12.4, CH2OH); 13C NMR (75 
 130 
 
MHz) 49.1 (CH2OC), 60.1 (C(CH2)3O), 62.6 (CH2OH); MS ES (+ve) found m/z 231 
([2M+23Na]+, 100%). 
 
11.2 Synthesis of (±)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate, 50. 
 
To a solution of 2-methylene-1,3-propanediol 86 (3.0 g, 34.0 mmol) in 
dichloromethane (340 ml, 0.1 M) was added 4-dimethylaminopyridine (208 mg, 1.70 
mmol), triethylamine (3.6 ml, 25.5 mmol) and acetyl chloride (1.2 ml, 17.0 mmol). 
The solution was stirred at room temperature for 16 hours. The mixture was reduced 
in vacuo to yield an oil which was purified by column chromatography (SiO2; 60% 
EtOAc in petroleum ether) to yield the monoacetylated compound as a colourless oil 
(1.4 g, 63% yield). 1H NMR (400 MHz, CDCl3) δH 2.08 (3H, s, CH3CO), 4.13 (2H, 
s, CH2OH), 4.63 (2H, s, CH2OAc), 5.17 (1H, s, CHaHbC(CH2)2), 5.23 (1H, s, 
CHaHbC(CH2)2); 13C NMR (100 MHz) 21.3 (CH3CO), 64.1 (CH2OH), 65.2 
(CH2OAc), 114.9 (CH2C(CH2)2), 143.8 (C(CH2)3, 171.4 (CO); MS ES (+ve) found 
m/z 131 ([M+H]+, 100%). To a solution of the above oil (500 mg, 3.85 mmol) in 
dichloromethane (0.1 M) was added m-CPBA (1.42 g, 5.77 mmol). The solution was 
stirred at room temperature for 20 hours. After this time potassium carbonate (9.4 g, 
68.0 mmol) was added to the solution and the slurry was stirred for 15 minutes. The 
mixture was filtered and concentrated in vacuo to yield the title compound 50 as 
colourless oil (551 mg, 98% yield). 1H NMR (300 MHz, CDCl3) δH 2.09 (3H, s, 
CH3CO), 2.80 (1H, d, J = 4.6, CHaHbOC), 2.92 (1H, d, J = 4.6, CHaHbOC), 3.68-
3.83 (2H, m, CH2OH), 4.14 (1H, d, J = 12.2, CHaHbOAc), 4.32 (1H, d, 12.2, 
CHaHbOAc); 13C NMR (75 MHz) 20.9 (CH3CO), 49.4 (CH2OC), 57.8 (C(CH2)3), 
61.7 (CH2OH), 64.4 (CH2OAc), 171.0 (CO); MS ES (+ve) found m/z 147 ([M+H]+,  
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11.3 Synthesis of acetic 2-acetoxymethyl-oxiranylmethyl ester, 49. 
 
To a solution of (2-hydroxymethyl-oxiranyl)-methanol 87 (252.0 mg, 2.42 mmol) in 
dichloromethane (24 ml, 0.1 M) was added 4-dimethylaminopyridine (29 mg, 0.1 
mmol), triethylamine (1.01 ml, 7.26 mmol) and acetyl chloride (0.43 ml, 6.1 mmol). 
The solution was stirred at room temperature for 1.5 hours. The mixture was 
extracted with diethyl ether and the organic extract was washed with brine (20 ml, 
three times). The organic extract was dried (MgSO4) and concentrated in vacuo to 
yield the title compound 49 as a colourless oil (348.0 mg, 76 % yield). 1H NMR (400 
MHz, CDCl3) δH 2.08 (6H, s, 2xCH3CO), 2.84 (2H, s, CH2OC), 4.13 (2H, d, J = 
12.0, CHaHbOAc), 4.27 (2H, d, J = 12.0, CHaHbOAc), 13C NMR (100 MHz) 20.7 
(CH3CO), 49.7 (CH2OC), 63.8 (CH2OAc), 55.3 (C(CH2)3O), 170.4 (CO); MS ES 
(+ve) found m/z 189 ([M+H]+, 40%), 147 ([M-Ac+2H]+, 60%), 129 ([M-OAc]+, 
80%). 
 
11.4 Enzymes. 
The enzymes used were sourced as follows: 
PPL: Lipase from porcine pancreas type II., Sigma-Aldrich, L3126. 
Amano L, AK: Amano L, AK from Pseudomonas fluorescens, Sigma-Aldrich, 
534730. 
Amano L, PS: Amano L, PS from Burkholderia cepacia (Pseudomonas cepacia), 
Sigma-Aldrich, 534641. 
CRL: Lipase from Candida rugosa, Fluka, 90860. 
CAL-B: Novozyme 435, Novozymes. 
A kit of immobilized enzymes was used from CODEXIS. The enzyme codes are as 
follows: 
NZL-101 Lipase A from Candida antarctica. 
NZL-102 Lipase B from Candida antarctica. 
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NZL-103 Lipase from Rhizomucor miehei. 
NZL-104 Lipase from Thermomyces lanuginosus. 
NZL-105 Lipase from Thermomyces lanuginosus, mutant. 
NZL-106 Lipase from Thermomyces lanuginosus, mutant, broad range. 
NZL-107 Lipase from fungal mutant, accepting bulky substrates. 
NZL-108 Lipase from fungal, broad range. 
NZL-109 Lipase from fungal mutant, broad range. 
 
11.5 General enzymatic reactions. 
To a mixture of (2-hydroxymethyl-oxiranyl)-methanol 87 (100 mg, 0.96 mmol), 
enzyme (200 mg, 2 wt. eq.) and molecular sieves (4 Å) in the corresponding solvent 
(10 ml, 0.1 M) was added the acyl donor (see Tables 1-3 in Results and Discussion 
section). The solution was shaken vigorously in an incubator set at the required 
temperature for the specified times (see Tables 1-3 in Results and Discussion 
section). The mixture was filtered through Celite® and the filtrate was reduced in 
vacuo to yield an oil which was purified by column chromatography (SiO2; 30% 
EtOAc in petroleum ether). The enantiomeric purity was determined by chiral gas 
chromatography; CP-Chirasil-Dex CB; 25 m × 0.25 mm × 0.39 mm; 130 °C; split 
50:1, He flow 1.0 ml/min; 1 µl injection using FID detection.  
 
11.6 General immobilised enzyme reactions.  
To a mixture of (2-hydroxymethyl-oxiranyl)-methanol 87 (10 mg, 0.1 mmol), the 
appropriate lipase (10 mg, 1 wt. eq.) and molecular sieves (4 Å, 10 mg) in 
dichloromethane (1 ml, 0.1 M) was added the acyl donor (see Tables 4-12 in Results 
and Discussion section). The solution was shaken vigorously (250 rpm) in an 
incubator set at the required temperature for the specified times (see Tables 4-12 in 
Results and Discussion section). The mixture was filtered through 0.3 µm filters and 
the filtrate was analysed by chiral gas chromatography; CP-Chirasil-Dex CB; 25 m x 
0.25 mm x 0.39 mm; 130 ºC; split 50:1, He flow 1.0 ml/min; 1 µl injection using FID 
detection. 
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11.7 General synthesis of tertiary alcohols 96a-j and 97a-g. 
To a solution of acetic (±)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate, 50 (200 
mg, 1.37 mmol) in ethanol (14 ml, 0.1 M) was added the corresponding amine (3 eq., 
see Table 13 in Results and Discussion). The solution was heated at reflux for 4 
hours with stirring. The mixture was reduced in vacuo and the crude material was 
purified by column chromatography (SiO2; MeOH/EtOAc). 
 
11.7.1 (±)-2,3-Dihydroxy-2-(piperidin-1-ylmethyl)propyl acetate, 96b. 
O
O N
HO
OH
 
Yield 55%, colourless oil. 1H NMR (400 MHz, CDCl3) δH 1.56 (6H, m, 
3xCH2CH2N), 2.07 (3H, s, CH3CO), 2.51 (6H, m, 3xCH2N), 3.53 (1H, d, J = 11.6 
CHaHbOH), 3.58 (1H, d, J=11.6 CHaHbOH), 3.96 (1H, d, J = 11.2 CHaHbOAc), 3.99 
(1H, d, J=11.2 CHaHbOAc). 13C NMR (100 MHz) 20.8 (CH3CO), 23.5 
(CH2CH2CH2N), 26.3 (CH2CH2N), 56.7 (CH2CH2N), 62.11 (CCH2N), 66.3 
(CH2OH), 66.8 (CH2OAc), 71.4 (C(CH2)3OH), 171.1 (CO); MS ES (+ve) found m/z 
232.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 232.1542 C11H21O4N+H+ requires 
232.1549. IR (cm-1) 3416, 1737. 
 
11.7.2 (±)-2,3-Dihydroxy-2-(morpholinomethyl)propyl acetate, 96c. 
O
O
O
N
HO
OH
 
Yield 81%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 2.10 (3H, s, CH3CO), 2.55 
(2H, d, J=4.0, CCH2N), 2.59 (2H, m, OCH2CH2N), 2.72 (2H, m, OCH2CH2N), 3.54 
(1H, d, J = 11.4 CHaHbOH), 3.58 (1H, d, J=11.4 CHaHbOH), 3.70 (4H, t, J = 4.8, 
2xOCH2CH2N), 4.00 (1H, d, J = 11.6 CHaHbOAc), 4.03 (1H, d, J=11.6 CHaHbOAc). 
13C NMR (100 MHz) 20.9 (CH3CO), 55.6 (OCH2CH2N), 61.7 (CCH2N), 65.9 
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(CH2OH), 66.6 (OCH2CH2N), 67.2 (CH2OAc), 72.2 (C(CH2)3OH), 171.2 (CO); MS 
ES (+ve) found m/z 234.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 234.1336 
C10H19O5N+H+ requires 234.1341. IR (cm-1) 3420, 1735, 1113. 
 
(±)-3-(2,6-Dimethylmorpholino)-2-hydroxy-2-(hydroxymethyl)propyl acetate, 
96d. 
 
Yield 84%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 1.14 (6H, d J=5.6, 
CH3CHO), 2.02 (1H, d, J=10.0),  2.07 (1H, d, J=10.0), 2.12 (3H, s, CH3CO),  2.48 
(1H, d, J= 9.2), 2.53 (1H, d, J= 6.4), 2.72 (1H, d, J= 11.2), 2.93 (1H, d, J= 11.2), 
3.56 (1H, d, J= 12.4 CCHaHbN), 3.61 (1H, d, J= 12.4 CCHaHbN), 3.64-3.70 (2H, m, 
CH2OH), 4.00-4.06 (2H, m, CH2OAc). 13C NMR (100 MHz) 19.0 (CH3CH), 20.9 
(CH3CO), 71.9 (NCH2CH), 61.2 (NCH2CH), 61.4 (CCH2N), 66.1 (CH2OH), 66.8 
(CH2OAc), 72.0 (C(CH2)3OH), 171.1 (CO); MS ES (+ve) found m/z 262.2 ([M+H]+, 
100%). HRMS FAB [M+H]+ 262.1648 C12H23O5N+H+ requires 262.1654. IR (cm-1) 
3435, 1736.
 
 
11.7.3 (±)-2,3-Dihydroxy-2-((4-(2-hydroxyethyl)piperidin-1-yl)methyl)propyl 
acetate, 96e. 
 
Yield 77%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 1.27-1.58 (5H, m, 
(CH2)2CHCH2CH2OH), 1.71-1.76 (2H, m, CCH2N), 2.13 (3H, s, CH3CO), 2.29-2.62 
(4H, m, N(CH2CH2)2CH), 2.88 (1H, m, CHaHbOH), 3.09 (1H, m, CHaHbOH), 3.60-
3.64 (2H, m, CH2CH2OH), 3.71-3.76 (2H, m, CH2CH2OH), 4.03-4.07 (2H, m, 
CH2OAc). 13C NMR (100 MHz) 20.9 (CH3CO), 31.6 (CHCH2CH2OH), 
32.7(CHCH2CH2OH), 32.9 (N(CH2CH2)2CH), 39.2 (N(CH2CH2)2CH, 56.1 
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(CCH2N), 60.5 (CH2CH2OH), 66.4 (CCH2OH), 66.91 (CH2OAc), 71.6 
(C(CH2)3OH), 171.1 (CO); MS ES (+ve) found m/z 276.2 ([M+H]+, 100%). HRMS 
FAB [M+H]+ 276.1814 C13H25O5N+H+ requires 276.1811. IR (cm-1) 3376, 1735. 
 
11.7.4 (±)-2,3-Dihydroxy-2-((methyl(prop-2-ynyl)amino)methyl)propyl 
acetate, 96f. 
 
 
Yield 80%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 2.10 (3H, s, CH3CO), 2.25 
(1H, t, J = 2.4, CHC), 2.46 (3H, s, CH3N), 2.62 (1H, d, J = 14.0, CCHaHbN), 2.67 
(1H, d, J = 14.0 CCHaHbN), 3.41 (2H, d, J = 2.4, CH2CCH), 3.53 (1H, d, J = 11.2, 
CHaHbOH), 3.57 (1H, d, J=11.2, CHaHbOH),  4.03 (2H, s, CH3OAc). 13C NMR (100 
MHz) 20.9 (CH3CO), 44.5 (CH3N), 47.9 (CH2CCH), 58.7 (CCH2N), 65.7 (CH2OH), 
66.4 (CH2OAc), 72.3 (C(CH2)3OH), 73.3 (CCH), 78.6 (CCH), 171.0 (CO); MS ES 
(+ve) found m/z 216.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 216.1232 
C10H17O4N+H+ requires 216.1236. IR (cm-1) 3419, 1729. 
 
11.7.5 (±)-3-(Allyl(methyl)amino)-2-hydroxy-2-(hydroxymethyl)propyl 
acetate, 96g. 
 
Yield 55%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 2.09 (3H, s, CH3CO), 2.39 
(3H, s, CH3N), 2.52 (1H, d, J = 13.8 CCHaHbN), 2.64 (1H, d, J = 13.8 CCHaHbN), 
3.06 (1H, dd, J = 7.2, 14, NCHaHbCH), 3.19 (1H, dd, J = 6.4, 14, NCHaHbCH), 3.53 
(1H, d, J = 11.4 CHaHbOH), 3.57 (1H, d, J = 11.4 CHaHbOH),  3.99 (1H, d, J = 11.8 
CHaHbOAc), 4.02 (1H, d, J = 11.8 CHaHbOAc), 5.17 (1H, s, CHCHaHb), 5.20 (1H, 
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d, J = 3.6, CHCHaHb), 5.85 (1H, m, CHCH2). 13C NMR (100 MHz) 20.8 (CH3CO), 
44.7 (CH3N), 59.8 (NCH2CH), 62.6 (CCH2N), 66.1 (CH2OH), 66.6 (CH2OAc), 72.2 
(C(CH2)3OH), 118.5 (CH2CHCH2N), 134.6 (CH2CHCH2N), 171.0 (CO); MS ES 
(+ve) found m/z 218.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 218.1384 
C10H19O4N+H+ requires 218.1392. IR (cm-1) 3384, 1736. 
 
11.7.6 (±)-3-(Benzyl(methyl)amino)-2-hydroxy-2-(hydroxymethyl)propyl 
acetate, 96h. 
 
Yield 63%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 2.06 (3H, s, CH3CO), 2.38 
(3H, s, CH3N), 2.58 (1H, d, J = 13.6 CCHaHbN), 2.69 (1H, d, J = 13.6 CCHaHbN), 
3.46 (1H, d, J = 11.4, CHaHbOH), 3.49 (1H, d, J = 11.4, CHaHbOH),  3.54 (1H, d, J 
= 12.8, CHaHbOAc), 3.72 (1H, d, J = 12.8, CHaHbOH), 3.97 (2H, s, CH2Ar), 7.31-
7.34 (5H, m, Ar). 13C NMR (100 MHz) 20.9 (CH3CO), 45.0 (CH3N), 60.2 (CH2Ar), 
64.3 (CH2OH), 66.1 (CH2OAc), 66.7 (CCH2N), 72.1 (C(CH2)3OH), 127.6, 128.6, 
129.2 (CH, Ar), 138.1 (C, Ar), 171.1 (CO); MS ES (+ve) found m/z 268.2 ([M+H]+, 
100%). HRMS FAB [M+H]+ 268.1542 C14H21O4N+H+ requires 268.1549. IR (cm-1) 
3386, 1735. 
 
11.7.7  (R)-(+)-3-(4-Fluorophenylamino)-2-hydroxy-2-(hydroxymethyl)propyl 
acetate, 96i. 
 
Yield 94%, green solid. M. p. 76-79 ºC. 1H NMR (400 MHz, CDCl3) δH 2.13 (3H, s, 
CH3CO), 3.17 (1H, d, J = 12.8, CHaHbN), 3.21 (1H, d, J = 12.8, CHaHbN), 3.61 (2H, 
s, CH2OH), 4.17 (1H, d, J = 11.6, CHaHbOAc), 4.20 (1H, d, J = 11.6, CHaHbOAc), 
6.61-6.65 (2H, m, Ar), 6.87-6.92 (2H, m, Ar). 13C NMR (100 MHz) 20.9 (CH3CO), 
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48.1 (CH2N), 64.4 (CH2OH), 65.2 (CH2OAc), 73.3 (C(CH2)3OH), 114.6 (J(C-F) = 
29, CHCF), 115.7 (J(C-F) = 88) (CHCN), 144.5 (CHCN), 168.1 (CHCF), 171.7 
(CO); MS ES (+ve) found m/z 258.0 ([M+H]+, 100%). HRMS FAB [M+H]+ 
258.1135 C12H16O4NF+H+ requires 258.1141. IR (cm-1) 3372, 1720. [αD] (EtOH, 
c=0.9)  +5.6. 
 
11.7.8  (R)-(+)-2,3-Dihydroxy-2-((2-methoxyphenylamino)methyl)propyl 
acetate, 96j. 
 
Yield 96%, oil. 1H NMR (400 MHz, CDCl3) δH 2.14 (3H, s, CH3CO), 3.25 (1H, d, J 
= 13.2, CHaHbN), 3.32 (1H, d, J = 13.2, CHaHbN), 3.63 (2H, s, CH2OH), 3.85 (3H, s, 
CH3OAr), 4.20 (2H, s, CH2OAc), 6.70-6.74 (2H, m, Ar), 6.79 (1H, dd, J = 1.4, 8.0, 
Ar), 6.85-6.89 (1H, m, Ar). 13C NMR (100 MHz) 20.9 (CH3CO), 47.2 (CH2N), 55.5 
(CH3O), 64.4 (CH2OH), 66.0 (CH2OAc), 73.4 (C(CH2)3OH), 109.6, 110.7, 117.6, 
121.2 (CH, Ar), 138.1 (CN), 147.3 (CHCO), 171.5 (CO); MS ES (+ve) found m/z 
270.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 270.1329 C13H19O5N+H+ requires 
270.1341. IR (cm-1) 3401, 1720. [αD] (EtOH, c=0.6)  +11.2.  
 
11.7.9  N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)-N-(2-morpholinoethyl) 
acetamide, 97a. 
 
Yield 89%, colourless oil. 1H NMR (400 MHz, CDCl3) δH 2.13 (3H, s, CH3CO), 2.46 
(4H, t, J= 4.4, 2xNCH2CH2O), 2.61 (2H, t, J= 5.6, NCH2CH2N), 3.41 (4H, s, 
2xNCH2CH2O), 3.50 (2H, t, J= 5.6, NCH2CH2N), 3.54 (2H, s, CCH2N), 3.65 (4H, t, 
J = 4.4, CH2OH).  13C NMR (100 MHz) 21.8 (CH3CO), 48.6 (NCH2CH2N), 52.3 
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(NCH2CH2N), 54.0 (CCH2N), 58.9 (NCH2CH2O), 65.3 (NCH2CH2O), 66.4 
(CH2OH), 74.6 (C(CH2)3OH), 174.1 (CO); MS ES (+ve) found m/z 277.2 ([M+H]+, 
100%). HRMS FAB [M+H]+ 277.1773 C12H24O5N2+H+ requires 277.1763. IR (cm-1) 
3376, 1612, 1113. 
 
11.7.10 N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)-N-isopropylacetamide, 
97b. 
 
Yield 18%, colourless oil. 1H NMR (400 MHz, CDCl3) δH 1.24 (6H, d, J=6.8, 
(CH3)2CH), 2.20 (3H, s, CH3CO), 3.43 (2H, s, CH2N), 3.48 (4H, m, 2xCH2OH), 4.03 
(1H, m, CH3CH). 13C NMR (100 MHz) 21.2 (CH3CO), 22.6 (CH3CH), 46.9 (CH2N), 
64.5 (CH2OAc), 51.2 (CHCH3), 74.3 (C(CH2)3OH), 174.6 (CO); MS ES (+ve) found 
m/z 206.1 ([M+H]+, 100%). HRMS FAB [M+H]+ 206.1393 C9H19O4N+H+ requires 
206.1392. IR (cm-1) 3242, 1613. 
 
11.7.11 N-cyclopentyl-N-(2,3-dihydroxy-2-(hydroxymethyl)propyl) acetamide, 
97c. 
 
Yield 31%, colourless oil. 1H NMR (400 MHz, CDCl3) δH 1.56 (4H, m, 
2xCH2CH2CH), 2.69-2.80 (4H, m, 2xCH2CH2CH), 2.15 (3H, s, CH3CO), 3.37 (2H, 
s, CH2N), 3.41 (4H, t, J=3.2, CH2OH), 3.98 (1H, m, NCH).  13C NMR (100 MHz) 
22.3 (CH2CH2CH), 22.3 (CH3CO), 29.7 (CH2CH2CH), 47.4 (CH2N), 61.2 (CHN), 
64.2 (CH2OH), 74.2 (C(CH2)3OH), 174.8 (CO); MS ES (+ve) found m/z 232.2 
([M+H]+, 100%). HRMS FAB [M+H]+ 232.1546 C11H21O4N+H+ requires 232.1549. 
IR (cm-1) 3363, 1601. 
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11.7.12 N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)-N-(prop-2-ynyl) 
acetamide, 97d. 
 
Yield 93%, white solid. M. p. 76-77 ºC. 1H NMR (400 MHz, CDCl3) δH 2.27 (3H, s, 
CH3CO), 2.35 (1H, t, J=2.4, CHC), 3.49 (6H, m, CH2C(CH2OH)2), 4.21 (2H, d, 
J=2.4, CH2CCH).  13C NMR (100 MHz) 22.1 (CH3CO), 41.3 (NCH2CCH), 49.9 
(CCH2N), 64.5 (CH2OH), 73.7 (CHCCH2), 76.0 (C(CH2)3OH), 78.7 (CHCCH2), 
174.6 (CO); MS ES (+ve) found m/z 202.2 ([M+H]+, 100%). HRMS FAB [M+H]+ 
202.1085 C9H15O4N+H+ requires 202.1079. IR (cm-1) 3232, 1729. 
 
11.7.13 N-allyl-N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)acetamide, 97e. 
 
Yield 96%, yellow solid. M. p. 84-86 ºC. 1H NMR (400 MHz, CDCl3) δH 2.14 (3H, 
s, CH3CO), 2.44 (6H, m, CH2C(CH2OH)2), 4.07 (2H, d, J=4.0, NCH2CHCH2), 5.12 
(1H, d, J=17.6, NCH2CHCHaHb), 5.25 (1H, d, J=12.0, NCH2CHCHaHb), 5.79 (1H, 
ddt, J=4.0, 12.0, 17.6, NCH2CHCH2).  13C NMR (100 MHz) 21.3 (CH3CO), 48.8 
(NCH2CHCH2), 53.0 (CCH2N), 63.7 (CH2OH), 75.4 (C(CH2)3OH), 116.8 
(NCH2CHCH2), 131.9 (NCH2CHCH2), 174.3 (CO); MS ES (+ve) found m/z 204.1 
([M+H]+, 100%). HRMS FAB [M+H]+ 204.1246 C9H17O4N+H+ requires 204.1236. 
IR (cm-1) 3216, 1611. 
 
11.7.14 N-benzyl-N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)acetamide, 97f. 
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Yield 74%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 2.11 (3H, s, CH3CO), 3.43 
(6H, m, CH2C(CH2OH)2), 4.68 (2H, s, CH2Ar), 7.07 (2H, d, J = 6.8, Ar), 7.30 (1H, 
m, Ar), 7.37 (2H, m, Ar).  13C NMR (100 MHz) 21.6 (CH3CO), 49.0 (CH2Ar), 54.0 
(CCH2N), 64.0 (CH2OH), 75.8 (C(CH2)3OH), 126.1, 127.8, 129.1 (CH, Ar), 136.1 
(NCH2C), 174.1 (CO); MS ES (+ve) found m/z 254.2 ([M+H]+, 100%). HRMS FAB 
[M+H]+ 254.1380 C13H19O4N+H+ requires 254.1348. IR (cm-1) 3295, 1605. 
 
11.7.15 N-(2,3-dihydroxy-2-(hydroxymethyl)propyl)-N-phenethylacetamide, 
97g. 
 
Yield 54%, oil. 1H NMR (400 MHz, CDCl3) δH 1.97 (3H, s, CH3CO), 2.88 (2H, t, J 
= 7.6, NCH2CH2Ar), 3.38-3.49 (6H, m, CH2C(CH2OH)2), 3.66 (2H, t, J = 7.6, 
NCH2CH2Ar), 7.15 – 7.33 (5H, m, Ar). 13C NMR (100 MHz) 21.08 (CH3CO), 34.6 
(NCH2CH2Ar), 48.2 (NCH2CH2Ar), 52.2 (CCH2N), 64.0 (CH2OH), 75.6 
(C(CH2)3OH), 128.7, 128.8, 128.9 (CH, Ar), 137.7 (C, Ar), 174.0 (CO); MS ES 
(+ve) found m/z 268.2 ([M+H]+, 100%). HRMS FAB [M+H]+ 268.1541 
C14H21O4N+H+ requires 268.1504. IR (cm-1) 3272, 1602. 
 
11.8 General synthesis of chiral tertiary alcohols 96i-j. 
To a solution of 87 (100 mg, 0.96 mmol), Amano L, AK (200 mg, 2 wt. eq.) and 
molecular sieves (4 Å) in dichloromethane (10 ml, 0.1 M) was added acetic 
anhydride (1.8 equivalents) and the reaction was left for one hour with stirring at 37 
ºC. The mixture was filtered through Celite® and the filtrate was reduced in vacuo. 
Ethanol (10 ml, 0.1 M) and the corresponding amine (3 equivalents, see Table 15 in 
Results and Discussion section) was added and the mixture heated at reflux for 4 
hours. The mixture was reduced in vacuo and purified by column chromatography 
(SiO2). The enantiomeric purity was determined by HPLC; Agilent 1100 Series. 
Chiralpack AD, 1 ml/min, 80/20 isohexene in EtOH at 25ºC. 
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11.9 Synthesis of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-
yl)methyl acetate, 98. 
 
To a solution of (±)-(2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 (150 mg, 1.03 
mmol) in dichloromethane (10 ml, 0.1 M) was added 4-dimethylaminopyridine (13 
mg, 0.10 mmol), triethylamine (430.7 µl, 3.09 mmol) and tert-butyldimethylsilyl 
chloride (170 mg, 1.13 mmol). The solution was stirred and heated at reflux for 5 
hours. The mixture was reduced in vacuo and the crude material was purified by 
column chromatography (SiO2; 5% ethyl acetate in petroleum ether) to yield the title 
compound as a colorless oil (220 mg, 82% yield). 1H NMR (400 MHz, CDCl3) δH 
0.00 (3H, s, SiCH3), 0.08 (3H, s, SiCH3), 0.89 (9H, s, SitBu), 2.09 (3H, s, CH3CO), 
2.70 (1H, d, J = 5.2, CHaHbOC), 2.81 (1H, d, J = 5.2, CHaHbOC), 3.71 (1H, d, J = 
11.6, CHaHbOAc), 3.80 (1H, d, J = 11.6, CHaHbOAc), 4.11 (1H, d, J = 12.0, 
CHaHbOSi), 4.32 (1H, d, J = 12.0, CHaHbOSi); 13C NMR (100 MHz) -5.5 (SiCH3), 
18.3 (SiC(CH3)), 20.8 ((CH3)CO), 25.8 (SiC(CH3)), 49.3 (CH2OC), 57.6 (COCH2), 
63.2 (CH2OAc), 63.8 (CH2OSi), 170.6 (C(CH2)3O); MS ES (+ve) found m/z 261.2 
([M+H]+, 30%), 201.1 (100%); HRMS FAB [M+H]+ 261.1530, C12H24O4Si+H+ 
requires 261.1522; νmax/cm-1  3417, 1746. 
 
11.10 Synthesis of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-
yl)methanol, 99. 
 
To a solution of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 
acetate 98 (220 mg, 0.84 mmol) in methanol (8 ml, 0.1 M) was added potassium 
carbonate (350 mg, 2.53 mmol). The solution was stirred at room temperature for 1 
hour. The mixture was evaporated in vacuo and the crude material was filtered 
through Celite® to yield the title compound as a colorless oil (199 mg, 91% yield). 
1H NMR (400 MHz, CDCl3) δH 0.00 (3H, s, SiCH3), 0.09 (3H, s, SiCH3), 0.89 (9H, 
 142 
 
s, SitBu), 2.76 (1H, d, J = 4.8, CHaHbOC), 2.87 (1H, d, J = 4.8, CHaHbOC), 3.74 (1H, 
dd, J = 7.2, 12.2, CHaHbOSi), 3.80 (2H, s, CH2OH), 3.89 (1H, dd, J = 3.6, 12.2, 
CHaHbOSi); 13C NMR (100 MHz) -5.5 (SiCH3), 18.3 (SiC(CH3)), 25.8 (SiC(CH3)), 
49.0 (CH2OC), 56.5 (CO), 62.2 (CH2OCO), 64.4 (CH2OSi); MS ES (+ve) found m/z 
260.0 ([M+H+MeCN]+, 100%); HRMS FAB [M+H+MeCN]+ 260.1687, 
C10H22O3Si+H++MeCN requires 260.1682; νmax/cm-1 3427. 
 
11.11 Synthesis of tertiary alcohols using primary aliphatic amines. 
To a solution of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methanol 99 
(100 mg, 0.46 mmol) in ethanol (4.6 ml, 0.1 M) was added the corresponding amine 
(3 equivalents, see Table 16 in results and discussion). The solution was heated with 
stirring at reflux for 1 hour then allowed to cool slowly to room temperature. The 
mixture was evaporated in vacuo and the crude material was purified by column 
chromatography (SiO2; methanol/ ethyl acetate). 
 
11.11.1 (±)-3-(Tert-butyldimethylsilyloxy)-2-((prop-2-ynylamino)methyl) 
propane-1,2-diol, 100a. 
 
Yield 70%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.07 (6H, s, SiCH3), 0.89 
(9H, s, SitBu), 2.23 (1H, t, J = 2.4, CHC), 2.75 (1H, d, J = 12.0, HOCCHaHbNH), 
2.90 (1H, d, J = 12.0, HOCCHaHbNH), 3.40 (1H, dd, J = 2.4, 16.8, CHCCHaHbNH), 
3.48 (1H, dd, J = 2.4, 16.8, CHCCHaHbNH), 3.53 (1H, d, J = 9.6, CHaHbOH), 3.56 
(1H, d, J = 9.6, CHaHbOH), 3.59 (1H, d, J = 11.6, CHaHbOSi), 3.63 (1H, d, J = 11.6, 
CHaHbOSi); 13C NMR (100 MHz) -5.5 (SiCH3), 18.2 (SiC(CH3), 25.8 (SiC(CH3)), 
38.7 (CHCCH2NH), 52.6 (HOCCH2NH), 66.8 (CH2OH), 66.9 (CH2OSi), 71.9 
(CHC), 72.9 (C(CH2)3OH), 81.4 (CHC); MS ES (+ve) found m/z 274.1 ([M+H]+, 
100%); HRMS FAB [M+H]+ 274.1845, C13H27NO3Si+H+ requires 274.1838; 
νmax/cm-1 3416, 1638. 
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11.11.2 (±)-3-(Allylamino)-2-((tert-butyldimethylsilyloxy)methyl)propane-1,2-
diol, 100b. 
 
Yield 53%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.06 (6H, s, SiCH3), 0.89 
(9H, s, SitBu), 2.72 (1H, d, J = 12.0, HOCCHaHbNH), 2.79 (1H, dd, J = 0.8, 12.0, 
HOCCHaHbNH), 3.26 (2H, m, CH2CHCH2NH), 3.51 (1H, d, J = 10.0, CHaHbOH), 
3.55 (1H, d, J = 10.0, CHaHbOH), 3.60 (1H, dd, J = 0.8, 11.2, CHaHbOSi), 3.64 (1H, 
dd, J = 11.2, CHaHbOSi), 5.11 (1H, ddd, J = 1.4, 3.2, 10.2, CHaHbCH), 5.22 (1H, 
ddd, J = 1.4, 3.2, 17.2, CHaHbCH), 5.86 (1H, ddt, J = 6.2, 10.2, 17.2, CH2CH); 13C 
NMR (100 MHz) -5.6 (SiCH3), 18.2 (SiC(CH3)3), 25.8 (SiC(CH3)3), 52.7 
(HOCCH2NH), 53.1 (CH2CHCH2NH), 66.9 (CH2OH), 67.4 (CH2OSi), 72.6 
(C(CH2)3OH), 116.4 (CH2CH), 136.2 (CH2CH); MS ES (+ve) found m/z 276.2 
([M+H]+, 100%); HRMS FAB [M+H]+ 276.1993, C13H29NO3Si+H+ requires 
276.1995; νmax/cm-1  3399, 1639. 
 
11.11.3 (±)-3-(Benzylamino)-2-((tert-butyldimethylsilyloxy)methyl)propane-
1,2-diol 100c. 
 
Yield 83%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.04 (6H, s, SiCH3), 0.87 
(9H, s, SitBu), 2.74 (1H, d, J = 11.6, HOCCHaHbNH), 2.81 (1H, d, J = 11.6, 
HOCCHaHbNH), 3.49 (1H, d, J = 10.4, CHaHbOH), 3.52 (1H, d, J = 10.4, 
CHaHbOH), 3.59 (1H, d, J = 11.2, CHaHbOSi), 3.63 (1H, d, J = 11.2, CHaHbOSi), 
3.78 (1H, d, J = 12.8, CHaHbAr), 3.82 (1H, d, J = 12.8, CHaHbAr), 7.30 (5H, m, Ar); 
13C NMR (100 MHz) -5.6 (SiCH3), 18.2 (SiC(CH3)3), 25.8 (SiC(CH3)3), 53.2 
(HOCCH2NH), 54.3 (CH2OH), 66.8 (CH2OSi), 67.4 (CH2Ar), 72.8 (C(CH2)3OH), 
127.2, 128.1, 128.5 (CH, Ar), 139.4 (C, Ar); MS ES (+ve) found m/z 326.1 ([M+H]+, 
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100%); HRMS FAB [M+H]+ 326.2149, C17H31NO3Si+H+ requires 326.2151; 
νmax/cm-1 3395, 1638. 
 
11.12 Synthesis of (S)-(+)-3-(benzylamino)-2-((tert-
butyldimethylsilyloxy)methyl)propane-1,2-diol 100c. 
 
To a solution of 90 (100 mg, 0.96 mmol), immobilised R. miehei (100 mg, 1 wt. eq.) 
and molecular sieves (4 Å, 100 mg) in dichloromethane (10 ml, 0.1 M) was added 
vinyl acetate (1 eq.) and the reaction was left for 8 hour with shaking at 37 ºC. The 
mixture was filtered through Celite® and the filtrate was evaporated in vacuo. 
Dichloromethane (10 ml, 0.1 M), 4-dimethylaminopyridine (11 mg, 0.09 mmol), 
triethylamine (401.4 µl, 2.88 mmol) and tert-butyldimethylsilyl chloride (145 mg, 
0.96 mmol) were added to the colourless oil. The solution was heated at reflux for 5 
hours. The mixture was evaporated in vacuo and the crude material was purified by 
column chromatography (SiO2; 5% ethyl acetate in petroleum ether). To the pure oil 
was added methanol (5 ml, 0.1 M) and potassium carbonate (199 mg, 1.44 mmol). 
The solution was stirred at room temperature for 1 hour. The mixture was reduced in 
vacuo and the crude material was filtered through Celite®. To a solution of the 
resulting oil (97 mg, 0.44 mmol) in ethanol (4.4 ml, 0.1 M) was added benzylamine 
(144 µl, 1.32 mmol). The solution was heated at reflux for 1 hour and allowed to cool 
slowly to room temperature. The mixture was evaporated in vacuo and the crude 
material was purified by column chromatography (SiO2; methanol/ ethyl acetate). 
The enantiomeric excess was determined by HPLC; Agilent 1100 Series. Chiralpack 
AS-H, 1 ml/min, 80/20 iso-hexene in EtOH at 25 ºC. [α]D (H2O, c=0.16) +8.75. 
1NMR obtained was identical that of racemic 100c. 
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11.13 Synthesis of (2-formyloxiran-2-yl)methyl acetate, 102. 
 
To a solution of (2-(hydroxymethyl)oxiran-2-yl)methyl acetate 50 (100 mg, 0.685 
mmol) in anhydrous dichloromethane (7 mL, 0.1 M) at room temperature, were 
added tetrapropylammonium perruthenate (TPAP) (12.04 mg, 0.034 mmol) and N-
methylmorpholine-N-oxide (NMO) (120.36 mg, 1.027 mmol) under an atmosphere 
of nitrogen. After 3 hours the mixture was evaporated in vacuo and the crude 
material was filtered through silica (2.5 g, column diameter = 1 cm, 100 ml EtOAc). 
The resulting fraction was evaporated in vacuo and the crude material was purified 
by column chromatography (SiO2; 50 % petroleum ether in ethyl acetate) to yield the 
title compound as a colorless oil (65.7 mg, 66% yield). 1H NMR (400 MHz, CDCl3) 
δH 3.07 (3H, s, CH3CO), 3.15 (1H, d, J = 4.8, CHaHbOC)), 3.19 (1H, d, J = 4.8, 
CHaHbOC)), 4.27 (1H, d, J = 12.4, CHaHbOAc), 4.65 (1H, d, J = 12.4, CHaHbOAc), 
8.97 (1H, s, CHO). 
 
11.14 Synthesis of (±)-N-(2,3-dihydroxy-2-methylpropyl)-N-(4-
fluorophenyl)-4-methylbenzenesulfonamide, 106. 
 
To a solution of 3-(4-fluorophenylamino)-2-hydroxy-2-(hydroxymethyl)propyl 
acetate 96i (100 mg, 0.39 mmol) in pyridine (3.7 mL) at 0 ºC was added p-toluene-
sulfonyl chloride (223.06 mg, 1.17 mmol) and the reaction was stirred overnight at 
room temperature. The mixture was evaporated in vacuo and the crude material was 
diluted in ethyl acetate. The resulting solution was washed with 10% HCl solution 
(10 ml), saturated NaHCO3 solution (10 ml) and saturated NaCl solution (10 ml), 
respectively. The organic layer was dried (MgSO4) and the resulting filtrate was 
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evaporated in vacuo to obtain a colorless oil. The oil was dissolved in anhydrous 
diethyl ether (4 mL), under an atmosphere of nitrogen at 0 ºC, and LiAlH4 (74.0 mg, 
1.96 mmol) was added to the cold solution and the reaction was allow to warm 
slowly to room temperature. After 1 hour the crude mixture was cooled down to 0 ºC 
and 74 µL of water were added slowly. NaOH (74 µL of 15 % aqueous solution) and 
water (222 µL) were added and the mixture was allowed to warm at room 
temperature. After an hour the white solid was diluted with diethyl ether and filtered. 
The solution was dried (MgSO4) and the resulting filtrate was evaporated in vacuo to 
yield the title compound as a colorless oil (50 mg, 36% yield). 1H NMR (400 MHz, 
CDCl3) δH 0.96 (3H, s, C(CH2)2CH3OH), 2.43 (3H, s, CH3Ts), 3.43 (1H, d, J = 12.8, 
NCHaHb), 3.45 (1H, d, J = 12.8, NCHaHb), 3.67 (1H, d, J = 13.2, CHaHbOH), 3.78 
(1H, d, J = 13.2, CHaHbOH), 7.02 (4H, m, NCCH), 7.26 (2H, m, FCCH), 7.40 (2H, 
m, ArTs); 13C NMR (100 MHz) 21.6 (C(CH2)2CH3OH), 22.4 (CH3Ts), 57.2 (NCH2), 
66.7 (CH2OH), 73.3 (C(CH2)2CH3OH), 121.7 (J(C-F) = 80, NCCH), 130.0 (J(C-F) = 
40, FCCH), 133.8 (NC), 137.0 (SC), 144.3 (CHCCH3), 160.6 (CF); MS ES (+ve) 
found m/z 376.1 ([M+H+Na]+, 100%); HRMS FAB [M+H+Na]+ 376.0994, 
C17H20FNO4S+H++Na requires 376.0995; νmax/cm-1 3387, 1232. 
 
11.15 Synthesis of (±)-3-(tert-butyldimethylsilyloxy)-2-hydroxy-2-
(morpholinomethyl)propyl acetate, 107. 
 
To a solution of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 
acetate 98 (273.7 mg, 1.05 mmol) in ethanol (10.0 ml, 0.1 M) was added morpholine 
(272.4 µL, 3.15 mmol). The solution was heated at reflux for 1 hour and allowed to 
cool slowly to room temperature. The mixture was evaporated in vacuo and the crude 
material was purified by column chromatography (SiO2; 100% ethyl acetate) to 
obtain the title compound as colorless oil (345.7 mg, 95% yield). 1H NMR (400 
MHz, CDCl3) δH 0.05 (6H, s, SiCH3), 0.88 (9H, s, SitBu), 2.08 (3H, s, CH3OCO), 
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2.36 (1H, d, J = 13.8, CCHaHbN), 2.56 (1H, d, J = 13.8, CCHaHbN), 2.60 (4H, m, 
(2xNCH2CH2O)), 3.45 (1H, d, J = 10.0, CHaHbOAc), 3.58 (1H, d, J = 10.0, 
CHaHbOAc), 3.69 (4H, t, J = 4.4 (2xNCH2CH2O)), 3.99 (1H, d, J = 11.2, 
CHaHbOSi), 4.07 (1H, d, J = 11.2, CHaHbOSi); 13C NMR (100 MHz) -5.6 (SiCH3), 
18.2 (SiC(CH3)3), 20.9 (CH3OAc), 25.8 (SiC(CH3)3), 55.6 (NCH2CH2O), 59.9 
(CCH2N), 64.6 (NCH2CH2O), 66.1 (CH2OSi), 67.2 (CH2OAc), 72.7 (C(CH2)3OH), 
170.9 (CO); MS ES (+ve) found m/z 348.1 ([M+H]+, 100%); HRMS FAB [M+H]+ 
348.2201, C16H33NO5Si+H+ requires 348.2206; νmax/cm-1 3351, 1730. 
 
11.16 Synthesis of (±)-3-(tert-butyldimethylsilyloxy)-2-
(morpholinomethyl)propane-1,2-diol, 100d. 
 
To a solution of 3-(tert-butyldimethylsilyloxy)-2-hydroxy-2-
(morpholinomethyl)propyl acetate 107 (100 mg, 0.29 mmol) in methanol (3 ml, 0.1 
M) was added potassium carbonate (118.8 mg, 0.86 mmol). The solution was stirred 
at room temperature for 1 hour. After that time water (10 ml) was added to the 
mixture and the product extracted with DCM (10 ml x 3). The organic layer was 
dried (MgSO4), filtered and the solution was evaporated in vacuo to yield the title 
compound as colourless oil (86.4 mg, 98% yield). 1H NMR (400 MHz, CDCl3) δH 
0.06 (6H, s, SiCH3), 0.89 (9H, s, SitBu), 2.55 (4H, m, (2xNCH2CH2O)), 2.75 (2H, m, 
CCH2N), 2.46 (1H, d, J = 9.6, CHaHbOSi), 3.49 (1H, d, J = 9.6, CHaHbOSi), 3.59 
(1H, d, J = 11.4, CHaHbOH), 3.65 (1H, d, J = 11.4, CHaHbOH), 3.69 (4H, t, J = 4.4, 
(2xNCH2CH2O)); 13C NMR (100 MHz) -5.5 (SiCH3), 18.2 (SiC(CH3)3), 25.8 
(SiC(CH3)3), 55.6 (NCH2CH2O), 62.6 (CCH2N), 66.5 (CH2OSi), 67.2 (CH2OH), 67.3 
(NCH2CH2O), 72.9 (C(CH2)3OH); MS ES (+ve) found m/z 307.4 ([M+2H]+, 100%); 
HRMS FAB [M+H]+ 306.2097, C14H31NO4Si+H+ requires 306.2100; νmax/cm-1 3298. 
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11.17 Synthesis of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-
yl)methyl-4-methylbenzenesulfonate, 110.  
OO
O
S
O
O
Si
 
To a solution of (±)-(2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methanol 99 
(1.09 g, 5.01 mmol) in dichloromethane (50 ml, 0.1 M) was added 4-
dimethylaminopyridine (61.2 mg, 0.50 mmol), triethylamine (2.09 ml, 15.03 mmol) 
and 4-toluenesulfonyl chloride (1.05 g, 5.51 mmol). The solution was heated at 
reflux for 5 hours. The mixture was evaporated in vacuo and the crude material was 
purified by column chromatography (SiO2; 10% ethyl acetate in petroleum ether) to 
yield the title compound as a colorless oil (1.59 g, 90% yield). 1H NMR (400 MHz, 
CDCl3) δH 0.01 (3H, s, SiCH3), 0.02 (3H, s, SiCH3), 0.84 (9H, s, SitBu), 2.45 (3H, s, 
CH3Ts), 2.72 (1H, d, J = 4.8, CHaHbOC), 2.75 (1H, d, J = 4.8, CHaHbOC), 3.65 (1H, 
d, J = 11.6, CHaHbOTs), 3.73 (1H, d, J = 11.6, CHaHbOTs), 4.10 (1H, d, J = 10.4, 
CHaHbOSi), 4.18 (1H, d, J = 10.4, CHaHbOSi), 7.34 (2H, d, J = 8.4, CH, Ar), 7.79 
(2H, d, J = 8.4, CH, Ar); 13C NMR (100 MHz) -5.4 (SiCH3), 18.3 (SiC(CH3)3), 25.6 
(CH3CCH), 25.8 (SiC(CH3)3), 63.3 (CH2OC), 63.4 (CH2OSi), 68.0 (CH2OTs), 70.0 
(C(CH2)3O), 128.3, 128.4 (CH, Ar), 139.4 (CH3CCH), 146.4 (CS); MS ES (+ve) 
found m/z 395.1 ([M+H+Na]+, 100%); HRMS FAB [M+H+Na]+ 395.1315, 
C17H28O5SSi+Na+H+ requires 395.1324, IR 1196. 
 
11.18 Synthesis of 3-(allylamino)-2-((tert-butyldimethylsilyloxy)methyl)-
2-hydroxypropyl 4-methylbenzenesulfonate, 108. 
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To a solution of (2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 4-
methylbenzenesulfonate 110 (100 mg, 0.27 mmol) in ethanol (2.7 ml, 0.1 M) was 
added allylamine (3 equivalents, 46.2 µl). The solution was heated at reflux for 1 
hours and allowed to cool slowly to room temperature. The mixture was evaporated 
in vacuo and the crude material was purified by column chromatography (SiO2; 50% 
ethyl acetate in petroleum ether). Yield 21%, yellow oil. 1H NMR (400 MHz, CDCl3) 
δH 0.12 (6H, s, SiCH3), 0.93 (9H, s, SitBu), 2.37 (3H, s, CH3CCH), 3.43 (1H, s, 
CCH2), 3.44 (1H, s, CCH2), 3.65 (2H, s, NCH2CH), 3.76 (4H, m, CH2O), 5.35 (2H, 
m, CH2CH), 5.80 (1H, m, CH2CH), 7.21 (2H, d, J = 7.8, CH, Ar), 7.81 (2H, d, J = 
7.8, CH, Ar). 
 
11.19 Synthesis of azetidines. 
To a solution of (2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl 4-
methylbenzenesulfonate 110 (100 mg, 0.27 mmol) in ethanol (2.7 ml, 0.1 M) was 
added the corresponding amine (3 equivalents, see Tables 18 and 19 in Results and 
Discussion section). The solution was heated at reflux for 8 hours and allowed to 
cool slowly to room temperature. The mixture was evaporated in vacuo and the crude 
material was purified by column chromatography (SiO2; ethyl acetate in petroleum 
ether). 
 
11.19.1 1-Allyl-3-((tert-butyldimethylsilyloxy)methyl)azetidin-3-ol, 114a. 
 
Yield 50%, yellow solid. M. p. 65-67 ºC. 1H NMR (400 MHz, CDCl3) δH 0.09 (6H, 
s, SiCH3), 0.90 (9H, s, SitBu), 2.96 (1H, d, J = 1.6, CHaHbCH), 2.98 (1H, d, J = 1.6, 
CHaHbCH), 3.12 (1H, t, J = 1.2, (CCHaHbN), 3.13 (1H, t, J = 1.2, CCHaHbN), 3.36 
(1H, d, J = 1.8, CCHa’Hb’N)), 3.38 (1H, d, J = 1.8, CCHa’Hb’N), 3.79 (2H, s, 
CH2OSi), 5.10 (1H, ddt, J = 1.2, 1.6, 10.4, CHCHaHb), 5.17 (1H, ddt, J = 1.6, 3.2, 
17.2, CHCHaHb), 5.76 (1H, ddt, J = 6.2, 10.4, 17.2, CHCH2); 13C NMR (100 MHz) -
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5.4 (SiCH3), 18.3 (SiC(CH3)3), 25.8 (SiC(CH3)3), 61.9 (CCH2N), 63.3 (NCH2CH), 
67.9 (CH2OSi), 69.9 (CCH2N), 117.4 (CH2CH), 134.3 (CH2CH); MS ES (+ve) found 
m/z 258.0 ([M+H]+, 100%); HRMS FAB [M+H]+ 258.1897, C13H27NO2Si+H+ 
requires 258.1811; νmax/cm-1 3395.  
 
11.19.2 3-((Tert-butyldimethylsilyloxy)methyl)-1-(prop-2-ynyl)azetidin-3-ol, 
114b. 
 
Yield 88%, yellow solid. M. p. 70-73 ºC. 1H NMR (400 MHz, CDCl3) δH 0.09 (6H, 
s, SiCH3), 0.90 (9H, s, SitBu), 2.27 (1H, t, J = 2.0, CHC), 3.19 (1H, d, J = 2.0, 
CHaHbOSi), 3.21 (1H, d, J = 2.0, CHaHbOSi), 3.33 (4H, m, (2xCCH2N)), 3.81 (2H, s, 
CH2CCH); 13C NMR (100 MHz) -5.4 (SiCH3), 18.3 (SiC(CH3)3), 25.8 (SiC(CH3)3), 
45.3 (CH2CCH), 61.4 (CCH2N), 68.0 (CH2OSi), 69.5 (C(CH2)3OH), 73.1 (CHC), 
78.6 (CHC); MS ES (+ve) found m/z 256.1 ([M+H]+, 100%); HRMS FAB [M+H]+ 
256.1733, C13H25NO2Si+H+ requires 256.1733; νmax/cm-1 3391. 
 
11.19.3 1-Benzyl-3-((tert-butyldimethylsilyloxy)methyl)azetidin-3-ol, 114c. 
 
Yield 84%, oil. 1H NMR (400 MHz, CDCl3) δH 0.09 (6H, s, SiCH3), 0.90 (9H, s, 
SitBu), 3.01 (2H, d, J = 2.0, (2xCCHaHbN), 3.35 (2H, d, J = 2.0, (2xCCHaHbN), 3.67 
(2H, s, CH2OSi), 3.80 (2H, s, CH2Ar), 7.28 (5H, m, Ar); 13C NMR (100 MHz) -5.4 
(SiCH3), 18.3 (SiC(CH3)), 25.8 (SiC(CH3)), 63.5(CCH2N), 63.5 (CH2Ar) 68.1 
(CH2OSi), 70.0 (C(CH2)3OH), 127.0, 128.3, 128.4 (CH, Ar), 138.1 (C, Ar); MS ES 
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(+ve) found m/z 308.1 ([M+H]+, 100%); HRMS FAB [M+H]+ 308.2053, 
C17H29NO2Si+H+ requires 308.2046; νmax/cm-1 3388. 
 
11.19.4 3-((Tert-butyldimethylsilyloxy)methyl)-1-(4-fluorophenyl)azetidin-3-ol, 
114d. 
 
Yield 43%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 0.12 (6H, s, SiCH3), 0.92 
(9H, s, SitBu), 3.65 (2H, d, J = 8.0, CCHaHbN), 3.81 (2H, d, J = 8.0, CCHaHbN), 3.86 
(2H, s, CH2OSi), 6.41 (2H, m, Ar), 6.92 (2H, m, Ar);13C NMR (100 MHz) -5.3 
(SiCH3), 18.3 (SiC(CH3)3), 25.9 (SiC(CH3)3), 61.9 (CCH2N), 68.2 (CH2OSi), 70.1 
(C(CH2)3OH), 112.8 (J(C-F) = 40, CH, Ar), 115.4 (J(C-F) = 80, CH, Ar), 148.2 
(CN), 157.3 (CF); MS ES (+ve) found m/z 312.1 ([M+H]+, 100%); HRMS FAB 
[M+H]+ 312.1565, C16H26FNO2Si+H+ requires 312.1750; νmax/cm-1 3388. 
 
11.19.5 3-((Tert-butyldimethylsilyloxy)methyl)-1-cyclopentylazetidin-3-ol, 114f. 
 
Yield 80%, white solid. 1H NMR (400 MHz, CDCl3) δH 0.09 (6H, s, SiCH3), 0.90 
(9H, s, SitBu), 1.48 (4H, m, 2xCHCH2CH2), 1.71 (4H, m, 2XCHCH2CH2), 2.88 (1H, 
m, CH), 3.16 (2H, d, J = 8.0, 2xCCHaHbN), 3.45 (2H, d, J = 8.0, 2xCCHaHbN), 3.73 
(2H, s, CH2OSi); 13C NMR (100 MHz) -5.4 (SiCH3), 18.2 (SiC(CH3)3), 24.4 
(CHCH2CH2), 25.8 (SiC(CH3)3), 30.0 (CHCH2CH2), 62.3 (CCH2N), 67.4 (CH2OSi), 
69.1 (CHCH2CH2), 69.5 (C(CH2)3OH); MS ES (+ve) found m/z 287.4 ([M+2H]+, 
100%); HRMS FAB [M+H]+ 286.2205, C15H31NO2Si+H+ requires 286.2202; 
νmax/cm-1 3355. 
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11.19.6 3-((Tert-butyldimethylsilyloxy)methyl)-1-isopropylazetidin-3-ol, 114g. 
 
Yield 92%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.07 (6H, s, SiCH3), 0.88 
(9H, s, SitBu), 0.94 (6H, d, J = 6.4, CH(CH3)2), 2.38 (1H, hept, J = 6.4, CHCH3), 
2.99 (2H, d, J = 9.6, 2xCCHaHbN), 3.36 (2H, d, J = 9.6, 2xCCHaHbN)), 3.72 (2H, s, 
CH2OSi); 13C NMR (100 MHz) -5.4 (SiCH3), 18.2 (SiC(CH3)3), 19.5 (CHCH3), 25.8 
(SiC(CH3)3), 58.6 (CHCH3), 62.1 (CCH2N), 67.7 (CH2OSi), 68.6 (C(CH2)3OH); MS 
ES (+ve) found m/z 260.1 ([M+H]+, 100%); HRMS FAB [M+H]+ 260.2043, 
C13H29NO2Si+H+ requires 260.2046; νmax/cm-1 3371. 
 
11.19.7 (S)-3-((Tert-butyldimethylsilyloxy)methyl)-1-(1-phenylethyl)azetidin-3-
ol, 114h. 
O N
HO
Si
 
Yield 88%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.08 (3H, s, SiCH3), 0.10 
(3H, s, SiCH3) 0.90 (9H, s, SitBu), 1.21 (3H, d, J = 6.8, CHCH3), 2.84 (1H, d, J = 
7.8, CCHaHbN)), 2.99 (1H, d, J = 7.8, CCHaHbN), 3.09 (1H, d, J = 7.6, CCHa´Hb´N), 
3.34 (1H, q, J = 6.8, CHCH3), 3.42 (1H, d, J = 7.6, CCHa´Hb´N), 3.79 (1H, d, J = 
10.0, SiOCHaHb), 3.81 (1H, d, J = 10.0, SiOCHaHb), 7.27 (5H, m, (CH, Ar)); 13C 
NMR (100 MHz) -5.3 (SiCH3), 18.3 (SiC(CH3)3), 21.5 (CHCH3), 25.9 (SiC(CH3)3), 
62.4 (CCH2N), 62.5 (CCH2N), 68.3 (CH2OSi), 68.7 (CHCH3), 69.0 (C(CH2)3OH), 
127.0, 127.1, 128.3 (CH, Ar), 143.4 (C, Ar); MS ES (+ve) found m/z 322.1 ([M+H]+, 
100%); HRMS FAB [M+H]+ 322.2204, C18H31NO2Si+H+ requires 322.2202; 
νmax/cm-1 3397. [αD] (EtOH, c=0.034) –29.4. 
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11.19.8  (S)-3-((Tert-butyldimethylsilyloxy)methyl)-1-(1-phenylpropyl)azetidin-
3-ol, 114i 
 
Yield 78%, white solid. M. p. 59-61 ºC. 1H NMR (400 MHz, CDCl3) δH 0.06 (3H, s, 
SiCH3), 0.08 (3H, s, SiCH3), 0.66 (3H, t, J= 7.6, CH2CH3), 0.88 (9H, s, SitBu), 1.45 
(1H, dqd, J= 13.4, 9.6, 7.6 (CHaHbCH3), 1.69 (1H, dqd, J= 13.4, 7.6, 3.6 
CHaHbCH3), 2.82 (1H, d, J= 8.0, CCHaHbN), 2.95 (1H, d, J= 8.0, CCHaHbN), 3.03 
(1H, ddd, J= 7.8, 2.0, 0.8, CCHa’Hb’N), 3.07 (1H, dd, J= 3.6, 9.6, CHCH2), 3.40 (1H, 
ddd, J= 7.8, 2.0, 0.8, CCHa’Hb’N), 3.73 (1H, d, J= 10.4, CHaHbOSi), 3.77 (1H, d, J= 
10.4, CHaHbOSi), 7.24 (5H, m, Ar); 13C NMR (100 MHz) -5.4 (SiCH3), 10.0 
(CH3CH2), 18.3 (SiC(CH3)3), 25.8 (SiC(CH3)3), 27.3 (CH3CH2), 62.3 (CCH2N), 62.5 
(CCH2N), 68.2 (CH2OSi), 69.3 (C(CH2)3OH), 75.5 (CHCH2), 127.0, 128.0, 128.1 
(CH, Ar), 141.3 (C, Ar); MS ES (+ve) found m/z 336.1 ([M+H]+, 100%); HRMS 
FAB [M+H]+ 336.2356, C19H33NO2Si+H+ requires 336.2359; νmax/cm-1 3375. [αD] 
(EtOH, c=0.30) +40.3. 
 
7.20.9 (S)-3-((Tert-butyldimethylsilyloxy)methyl)-1-(1-(naphthalen-2-
yl)ethyl)azetidin-3-ol, 114j. 
 
Yield 97%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.11 (3H, s, SiCH3), 0.12 
(3H, s, SiCH3), 0.92 (9H, s, SitBu), 1.31 (3H, d, J = 6.4, CH3CHN), 2.96 (1H, d, J = 
8.0, CCHaHbN), 3.06 (1H, d, J = 8.0, CCHaHbN), 3.16 (1H, d, J = 8.4, CCHa´Hb´N), 
3.49 (1H, d, J = 8.4, CCHa´Hb´N), 3.54 (1H, q, J = 6.4, CH3CHN), 3.80 (1H, d, J = 
10.0, SiOCHaHb), 3.84 (1H, d, J = 10.0, SiOCHaHb), 7.46 (3H, m, (CH, Ar)), 7.79 
(4H, m, (CH, Ar)); 13C NMR (100 MHz) -5.4 (SiCH3), 18.3 (SiC(CH3)3), 21.3 
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(CHCH3), 25.9 (SiC(CH3)3), 62.5 (CCH2N), 62.6 (CCH2N), 68.1 (CH2OSi), 68.8 
(CHCH3), 69.0 (C(CH2)3OH), 125.4, 125.5, 125.7, 125.8, 127.6, 127.7, 128.0 (CH, 
Ar), 132.8, 133.3, 141.0 (C, Ar); MS ES (+ve) found m/z 372.2 ([M+H]+, 100%); 
HRMS FAB [M+H]+ 372.2280, C22H33NO2Si+H+ requires 372.2314; νmax/cm-1 3348. 
[αD] (EtOH, c=0.024) +225.0. 
 
11.20 Synthesis of tertiary alcohols using secondary amines from 
epoxide 110. 
To a solution of (2-((tert-butyldimethylsilyloxy)methyl)oxiran-2-yl)methyl-4-
methylbenzenesulfonate 110 (100 mg, 0.27 mmol) in ethanol (2.7 ml, 0.1 M) was 
added the corresponding amine (3 equivalents, Table 20 in Results and Discussion 
section). The solution was heated at reflux for 8 hours and allowed to cool slowly to 
room temperature. The mixture was evaporated in vacuo and the crude material was 
purified by column chromatography (SiO2; methanol in ethyl acetate). 
 
11.20.1 1,3-bis(Allyl(methyl)amino)-2-((tert-butyldimethylsilyloxy)methyl) 
propan-2-ol, 115a. 
  
Yield 81%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 0.03 (6H, s, 2xSiCH3), 0.87 
(9H, s, SitBu), 2.31 (6H, s, 2xCH3N), 2.37 (2H, d, J = 13.6, 2xCCHaHbN), 2.48 (2H, 
d, J = 13.6, 2xCCHaHbN), 3.05 (2H, dd, J = 6.4, 14.0, 2xNCHaHbCH), 3.14 (2H, dd, 
J = 6.4, 14.0, 2xNCHaHbCH), 3.40 (2H, s, CH2OSi), 5.11 (4H, m, 2xCH2CH), 5.83 
(2H, m, 2xCH2CH); 13C NMR (100 MHz) -5.5 (SiCH3), 18.1 (SiC(CH3)3), 25.8 
(SiC(CH3)3), 44.4 (CH3N), 59.8 (NCH2CH), 62.6 (CH2OSi), 65.2 (CCH2N), 73.8 
(C(CH2)3OH), 117.0 (CH2CH), 136.2 (CH2CH); MS ES (+ve) found m/z 343.2 
([M+H]+, 100%); HRMS FAB [M+H]+ 343.2770, C18H38N2O2Si+H+ requires 
343.2736; νmax/cm-1 3295. 
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11.20.2 1-(Tert-butyldimethylsilyloxy)-3-(methyl(prop-2-ynyl)amino)-2-
((methyl(prop-2-ynyl)amino)methyl)propan-2-ol, 115b. 
 
Yield 78%, colorless oil. 1H NMR (400 MHz, CDCl3) δH 0.05 (6H, s, 2xSiCH3), 0.88 
(9H, s, SitBu), 2.20 (2H, t, J = 2.0, 2xCHC), 2.39 (2H, d, J = 15.6, 2xCCHaHbN), 
2.40 (6H, s, 2xNCH3), 2.56 (2H, d, J = 15.6, 2xCCHaHbN), 3.41 (4H, d, J = 2.0, 
2xCH2CCH), 3.43 (2H, s, CH2OSi); 13C NMR (100 MHz) -5.5 (SiCH3), 18.1 
(SiC(CH3)3), 25.8 (SiC(CH3)3), 44.2 (CH3N), 47.6 (CCH2N), 58.4 (NCH2CH), 65.0 
(CH2OSi), 72.5 (CHC), 73.8 (C(CH2)3OH), 79.6 (CHC); MS ES (+ve) found m/z 
339.2 ([M+H]+, 100%); HRMS FAB [M+H]+ 339.2420, C18H34N2O2Si+H+ requires 
339.2423; νmax/cm-13371. 
 
11.20.3 1,3-bis(Benzyl(methyl)amino)-2-((tert-butyldimethylsilyloxy)methyl) 
propan-2-ol, 115c. 
 
 
 
 
 
Yield 83%, yellow oil. 1H NMR (400 MHz, CDCl3) δH 0.04 (6H, s, 2xSiCH3), 0.80 
(9H, s, SitBu), 2.22 (6H, s, 2xCH3N), 2.52 (4H, s, 2xCCH2N), 3.44 (2H, s, CH2OSi), 
3.54 (2H, d, J = 13.6, CHaHbAr), 2.65 (2H, d, J = 13.6, CHaHbAr), 7.23 (10H, m, 
Ar); 13C NMR (100 MHz) -5.6 (SiCH3), 18.0 (SiC(CH3)3), 25.8 (SiC(CH3)3), 44.4 
(CH3N), 60.2 (NCH2CH) , 63.9 (CH2OSi) 65.6 (NCH2CH), 74.2 (C(CH2)3OH), 
126.9, 128.2, 128.8 (CH, Ar), 139.6 (C, Ar); MS ES (+ve) found m/z 443.3 ([M+H]+, 
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100%); HRMS FAB [M+H]+ 443.3091, C26H42N2O2Si+H+ requires 443.3094; 
νmax/cm-1 3329. 
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APPENDIX 
 
Table 1: Results of the enzymatic desymmetrisation of 87 with Amano L, AK in 
organic solvents. 
 
Entrya Eq acyl donor % 50b % eec % 49b 
1d 1 56 72 9 
2e 1.2 59 76 9 
3e 1.5 50 95 14 
4e 1.8 44 96 18 
5f 2 42 97 22 
 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride and Amano L, AK (2 weight equivalents) at 37 ºC for 1 hour. b 
Isolated yields. c Results from GC of the crude reaction mixture. d Average of two 
reactions. e Average of three reaction. f Average of four reaction. (More results in 
table 2). 
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Table 2: Results of the enzymatic desymmetrisation of 87 with Amano L, AK in 
organic solvents. 
 
Entrya Eq acyl donor % 50b % eec % 49b 
1 1 60 77 10 
2 1 52 67 7 
3 1 37 90 8 
4 1.2 55 79 8 
5 1.2 67 75 10 
6 1.2 55 74 9 
7 1.5 66 69 11 
8 1.5 38 92 11 
9 1.5 63 94 11 
10 1.5 50 98 19 
11 1.8 53 97 24 
12 1.8 33 94 11 
13 1.8 76 95 25 
14 1.8 46 97 19 
15 2 53 97 22 
16 2 28 97 18 
17 2 41 95 25 
18 2 46 99 21 
 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride (1 equivalent) and Amano L, AK (2 weight equivalents) at 37 
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ºC for 1 hour. b Isolated yields. c Results from GC of the crude reaction mixture. 
Results in red were excluded from the average of table 1. 
 
Table 3: Results of the enzymatic desymmetrisation of 87 with Amano L, AK in 
organic solvents. 
 
Entrya Time (min) % 50b % eeb % 49b % 87b 
1 5 35 63 23 42 
2 10 55 75 24 20 
3 20 48 82 45 6 
4 30 47 96 53 0 
5 40 42 99 58 0 
6 50 37 99 63 0 
7 60 37 99 63 0 
 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride (1.5 equivalents) and Amano L, AK (2 weight equivalent) at 
37 ºC. b Results from GC of the crude reaction mixture. 
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Table 4: Results of the enzymatic desymmetrisation of 87 with Amano L, AK in 
organic solvents. 
 
Entrya Time (min) % 50b % eeb % 49b % 87b 
1 5 32 65 14 54 
2 10 48 82 46 6 
3 20 44 95 56 0 
4 30 40 98 61 0 
5 40 36 99 64 0 
6 50 34 99 66 0 
7 60 31 99 69 0 
 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (100 
mg), acetic anhydride (1.8 equivalents) and Amano L, AK (2 weight equivalents) at 
37 ºC. bResults from GC of the crude reaction mixture. 
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Table 5: Results of the enzymatic desymmetrisation of 87 with different proteases in 
organic solvents. 
 
Entry Enzymeb Acyl Agentc 
Time 
(h) 
% 
50d 
% 
eed 
% 
49d 
% 
87d 
1  Ac2O 48 43 4 4 53 
2 NZP-101 VA 48 10 20 0 90 
3 Bacillus clausii iPrOAc 24 0 - 0 100 
4  PentylOAc 24 0 - 0 100 
5  EtOAc 24 0 - 0 100 
6  Ac2O 48 79 6 12 9 
7 NZP-102 VA 48 9 18 0 91 
8 Bacillus lhalodurans iPrOAc 24 0 - 0 100 
9  PentylOAc 24 0 - 0 100 
10  EtOAc 24 0 - 0 100 
11  Ac2O 48 84 6 16 0 
12 NZP-103 VA 48 10 24 0 90 
13 Bacillus licheniformis iPrOAc 24 0 - 0 100 
14  PentylOAc 24 0 - 0 100 
15  EtOAc 24 0 - 0 100 
16  Ac2O 48 18 10 82 0 
17 NZL-104 VA 48 7 20 0 93 
18 Bacillus licheniformis iPrOAc 24 0 - 0 100 
19  PentylOAc 24 0 - 0 100 
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20  EtOAc 24 0 - 0 100 
21  Ac2O 48 61 3 10 29 
22 NZP-105 VA 48 7 1 0 93 
23 Fusarium oxysporum iPrOAc 24 0 - 0 100 
24  PentylOAc 24 0 - 0 100 
25  EtOAc 24 0 - 0 100 
26  Ac2O 48 45 1 4 51 
27  VA 48 5 3 0 95 
28 NZP-106 iPrOAc 24 0 - 0 100 
29 Rhizomucor miehei PentylOAc 24 0 - 0 100 
30  EtOAc 24 0 - 0 100 
 
a
 Biotransformations were carried out in dichloromethane (0.1 M) at 37 ºC using 
prochiral diol 87 (10 mg), acyl donor (1 equivalent) and 1 weight equivalent of the 
immobilised enzyme for the corresponding time (biotransformations were followed 
by TLC until no changes were seen). b Names of enzyme provide from Codexis. 
cAbbreviations: acetic anhydride (Ac2O), vinyl acetate (VA), iso-propylacetate 
(iPrOAc), pentyl acetate (PentylOAc), ethyl acetate (EtOAc), d Results from GC of 
the crude reaction mixture. 
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Table 6: Results of the enzymatic desymmetrisation of 87 with R. miehei in organic 
solvents. 
 
Entrya Time (min) % 50b % eec % 49b % 87b 
1 10 29 69 0 71 
2 20 39 70 1 60 
3 30 53 74 2 45 
4 40 55 75 2 43 
5 60 84 77 11 5 
6 90 84 74 13 3 
7 120 85 78 13 2 
8 240 78 88 22 0 
9 360 44 99 56 0 
10 480 29 99 71 0 
 
a
 Biotransformations were carried out in DCM (0.1 M) using prochiral diol 87 (10 
mg), 1 equivalent of vinyl acetate and 1 weight equivalent of NZL-103 from R. 
miehei at 37ºC. bResults from GC of the crude reaction. 
 
